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Abstract 
The microbiome in the human gastrointestinal tract (GIT) is the largest body community of 
bacteria. In conjunction within an appropriate internal milieu, the microbiome induces the 
development of regulated pro– and anti–inflammatory signals that promote immunological 
tolerance. In addition, microbial interactions provide cues for upholding metabolic regulations and 
controlling and regulating GIT inflammation. Failure to regulate inflammatory responses can 
increase the risk of developing inflammatory conditions such as Inflammatory Bowel Diseases 
(IBD) or Irritable Bowel Syndrome (IBS). Disruption to the microbiome homeostasis can also affect 
other end–organs (e.g., liver, kidneys).  For example, the liver receives 70% of its blood supply 
from the GIT, making regulation of the gut-liver-axis vital. Inflammation of the GIT may lead to 
inflammatory conditions of the liver and the development of diseases such as non-alcoholic fatty 
liver disease (NAFLD).  
 
The first study in this thesis examined the effects of a multi–strain probiotics supplement that was 
administered to mice prone to tumour development (atm-/-) and housed in a ‘dirty’ environment. 
This study proved unsuccessful due to uncontrollable changes in animal housing conditions. The 
changes limited the exposure of mice to pathogens that have previously been reported to accelerate 
tumour development. The second study investigated the effects of a multi–strain probiotics 
supplement that was administered to mice fed a high fat diet (HFD). The results suggested that the 
multi–strain probiotic investigated may assist with reducing HFD induced steatosis and lipid 
disposal by reducing the accumulation of fat deposits in the liver and preventing reductions in tight 
junction proteins ZO-1 and ZO-2. The third study investigated the effectiveness of a multi–strain 
probiotics supplement in mice on a HFD that were prone to iron overload (hemochromatosis). This 
study showed that a multi-strain probiotic supplement had reduced efficacy in the presence of high 
iron concentrations. Probiotics fed to hfe-/- mice partly rescued genes involved in lipid metabolism 
(Cpt1, Lfabp, AdipoR2), hepatic iron concentration, proteins involved in iron uptake (Tfr2), serum 
ALT, AST and triglycerides. However, probiotics did not alter serum cholesterol, hepatic lipid 
peroxidation, triglycerides, genes involved in lipid metabolism (PPAR-α, PPAR-γ, LDLr, CD36) 
and proteins involved in iron uptake (Tfr1). The fourth study investigated the effectiveness of 
curcumin, vitamin E or a combination of the two in both wild type and mice prone to iron overload 
(hemochromatosis). The combination of curcumin (CU) and vitamin E (VE) proved to be the most 
effective for reducing the effects of a HFD. Curcumin plus vitamin E (CUVE) reduced total body 
and liver weight and reduced the severity of steatosis and liver injury. Treatment groups CU or VE 
alone showed reduced fat deposits; however, the combination treatment, CUVE, resulted in a 
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greater reduction of both macro- and micro-vesicular fat deposits and the degree of change was 
similar to the chow group. However, nothing compared with simply returning the animals to a 
healthy, balanced diet. Removal of the HFD resulted in a reduction of body and liver weight and a 
return to normal liver pathology in 80-90% of mice.  
 
These findings propose that neither probiotics, curcumin, vitamin E or a combination treatment is a 
panacea for over consumption of calories through a high saturated fat diet in the hope of down–
regulating GIT inflammation and or liver fatty acid metabolism. However, they may provide a 
therapeutic measure whereby there is a significant reduction in risk for NAFLD progression.  
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Chapter 1  
Literature review 
Probiotics as a prophylactic and therapeutic intervention for intestinal 
inflammation 
 
1.1. ABSTRACT 
Probiotic bacterial species can modify the milieu of the gastrointestinal tract, by reducing the 
triggers that can induce inflammatory episodes in conditions such as inflammatory bowel disease 
(IBD) and irritable bowel syndrome (IBS). The microbiota acts in an immuno-surveillance capacity, 
detecting pathogenic bacteria with resulting stimulation of local innate immune inflammatory 
responses that clear the pathogenic cells. I have conducted a systematic literature review to evaluate 
the efficacy of probiotics treatment in modulating the inflammatory responses and cellular 
signalling pathways that regulate the pathophysiology of intestinal inflammation specifically in IBD 
and IBS. Evidence exists that probiotics can enhance intestinal permeability, control the synthesis 
of pro-inflammatory and anti-inflammatory mediators. Almost all probiotic strains tested induced a 
beneficial effect on inflammation. The weight of the evidence supports that treatment with 
probiotics benefit patients with both IBD and IBS, in part by reducing the synthesis of pro-
inflammatory cytokines (e.g., IL-17, IFN-γ, TNF-α and IL-12) and increasing the synthesis of anti-
inflammatory cytokines (e.g., IL-27 and IL-10). This effect, I postulate is a rescuing of pathological 
inflammation toward normal, which the gastrointestinal tract (GIT) is subjected to throughout life. 
The magnitude of the effect, and the most effective species and strains remain equivocal. Probiotics 
are effective as either a prophylactic or therapeutic intervention, but they appear more effective 
when used prophylactically, and with a mixture of strains. Further research is required to investigate 
and understand the metabolic and signalling mechanisms of probiotics in greater detail, particularly 
in the IBD model. Such effort will help to develop better efficacy of treatment with probiotics, and 
to establish the optimal dose and duration of treatment.  
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1.2. INTRODUCTION 
The human GIT contains more than 1,000 different commensal bacterial species.1-4 Commensal 
bacteria perform a number of functions such as  (i) regulating the normal development and function 
of the mucosal barrier function5; (ii) assisting the maturation of immunological tissues, which in 
turn promotes immunological tolerance to antigens from foods or pathogenic organisms6; (iii) 
controlling nutrient uptake and metabolism,7, 8 and (iv) preventing the propagation of pathogenic 
micro-organisms.9 Changes in the number of commensal bacteria may reduce their function, and 
alter the GI immune response. 
 
Immune responses are necessary to reduce the GIT concentration of pathogenic cells. The immune 
system does this by initiating a pro-inflammatory response. The microbiota acts in part in an 
immuno-surveillance role detecting pathogenic bacteria, stimulating the immune system, and 
subsequently initiating an appropriate regulated inflammatory response. Once the overload of 
pathogenic cells have been cleared, anti-inflammatory signals are switched on to restore the pro-
inflammatory response back to normal. Accordingly, the gut is in a constant state of ‘regulated 
inflammation’. The role that microbiota play in triggering the anti-inflammatory response is still 
unclear. Failure to ‘re-regulate’ inflammatory responses increases the risk of developing 
inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS). 
 
IBD comprises a group of inflammatory conditions of the colon and small intestine. The etiology of 
IBD is not fully understood, but it is considered to be a T-cell-driven inflammation resulting from a 
persistent preponderance of pro- over anti-inflammatory cytokine production.10 Crohn’s disease and 
ulcerative colitis are the two main types of IBD.11 Crohn’s disease and ulcerative colitis differ in the 
nature and location of the affected part of the GIT. Crohn’s disease is driven by T-helper 1 (TH1) 
immune responses,12, 13 and can affect any part of the GIT, from the mouth to the anus. In contrast, 
ulcerative colitis is T-helper 2 (TH2) driven, and is restricted to the mucosa of the colon and 
rectum.12, 14 Alternatively, IBS is a functional bowel disorder affecting mostly the large intestine. 
While the cause remains unknown, symptoms including abdominal pain, diarrhea and constipation. 
It has however been presented that disruption to the gut microbiome may result in altered bowel 
function.15   
 
Accumulating evidence indicates that the balance of commensal bacteria within the GIT may be 
associated with the development of some GI disorders16. Patients with IBD or IBS present with 
increased numbers of the pro-inflammatory bacteroids,16 Escherichia coli,17, 18 enterococci and 
decreased Bifidobacterium and Lactobacillus species.19, 20 IBD is one of the more prevalent GI 
3 
disorders, with a prevalence of 206 cases per 100,000 in Switzerland,7, 21, 22 61,000 affected in 
Australia 23 (about 290 per 100,000), and 388 per 100,000 in the USA.24 
 
The past 50 years has witnessed an increase in the prevalence of autoimmune diseases.25 The 
hygiene hypothesis provides a biologically plausible explanation for this trend that implicates a loss 
or diminished early childhood infectivity with an enhanced risk for later life GIT inflammatory 
problems such as autoimmune diseases.26 With the increasing prevalence of GI diseases, and 
bacteria resistant to antibiotic medications,27 multi-strain probiotics may significantly reduce the 
risk of developing GI diseases by promoting restoration of GIT commensal bacteria balance 
Probiotics are live microorganisms that when administered in adequate amounts confer health 
benefits to the host.28 The mechanisms through which probiotics reduce inflammation are complex 
and diverse, and depend on a number of factors that include strain specificity, dosage, the presence 
and concentration of other bacteria, and the specific disease state of the individual. One mechanism 
through which probiotics act is by regulating cell signalling pathways that mediate the production of 
pro- and anti-inflammatory cytokines. 
 
Probiotic research is still in its infancy; interpreting the results of currently available publications 
can be equivocal. Some of the problems associated with probiotic research include a great deal of 
variability regarding: (a) the specific strains or combination of strains used; (b) the dosages 
administered; (c) the models used (cell, animal or human); (d) the number, age and sex of 
participants; (e) the timing of when the dose is administered, and the study design (e.g., blinded vs. 
non-blinded). 
 
The aim of this review is to review the literature investigating the effects of probiotics on 
inflammatory and cellular signalling pathways, specifically in the gastrointestinal tract of IBD and 
IBS models. IBD and IBS are two distinct disorders with clinical and biological variations; 
however, the main focus is on the common underlying mechanisms of each disease, as opposed to 
the disease symptoms. 
 
In the first section I discuss the in vivo response to probiotics with no inflammation present. The 
second section discusses in vitro and in vivo response when probiotics are administered 
simultaneously as inflammation occurs. The third section discusses the prophylactic effects of 
probiotics, and the fourth section details the therapeutic effects of probiotics. Each section is further 
divided into sub-sections covering probiotics applied to cells, animals and humans. 
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1.3. PROBIOTICS ADMINISTERED IN THE ABSENCE OF INFLAMMATION 
To understand the mechanisms by which probiotics function, it is necessary to evaluate the effects 
of probiotics in the absence of inflammation. The following section discusses the response to 
probiotics, including the cytokine and signalling response and GI tissue morphology in cell culture 
models or animals without inflammation. The results of studies using no inflammatory stimulation 
are summarised in Table 1. 
 
1.3.1. Probiotics in cell cultures 
Cell culture studies incorporate a diverse range of experimental conditions. The cell lines presented 
in this section are: Caco-2, HeLa, T84 (human) and IEC-6 (rat) cells. These cell lines were used to 
investigate the effects of probiotics on the Nedd8 pathway. 
 
Kumar and colleagues29 investigated the effects of L. rhamnosus, Bacteroides thetaiotaomicron, 
and E. coli stimulation on Caco-2, HeLa, T84 (human) and IEC-6 (rat) cells. Bacterial stimulation 
oxidized both thioredoxin-1 (Trx1) and glutathione (GSH) (two major antioxidant systems), with L. 
rhamnosus inducing the greatest change. Further supporting a bacterial induced increase in reactive 
oxygen species (ROS), L. rhamnosus rapidly increased luminol chemiluminescence in these cells. 
An increase in ROS causes oxidative inactivation of the Nedd8-conjugating enzyme (catalytic 
cysteine residue of Ubc12), leading to a loss of Cul-1 neddylation. Neddylation is the process that 
conjugates Nedd8 to the conserved lysines of cullins (Cul-1 and Cul-3).30 Co-culture of the 
epithelial cells with L. rhamnosus reduced Cul-1 neddylation within 30 minutes compared with 
control cells. Reduced Cul-1 neddylation blocks the NF-κB pathway,31 and is therefore an important 
process that regulates inflammation. Pre-treating epithelial cells with the antioxidant N-
acetylcysteine (NAC) or diphenyliodonium (DPI) maintained Cul-1 neddylation when the cells 
were colonised with commensal bacteria (Figure 1.1).  
 
These results indicate that if the inflammatory response is dysregulated, as is the case in IBD and 
IBS, bacterial stimulation may help to re-regulate the inflammation by reducing Cul-1 neddylation 
and blocking the NF-κB pathway. ROS appear to inactivate the Nedd8-conjugating enzyme, 
thereby preventing Cul-1 neddylation and subsequent activation of NF-κB. Unregulated production 
of ROS may also create a state of oxidative stress, however. Oxidative stress can increase 
inflammation by activating various inflammatory pathways, including the NF-κB pathway. 32 
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1.3.2. Probiotics in healthy animals 
Animal models provide much of the current understanding of how probiotics influence intestinal 
inflammation. The animal models presented below include: BALB/c, germ free wild type (WT) and 
germ free IL-10 knockout (KO) mice. These models were used to test the effects of probiotics on 
the Nedd8 pathway, cytokine producing cells and the histology of the intestinal tract. 
Supporting their in vitro findings, Kumar and colleagues29 investigated the effects of L. rhamnosus, 
Bacteroides thetaiotaomicron, and E. coli stimulation in female BALB/c mice. L. rhamnosus, and 
to a lesser extent B. thetaiotaomicron, increased ROS in the mucosa of the small bowel 30 minutes 
after oral or rectal inoculation of bacteria. L. rhamnosus administered into the ileal loops of mice 
attenuated Cul-1 neddylation in mucosal lysates within 30 minutes. 
 
Demonstrating the disparity in the effects between differing strains of bacteria, Maassen and 
colleagues33 administered eight individual strains of Lactobacillus to female BALB/c mice resulting 
in a number of immunomodulatory responses. Immunohistochemical analysis of cytokine-
producing cells in the gut villi showed that all eight probiotics did not significantly alter the 
concentration of IL-1α, IL-4, IL-10 and IFN-γ producing cells. In contrast, with the exception of L. 
fermentum, all probiotic strains increased the concentration of TNF-α producing cells. L. reuteri and 
L. brevis increased the concentration of IL-2 cytokine-producing cells, and L. reuteri alone 
increased the concentration of IL-1β cytokine-producing cells. These strains therefore appeared to 
promote a TH1 cytokine response, which favours cell-mediated immune reactions. 
 
Investigating the effects of administering probiotics in an environment lacking in natural 
microbiota, Moran and colleagues34 applied B. animalis, B. infantis or B. bifidum to germ free WT 
and germ free IL-10 KO mice. Compared with WT mice, probiotics caused considerable thickening 
of the duodena, with massive cellular infiltration of mononuclear cells into the lamina propria 
(including the villi) and significant crypt hyperplasia in IL-10 KO mice. The mucosa was altered by 
the formation of abnormal crypt and villus structures consisting of branched and fused villi. 
Mucosal ulceration was localised to the duodenum. Colonic explants from IL-10 KO mice also 
spontaneously released higher amounts of IL-12/IL-23 p40.  
 
These findings highlight the importance of IL-10 in preventing and regulating inflammatory 
responses to bacteria as well as demonstrating that in a susceptible host, some probiotic bacteria 
strains may be potentially pathogenic. Taken together, these results indicate that depending on the 
model, probiotic administration have very diverse effects, even when strains from the same genus 
are administered. 
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1.4. PROBIOTICS APPLIED SIMULTANEOUSLY WITH INFLAMMATORY STIMULANTS 
The following section discusses probiotics applied simultaneously with inflammatory stimuli. The 
probiotics assessed in this section include: L. casei , Escherichia coli Nissle 1917, B. breve, B. 
adolescentis, B. longum, L. paracasei, L. plantarum, L. rhamnosus GG, S. Boulardii and a 
combination of S. thermophilus, L. acidophilus and B. lactis. The experimental models used include 
T84, Caco-2, RAW264.7 and CD4+ T cells, male Sprague-Dawley and Wistar rats and IL-10 KO 
mice. The inflammatory stimulants used in these studies included trinitrobenzene sulfonic acid 
(TNBS), TNF-α, IL-6, lipopolysaccharide (LPS) and dextran sodium sulphate (DSS). The efficacy 
of probiotics was assessed by measuring in vitro and in vivo cytokine production (IL-1β, IL-6, IL-8, 
IL-10, IL-12, TNF-α, INF-γ and SOCS proteins), intestinal permeability, junctional complex 
properties (ZO-1, PKC-ζ) and histology scoring of the intestinal tract for inflammation. The results 
are summarised in Table 2. 
 
1.4.1. Probiotics in cell cultures 
A significant problem for treating IBD and IBS is that the precise aetiology of these diseases 
remains unclear. A number of mechanisms are proposed to contribute to the development and 
progression of the disease. One such mechanism is degradation of the intestinal epithelial barrier 
leading to an increase in intestinal permeability. Enteropathogenic Escherichia coli (EPEC) has 
been shown to reduce transepithelial resistance by down-regulating and redistributing the tight 
junction proteins ZO-135 and ZO-236 away from the cell membrane and translocating the protein 
kinase C - ζ (PKC-ζ) away from the cytosol.36 Regardless of the timing of application, in T84 cells 
infected with EPEC and treated with 1 × 107 and 1 × 108 cfu/mL (colony forming units) of L. casei, 
ZO-1 staining was well-defined at the cell membrane and transepithelial resistance values were 
similar to non-stimulated cells. In contrast, in T84 cells stimulated with EPEC, and a lower dose (1 
× 106 cfu/mL) of L. casei, ZO-1 staining and transepithelial resistance was similar to cells 
stimulated with EPEC alone. Incubation with 1 × 106 or 1 × 107 cfu/mL of L. casei did not inhibit 
EPEC adhesion.35 Addition of the probiotic Escherichia coli Nissle 1917 (EcN) with EPEC blocked 
PKC-ζ from translocating to the membrane, and maintained transepithelial resistance.36 
 
The work of Parassol et al.35 and Zyrek et al.36 support the notion that increased intestinal 
permeability resulting from the translocation of PKC-ζ, ZO-1 and ZO-2 may initiate or promote  
dysregulated inflammation. Translocation of the proteins away from the cell membrane or cytosol 
reduces the cell membrane integrity, thereby allowing pathogens to move freely through the 
epithelial barrier causing dysregulated inflammation. Maintaining PKC-ζ in the cytosol protects 
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tight junctions, and maintains barrier function by preventing the removal of tight junction protein 
complexes.37, 38 Treatment of T84 and Caco-2 cells with probiotics helped to restore or maintain 
PKC-ζ within the cytosol and ZO-1 and ZO-2 to the tight junction complexes, thereby restoring the 
epithelial barrier function in EPEC-stimulated cells. Regardless of the timing, incubation with EcN 
or L. casei following or during EPEC infection restored the integrity of the epithelial cell barrier 
and redistributed ZO-2 to the cell boundary (figure 1.2).35, 36 
 
Okada and colleagues39 stimulated RAW264.7 cells with LPS, Enterococcus faecalis or LPS + E. 
faecalis. Stimulation significantly increased IL-1β, IL-12p40 and TNF-α synthesis, and reduced IL-
10 production. Simultaneous addition of B. breve or B. adolescentis blocked the production of IL-
1β in response to LPS, but increased TNF-α production. B. breve and B. longum attenuated the 
production of IL-12p40. When cells were co-cultured with B. breve plus LPS, IL-10 production 
increased significantly above the untreated cells, or cells treated with LPS, or LPS + E. faecalis. All 
Bifidobacterium strains suppressed IκB-α phosphorylation in response to LPS, whereas B. breve 
and B. longum suppressed IκB-α phosphorylation induced by LPS, E. faecalis or LPS + E. faecalis. 
Exposure to LPS alone increased mRNA levels of SOCS1 and SOCS3. Exposure to 
Bifidobacterium species further increased the expression of SOCS1 and SOCS3. B. longum has also 
been shown to reduce tissue supernatant production of TNF-α and IL-8 and NF-κB p65 expression 
in Lamina propria mononuclear (LPMC) cells derived from mucosal biopsies collected from 
patients diagnosed with ulcerative colitis40. 
 
Demonstrating that the effects of probiotics on cytokine production may rely on enhancement of 
additional signalling molecules, Reilly and colleagues41 investigated the effects of L. paracasei 
subsp. paracasei F19 or L. plantarum 2362 on Caco-2 cells treated with IL-1β or TNF-α. Treatment 
with IL-1β increased spontaneous IL-6 and IL-8 production. Co-culture of live or heat-inactivated 
L. paracasei or L. plantarum with IL-1β substantially increased IL-6 production above IL-1β 
treatment alone, but did not alter IL-8 synthesis. Further analysis showed that treatment with L. 
paracasei increased cellular levels of heat-shock protein 70 (HSP70) and HSP27. IL-1β treatment 
either alone or in combination with L. paracasei did not alter HSP expression. Silencing of the HSP 
genes reduced or blocked the L. paracasei-stimulated production of IL-6. 
 
Isolating intestinal CD4+ T cells from healthy individuals and patients with Crohn’s disease, Hvas 
and colleagues10 showed an imbalance in the production of pro- and anti-inflammatory cytokines. 
Following co-culture with autologous dendritic cells, intestinal T cells from patients with Crohn’s 
disease produced high levels of IFN-γ and low levels of IL-10. Conversely, T cells from healthy 
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individuals produced less IFN-γ but more IL-10. Subsequent incubation of T cells with L. 
rhamnosus GG alone or L. rhamnosus GG combined with L. acidophilus only reduced IFN-γ 
production in cells from the healthy individuals. These divergent cytokine responses indicate an 
imbalance in the pro- and anti-inflammatory cytokine response in patients with Crohn’s disease. A 
higher dose or different combination of probiotics may be required to normalise the cytokine 
response in cells from patients with Crohn’s disease. 
 
These results indicate that applying probiotics in adequate doses appears to prevent the detrimental 
effects of pathogens. Probiotics restore the integrity of the epithelial membrane in several ways by: 
(i) helping to retain restore ZO-1 and ZO-2 at the cell membrane, (ii) preventing PKC-ζ 
translocation to the membrane, (iii) increasing anti-inflammatory and reducing pro-inflammatory 
cytokines, (iv) reducing IκB-α phosphorylation induced by pathogens, and (v) increasing HSP 
(Figures 1.1 and 1.2). 
 
1.4.2. Probiotics in animal models of intestinal inflammation 
Simultaneously initiating inflammation and administering probiotics, Lee and colleagues42 
investigated the effects of S. Boulardii in male Sprague-Dawley rats. Compared with rats receiving 
TNBS alone, S. Boulardii treatment restored the histological appearance and the mass/length of the 
colon. S. Boulardii administered simultaneously with TNBS suppressed or abolished the down-
regulation of PPAR-γ mRNA, and up-regulation of IL-8, IL-1β, IL-6, IL-8R, TNF-α and iNOS 
mRNA in the colon tissue that occurred in response to TNBS. Similarly, Schultz and colleagues43 
found that compared with untreated IL-10 KO mice, simultaneous or pre-treatment with L. 
plantarum 299v reduced diarrhoea, improved total colonic, rectal and cecal histology scores, and 
attenuated spontaneous colonic mucosal production of IL-12 and IFN-γ by anti-CD3 stimulated 
mesenteric lymph node (MLN) cells. 
 
Demonstrating the importance of bacteria colonisation, Amit-Romach and colleagues44 investigated 
L. GG and a combination of S. thermophilus, L. acidophilus and B. lactis (YO-MIX™ Y 109 FRO 
1000) in male Wistar rats. Experimental colitis (using TNBS) resulted in macroscopic damage, with 
diarrhoea, shortening and thickening of the colon and severe disruption of the normal architecture 
of the colon, extensive ulceration and inflammation of all of its layers. YO-MIX™ only minimally 
improved the pathophysiology of colonic tissue, whereas L. GG significantly improved colonic 
tissue architecture. The degree of colonic inflammation was shown to be related to the colonisation 
of certain bacteria. Following TNBS induction the faecal concentration of Bifidobacteria and 
Lactobacillus bacteria did not significantly change relative to the controls. The appearance of E. 
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coli strains and Aeromonas was increased however. L. GG treatment slightly increased the amount 
of Lactobacillus bacteria but tended to reduce the propagation of E. coli and Aeromonas. Whereas 
YO-MIX™ raised Bifidobacteria bacteria compared with all other groups but had variability in the 
colonization of E. coli and Aeromonas. These findings illustrate the relationship between changes in 
microbiota and pathogenic bacteria populations and inflammation of the intestinal tract, and the 
importance of restoring the microbiota populations. 
 
Applying probiotics with an inflammatory agent showed that probiotics may prevent the detrimental 
effects of TNBS and DSS in mice and rats. This is achieved by improving both the appearance and 
histology score of the colon, preventing weight loss and the severity/onset of diarrhoea, increasing 
the expression of tight junction proteins such as ZO-1, reducing the production of pro-inflammatory 
cytokines IL-12 and INF-γ, and changing the bacterial composition of the faecal matter. 
 
1.5. PROBIOTICS APPLIED PROPHYLACTICALLY 
The issue of whether probiotics work better as a prophylactic or therapeutic intervention in patients 
with IBD is important to consider. Prophylactic treatment with probiotics is important for 
individuals with a genetic predisposition for IBD, or individuals in remission from IBS or IBD. 
Probiotics can act in a prophylactic fashion by colonising the GIT and counteracting inflammation 
caused by invading pathogens by regulating pro- and anti-inflammatory cytokine production, and 
improving the integrity of the intestinal barrier. The results of prophylactic studies are presented in 
Table 3. 
 
1.5.1. Prophylactic effects of probiotics in cell cultures 
Cell lines presented in the following section include HT-29, Caco-2, T84, colo329, SW480, 
RAW264.7 and young adult mouse colon cells. These cells were stimulated using gastrin or pro-
inflammatory cytokines INF-γ, TNF-α or IL-1β. The efficacy of probiotics was established by 
measuring changes in IL-8 synthesis, cytoskeletal and tight junction proteins, transepithelial 
resistance, PPAR-γ, COX-2 promoter activity and protein, PGE2 and NF-κB activity. In two 
separate studies, Resta-Lenert and colleagues45, 46 investigated the effects of S. thermophilus, L. 
acidophilus, a commensal bacterium or Bacteroides thetaiotaomicron on IFN-γ45, TNF-α45 or 
enteroinvasive Escherichia coli (EIEC)46 treated HT2945, 46 and Caco-245 cells. IFN-γ stimulation 
alone reduced forskolin-stimulated chloride secretion, cystic fibrosis transmembrane conductance 
regulator (CFTR) expression, and Na-K-Cl cotransporter expression. IFN-γ or TNF-α stimulation 
significantly reduced transepithelial resistance. Simultaneous treatment of cells with live bacteria 
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plus IFN-γ or TNF-α, or pre-treatment with heat-inactivated bacteria failed to modify the effects of 
IFN-γ or TNF-α. Pre-treatment with live S. thermophilus or L. acidophilus, however, protected 
against the effects of IFN-γ or TNF-α stimulation.45 Treatment with S. thermophilus and L. 
acidophilus maintained or increased the phosphorylation of cytoskeletal and tight junction proteins, 
and helped to maintain transepithelial resistance following EIEC stimulation. By contrast, pre-
treatment using S. thermophilus + L. acidophilus was superior. S. thermophilus + L. acidophilus 
also significantly limited adhesion, and physiological dysfunction induced by EIEC.46 
 
Together with the findings of Resta-Lenert and Barrett46, Otte and colleagues47 show the benefits of 
multi-strain probiotics compared with a single strain of probiotics. Stimulating the human colon 
cancer cell lines Colo329 and SW480 showed an increased COX-2 promoter activity when exposed 
to gastrin (up to 8-fold) or TNF-α (up to 3-fold). In a dose- and time-dependent manner, L. 
acidophilus applied alone increased COX-2 promoter activity, COX-2 protein expression and PGE2 
secretion. L. acidophilus applied prior to gastrin or TNF-α further enhanced COX-2 promoter 
activity and PGE2 secretion compared with gastrin or TNF-α alone. Conversely, the probiotic EcN 
and VSL#3 (a combination of 3 strains of Bifidobacterium, 4 strains of Lactobacillus and 
Streptococcus thermophilus) reduced COX-2 expression and PGE2 secretion. 
 
Lee and colleagues42 administered S. Boulardii to HT-29 cells treated with TNF-α or IL-1β. 
Compared with control cells, pre-treating HT-29 cells with S. Boulardii increased mRNA 
expression of PPAR-γ, decreased IL-8 expression and suppressed nuclear translocation of NF-κB in 
response to TNF-α stimulation. siRNA-mediated knockdown of PPAR-γ abolished the effects of S. 
Boulardii, indicating that PPAR-γ plays a crucial role in suppressing pro-inflammatory cytokine 
synthesis. PPAR-γ is primarily found in adipose tissue. However, it is also expressed in high levels 
in the colon, stomach and small intestine mainly by epithelial cells, stellate cells, 
monocytes/macrophages, Kupffer cells, dendritic cells (DCs), and B and T cells.48 The molecular 
mechanisms mediating the anti-inflammatory action of the PPAR-γ/RXR heterodimer are not fully 
understood at present. Activation of PPAR-γ may interfere with several signalling pathways 
regulating the expression of pro-inflammatory genes, such as those controlled by NF-κB, activating 
protein 1 (AP-1) and signal transducers and activators of transcription (STATs).49, 50 PPAR-γ 
therefore may modulate the production of inflammatory cytokines, chemokines and cell-adhesion 
molecules limiting the recruitment of inflammatory cells and promoting an anti-inflammatory 
state.49  
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The probiotic strain L. reuteri has also been shown to reduce IL-8 production in various cell lines. 
Ma and colleagues51 stimulated T84, HT-29 and Caco-2 cell lines with TNF-α. Pre-incubation of 
cells with 1 × 107 cells/mL L. reuteri significantly inhibited but did not completely block IL-8 
production in response to TNF-α stimulation. When T84 cells were incubated with L. reuteri (1 × 
107 cells/mL) and TNF-α simultaneously, IL-8 synthesis was similar to that of TNF-α stimulation 
alone. 
 
Investigating the mechanisms by which probiotics reduce NF-κB activation, Petrof and colleagues52 
administered L. plantarum, L. paracasei or L. acidophilus to murine RAW 264.7 macrophage and 
young adult mouse colon cells. Medium conditioned with L. plantarum inhibited NF-κB binding 
activity and degradation of IκBα in response to stimulation with TNF-α. Further analysis showed 
that this effect was due to less binding of the p50/p65 subunits of NF-κB (Figure 1.2). In turn, this 
effect attenuated the synthesis of monocyte chemotactic protein-1 (MCP-1). 
 
Together, the results from applying probiotics prophylactically to cell lines indicate the importance 
of timing and dose of probiotic therapy. The results indicated that probiotic treatment of cells was 
more effective when applied prophylactically compared with the simultaneous application with an 
inflammatory agent. Multi-strain probiotics also proved superior in reducing inflammation 
compared with single strains. 
 
1.5.2. Prophylactic effects of probiotics in animals 
The following section provides a summary of the prophylactic effects of various probiotic strains. 
The models include BALB/c, ICR, IL-10 KO, C57BL/6, C57BL/10J mice and female Wistar rats. 
Analysis included body mass, colon appearance, inflammatory scores, changes to dendritic cell 
migration, cytokine production (IL- 1β, IL-2, IL-4, IL-10, IL-12, TNF-α), PGE2, MyD88, 
myeloperoxidase (MPO), iNOS, COX-2 and glycosaminoglycan production. 
 
Kamada and colleagues53 investigated the effects of EcN in pathogen-free C57BL/6 and IL-10 KO 
mice. Administration of DSS to C57BL/6 mice caused loss of body mass, the shortening and 
thickening of the colon, increased disease activity index scores and colon mass, severe ulceration 
and inflammatory cell infiltration over the proximal and distal region of the colon. Treatment with 
EcN attenuated these effects of DSS. These results may indicate an increase in epithelial 
permeability following DSS administration allowing inflammatory cells to infiltrate the colon. This 
will lead to dysregulated inflammation and the observed effects on the colon. EcN has been shown 
to alter tight junction proteins to maintain transepithelial resistance.36 In IL-10 KO mice, treatment 
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with EcN reduced colon mass and spontaneous production of IFN-γ and macrophage inflammatory 
protein (MIP)-2 from lamina propria mononuclear cells. L. salivarius subspecies salivarius 433118 
and B. infantis 35624 showed similar effects in IL-10 KO mice. McCarthy et al.22 showed that both 
probiotic strains reduced intestinal inflammation scores, and in vitro stimulation with B. infantis 
significantly reduced the production of IFN-γ, TNF-α and IL-12 in response to stimulation with 
Salmonella typhimurium. B. infantis was more effective for modulating cytokine production 
compared with L. salivarius, even though a lower dose was administered.  
 
Extending on from the DSS model of colitis, results from Lee and colleagues54 and Mane and 
colleagues55 show the ability of probiotics to confer similar effects over a variety of colitis models. 
Lee and colleagues54 administered 14 lactic acid bacteria (eight Lactobacillus and six 
Bifidobacterium strains) with Bacteroides stercoris — a bacterium that produces 
glycosaminoglycan degradation enzymes in male ICR mice. They showed most bacteria inhibited 
glycosaminoglycan degradation. Subsequent research showed that B. longum HY8004 and L. 
plantarum AK8-4 prevented or inhibited TNBS-induced colon shortening, inflammation, 
glycosaminoglycan degradation, IL-1β and TNF-α expression, MPO activity and activation of NF-
κB in colon homogenate samples.  
 
Mane and colleagues55 fed L. fermentum CECT 5716 to BALB/c mice prior to administering TNBS. 
Mice fed L. fermentum maintained greater body mass and developed more mild colitis (as indicated 
by a lower histology score) compared with control mice. The improvement was associated with an 
increase in PGE2, IL-2 and IL-4, in addition to lower nitrotyrosine staining (for protein oxidation). 
L. fermentum did not alter immunohistochemistry staining for MyD88 in colon explant cultures. 
Increased PGE2, IL-2 and IL-4 synthesis may improve IBD by initiating an appropriate early 
immune response, and by repairing and improving the integrity of the intestinal barrier through the 
activation of toll-like receptors (TLRs)56, COX-256 and proliferation of regulatory T cells.57 MyD88 
is an adaptive protein that may aid in the reduction of TNBS induced inflammation due to its role in 
TLR-2, TLR-4 and TLR-9 signalling and subsequent NF-κB activation.58 
 
Peran and colleagues59, 60 conducted consecutive studies investigating the prophylactic effects of 
probiotics [L. fermentum or L. reuteri60 and L. casei, L. acidophilus or B. lactis59] in female Wistar 
rats. Following TNBS administration, intestinal inflammation was evident as loss of body mass, 
anorexia and diarrhea in both studies. Probiotics did not prevent these effects, with the exception 
that diarrhoea decreased in response to treatment with L. fermentum60 and B. lactis.59 Rats 
administered probiotics presented fewer signs of mucosal inflammation, but only the rats 
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administered L. fermentum or L. acidophilus showed significantly lower colonic damage scores (as 
indicated by a reduction in colonic necrosis and/or inflammation). Colonic MPO activity and 
adhesion of the colon to neighbouring organs were lower in rats treated with L. fermentum or L. 
acidophilus. TNBS increased colonic TNF-α, LTB4 and IL-1β60 expression, increased expression of 
iNOS and COX-2,59 and reduced IL-10 production.60 L. reuteri and L. fermentum administration 
reduced TNF-α production, B. lactis significantly reduced colonic TNF-α, iNOS and COX-2 
expression, whereas L. acidophilus significantly reduced colonic LTB4 production and expression 
of iNOS. 
 
Dendritic cells are a vital component for initiating an early immune response to foreign antigens. 
The interaction between probiotics and DC’s is largely unknown. Wang and colleagues61 
investigated the effects of VSL#3 on the distribution and phenotype of DCs in C57BL/10J mice. 
Administration of VSL#3 reduced the number of plasmacytoid DCs within the lamina, and 
increased the number of plasmacytoid DCs in the lymph nodes compared with the control group. In 
contrast, myeloid DC infiltration was greater in the control animals for all intestinal lymphoid tissue 
compartments compared with mice treated with VSL#3. These findings suggest that probiotics 
modulate the distribution of DCs, thus altering the immune response. How these responses might 
influence inflammation within the GIT is unknown. An extension to this research may include 
investigating the effects of probiotics and changes in DCs following DSS- or TNBS-induced 
inflammation. 
 
Extending the work of Resta-Lenert and Barrett,46 Roselli and colleagues62 investigated whether 
one combination of probiotics is more effective over another combination. One of two combinations 
of probiotics [(1) L. acidophilus Bar 13 and B. longum Bar 33 (2×109 cfu/mL), and (2) L. plantarum 
Bar 10, Streptococcus thermophilus Bar 20 and B. animalis subspecies lactis Bar 30 (3×109 
cfu/mL)] was applied to female BALB/c mice prior to administering TNBS. Both probiotic 
combinations reduced or prevented inflammation and loss of body mass following exposure to 
TNBS. The combination of L. acidophilus Bar 13 and B. longum Bar 33 prevented the systemic 
release of cytokines (IL-12, IFN-γ, TNF-α and MCP-1) and CD4+ T cells in the colon. In contrast, 
the combination of L. plantarum, S. thermophilus and B. animalis reduced the serum concentration 
of TNF-α and MCP-1. Both combinations of probiotics increased serum IL-10 concentration. 
Similar to the work of McCarthy and colleagues,22 the findings from this study also indicated that 
higher doses of probiotics were not more effective for modulating tissue inflammation compared 
with lower doses. 
 
14 
The prophylactic effect of probiotics in animals appears effective over a number of colitis models, 
but is strain-dependent. Various single probiotic strains prevent inflammation through a variety of 
cell signalling pathways. However, combining different single strains into a multi-strain probiotic is 
more effective, even at lower doses. The beneficial effects include altering the distribution of DC’s, 
improving the intestinal barrier via activation of TLR’s and decreasing pro-inflammatory cytokines 
(IFN-γ, TNF-α and IL-12) and increasing anti-inflammatory cytokines (IL-10). 
 
1.5.3. Prophylactic effects of probiotics in humans affected by IBD 
Guslandi and colleagues63 administered S. boulardii or a placebo to patients in remission with 
previously diagnosed Crohn’s disease in the past year. Following a 6-month course of probiotics, 
significantly fewer patients clinically relapsed compared with the control group. In contrast, 
supplementing patients with Crohn’s disease with L. rhamnosus strain GG or a placebo64, 65 resulted 
in no significant changes in the severity of Crohn’s disease. Patients relapsed in both the 
supplement and placebo groups.65 
 
The findings from these studies were limited by small sample size, and poor completion rates 
(~50%). Further investigation into the effects of probiotics in patients with IBD in remission is 
needed. Future research would benefit from an increased sample size and a more detailed analysis 
of inflammation variables from collection of blood and faecal matter, or where possible, intestinal 
tissue. 
 
1.6. PROBIOTICS APPLIED THERAPEUTICALLY 
Probiotics may function differently when inflammation is already present. The following section 
discusses the therapeutic effects of probiotics on monocyte-derived DCs, splenocytes and segments 
of distal colons from BALB/c mice. The efficacy of various probiotic strains was assessed by 
monitoring changes in existing inflammation, focusing on cell signalling, cytokine responses (IL-
1β, IL-4, IL-5, IL-6, IL-10, IL-12, IL-27 and TNF-α), symptoms and quality of life. The results of 
studies involving therapeutic interventions are summarised in Table 4. 
 
1.6.1. Therapeutic effects of probiotics in cell cultures 
The beneficial effects of probiotics on inflammation are fairly consistent when applied 
prophylactically. The therapeutic effects however appear to be more variable. Showing the 
variability between single strains of probiotics, Latvala and colleagues66 investigated the effects of 
L. rhamnosus GG and B. animalis subspecies lactis Bb12, in addition to seven bacterial strains with 
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potential probiotic characteristics. In monocyte-derived DCs from healthy individuals, stimulation 
with Streptococcus thermophilus (THS) increased the synthesis of TNF-α, IL-6, IL-12 and cytokine 
and chemokine (C-C motif) ligand 20 (CCL20). Incubation of monocyte-derived DCs with B. 
animalis or B. breve increased the production of TNF-α, IL-1β, IL-6, IL-10, IL-12 and IFN-γ. In 
contrast, L. rhamnosus and L. mesenteroides did not significantly alter cytokine production 
compared with control cells. All of the bacterial strains above altered CCL20 concentrations in a 
dose-dependent manner. Furthermore, all of the strains induced CCL20, whereas no strain induced 
CCL19. CCL19 and CCL20 play a unique role in the regulation of epithelial immunity. CCL19 and 
CCL20 are cytokines belonging to the CC chemokine family that attract cells of the immune 
system, particularly DCs, toward sites of inflammation. CCL20 is capable of inducing the most 
potent response, and is found in abundance in gut mucosa.67 CCL20 is up-regulated following 
inflammatory stimuli IL-1β and TNF-α or T cell signals.68 
 
Showing similar variability in the effectiveness of various probiotic strains, Tanabe and 
colleagues69 administered B. bifidum, B. catenulatum, B. infantis, L. acidophilus or L. bulgaricus to 
splenocytes isolated from female BALB/c mice, and segments of the distal colon tissue. Addition of 
TGF-β + IL-6 to splenocytes significantly increased IL-17 production, suppressed IL-4, IL-5, IL-12 
and IL-27 production and had no effect on IL-10. B. infantis suppressed IL-17 production, increased 
IL-10 production and partially restored IL-5, IL-12 and IL-27 synthesis. In contrast, B. bifidum, B. 
catenulatum, L. acidophilus and L. bulgaricus did not influence IL-17 production. DSS applied to 
segments of distal colon tissue enhanced IL-17 and eotaxin production in a dose-dependent manner, 
whereas production of IL-27 decreased slightly. All of the Bifidobacterium strains suppressed IL-17 
and eotaxin production in response to DSS. DSS markedly reduced IL-10 production, but B. infantis 
prevented this effect. 
 
These findings clearly illustrate the variable effects of different strains of probiotics. Some strains 
showed little or no effect when applied therapeutically to certain cell models. The results 
demonstrate that the effects of probiotics depend on the model and inflammatory agent. These 
results may begin to explain why the effects of one strain or mixture of probiotics may vary 
between subjects and between disease states (e.g. IBD vs. IBS, active vs. remission). 
 
1.6.2. Therapeutic effects of probiotics in animals 
The following section provides details on the therapeutic application of probiotics to BALB/c and 
IL-10 KO mice. Inflammation was assessed using cytokine production (IL-4 IL-6, IL-12p40, INF-γ 
and TNF-α) histology scoring for inflammation, MyD88 and MPO activity. In addition to their 
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prophylactic study, Mane and colleagues55 fed L. fermentum CECT 5716 to BALB/c mice after 
TNBS was administered. Body mass was similar in mice fed L. fermentum after TNBS treatment 
compared with control mice; however, body mass recovered more rapidly in mice treated with L. 
fermentum. In response to TNBS, histology scores were lower in mice fed L. fermentum at weeks 
two and three compared with control mice. IL-6 synthesis from cultured colon explants was also 
lower in mice fed L. fermentum at week two compared with the control group. 
Immunohistochemistry staining for MyD88 was greater in colon explants cultures from mice fed L. 
fermentum compared with control animals at week 2, but the difference was much less apparent by 
week three. Together with the prophylactic data, these results demonstrate that L. fermentum CECT 
5716 is effective as both a prophylactic or therapeutic intervention. Their results also indicate that 
probiotics may exert their effects at different points along the TLR cell signalling pathways. 
Prophylactically, probiotics activated pro- and anti-inflammatory mediators which initiate TLR-2, 
TLR-4 and appropriate immune responses, whereas therapeutically, probiotics increased MyD88 
concentration to achieve a similar (but potentially weaker) response. TLR’s (in particular TLR-2 
and TLR-4) play a central role in the immune response by detecting foreign substances and sending 
appropriate signals to the immune system. These signals can trigger the activation of NF-κB and the 
production of pro- or anti-inflammatory cytokines. 
 
Using a colitis model involving BALB/c mice with DSS induced colitis, Ukena et al.70 and Chen 
and colleagues71 both found probiotics of various strains [EcN70, E. faecalis, L. acidophilus, 
Clostridium butyricum or B. adolescentis71] were able to reduce, at least in part, the effects of 
colitis. Effects of DSS-induced colitis included: body mass loss,70, 71 higher disease activity index 
scores,71 shortening of the colon,70 reduced ZO-1 mRNA expression in IECs,70 increased leukocyte 
infiltration in the colon,70 increased Na+ absorption in the colonic mucosa,70 increased MPO 
activity71 and colonic IL-1β production, coupled with lower IL-4 production.71 All strains were 
effective in reducing the effects of colitis, EcN and E. faecalis proved most effective. 
 
The results of Chen and colleagues71 show that in the same model of colitis, different strains of 
probiotics are capable of achieving similar effects. When the model of colitis is changed however, 
so does the aetiology of the disease and the effects of probiotics. This is evident by Pena et al72 who 
found no change to IL-4 production when IL-10-deficient C57BL/6 mice were exposed to H. 
hepaticus. Pena et al72 isolated RNA from cecal tissue samples to asses mRNA expression of IL-4, 
IL-12p40, IFN-γ and TNF-α. IL-10 deficient mice with H. hepaticus stimulation had increased 
mRNA expression of TNF-α, IL-12p40, and IBD-like lesions, but no effect on IL-4. Administering 
L. paracasei 1602 and L. reuteri 6798 attenuated TNF-α and IL-12p40 mRNA expression, but did 
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not prevent formation of the IBD-like lesions. The probiotics also reduced cecocolic junction lesion 
scores in female mice, but not in male mice. In contrast, probiotics administered to mice without H. 
hepaticus showed no effect on cytokine production. 
 
Overall, the therapeutic effect of probiotics in animals appears to improve histology scores, increase 
the recovery of body mass and reduce pro-inflammatory cytokine production. The results support 
the notion that the same probiotic strain may not induce the same response from model to model, 
and that different probiotic strains may induce a different response or magnitude of response when 
applied within the same setting. 
 
1.6.3. Therapeutic effects of probiotics in patients with IBD 
The therapeutic effect of probiotics in patients with IBD is largely unknown because the majority of 
research has focused on IBS. Garcia Vilela and colleagues73 provided Saccharomyces boulardii to 
patients with Crohn’s disease and healthy volunteers. Patients with Crohn’s disease presented with 
increased intestinal permeability compared with healthy volunteers. Supplementation with 
Saccharomyces boulardii improved intestinal permeability in patients with Crohn’s disease 
compared with the placebo group. Probiotic treatment did not restore intestinal permeability 
completely, however. 
 
1.6.4. Therapeutic effects of probiotics in patients with IBS 
The following section evaluates the efficacy of probiotics in treating patients with existing IBS. The 
efficacy was assessed by comparing abdominal pain and discomfort, symptom scores for bowel 
habit satisfaction, flatulence and production of C-reactive protein (CRP) and cytokines (IL-2, IL-4, 
IL-6,IL-10, IL-12, IFN-γ and TNF-α,) before and after probiotics treatment. 
 
One of the problems with probiotic therapy is administering the ‘ideal’ dose. As each probiotic 
strain may require a different dose and different disease etiologies may require a different dose, 
finding the ‘ideal’ dose is complex. Whorwell and colleagues74 investigated the effects of three 
different doses of B. infantis 35624 (1 × 106, 1 × 108 & 1 × 1010 cfu/mL) in treating primary-care 
IBS patients. The dose of 1 × 108 cfu/mL proved superior in relieving abdominal pain compared 
with the placebo and other doses. Further investigation of the highest dosage demonstrated that the 
probiotics “coagulated” into a firm glue-like mass making them resistant to acid and agitation. The 
lowest dose of probiotics may not have been effective because of the duration of the study, or 
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insufficient biological activity. These findings highlight the potential importance of how probiotics 
are administered in order to maximise bioavailability within the GIT. 
 
To assess the efficacy of probiotics, improvements in disease symptoms is typically used due to its 
invasive nature. Probiotics have been shown to reduce abdominal pain and discomfort and symptom 
scores when patients with IBS when administered L. acidophilus75, L. plantarum 299V76 or 
ProSymbioflor (a combination of Escherichia coli DSM 17252 and E. faecalis DSM 16640)77 
compared to a placebo. In contrast, Drouault-Holowacz and colleagues78 found that B. longum LA 
101, L. acidophilus LA 102, L. lactis LA 103 and S. Thermophilus LA 104 were not superior to the 
placebo treatment in relieving disease symptoms due to a strong placebo effect. Probiotics 
supplementation did, however, significantly relieve abdominal pain to a greater extent compared 
with placebo treatment. Further analysis of the IBS sub-groups revealed that patients with 
alternating bowel habits reported significantly less abdominal pain, and patients with constipation-
predominant IBS reported less constipation. These results indicate that different disease aetiologies 
may exist between IBS sub groups and that some probiotics may be more efficient than others in 
treating symptoms within these sub groups. These results also point to the need to classify patients 
into relevant sub-groups when assessing the efficacy of probiotic therapy. 
 
A number of studies investigating the effects of probiotics within specific sub-groups of IBS have 
found beneficial effects of probiotics. Zeng and colleagues79 separated patients with IBS into sub-
groups, treating diarrhoea-predominant IBS (D-IBS) patients with S. thermophilus, L. bulgaricus, L. 
acidophilus and B. longum. The proportion of patients with increased small bowel permeability 
decreased significantly after treatment, and these patients also showed an improvement in their IBS 
score, abdominal pain and flatulence. Similarly, VSL#3 provided to subjects with either diarrhea-
predominant IBS (D-IBS)80 or IBS with bloating (B-IBS)81 was shown to reduce IBS symptoms. In 
subjects with B-IBS, VSL#3 reduced flatulence scores and retarded colonic transit time, without 
altering bowel function. In patients with D-IBS, VSL#3 only relieved abdominal bloating, with no 
effect on mean transit measures, bowel function scores or satisfactory relief of symptoms. VSL#3 
has also been shown to be superior to a placebo in children with IBS. VSL#3 supplementation 
improved overall IBS symptoms, abdominal pain/discomfort, abdominal bloating/gassiness and 
assessment of family life disruption.82 
 
To date, monitoring disease symptoms has been the most prevalent way to test the efficacy of 
probiotics in IBS and IBD patients. This subjective measure, usually assessed by the patient 
themselves, does not help to understand the underlying mechanisms of probiotics or the disease 
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aetiology. In an attempt to understand the physiological mechanisms of probiotics, Kajander and 
colleagues supplemented patients with IBS with LGG, L. rhamnosus LC705, B. breve Bb99 and P. 
freudenreichii ssp. shermanii JS in combination83 or L. rhamnosus GG, LGG, L. rhamnosus Lc705 
(DSM 7061), P. freudenreichii ssp. Shermanii JS (DSM 7067) and B. animalis ssp. lactis Bb12.84 
Serum C-reactive protein (CRP) and cytokine (IFN-γ, TNF-α, IL-2, IL-4, IL-6 and IL-10) 
concentrations were generally below the limit of detection, and therefore did not indicate any 
differences between the treatment groups.84 Both studies did, however, report an improvement in 
the IBS scores from baseline, particularly for distention and abdominal pain.  
 
In contrast with the benefits of probiotics in relieving IBS symptoms described above, some 
research has found few or no beneficial effects of probiotics. O’Mahony and colleagues85 showed 
disparity in the effects when providing L. salivarius UCC4331, B. infantis 35624 or a placebo to 
subjects with IBS and healthy volunteers. Following supplementation, the composite score (weeks 
1−8), pain/discomfort (weeks 1, 2, 4, 5, and 7), bloating/distention (weeks 2, 5, and 6) and bowel 
movement difficulty (weeks 2, 3, 5, and 6) was lower in the B. infantis group than in the placebo 
group. Composite score was only lower in the L. salivarius group than the control group in the 
second week of supplementation, indicating that the effects of L. salivarius are short-lived and 
intermittent. In vitro production of IL-10 and IL-12 by isolated mononuclear cells (peripheral blood 
mononuclear cells [PBMC]) from whole blood was dysregulated at baseline in patients with IBS. 
Patients with IBS had low levels of IL-10 and high levels of IL-12 synthesis compared with healthy 
volunteers. Supplementation with B. infantis restored IL-10 and IL-12 synthesis to levels similar to 
those observed in healthy volunteers. 
 
Adding to the lack of effect of probiotics, the placebo effect or natural healing cycle needs to be 
considered. Niv and colleagues86 provided L. reuteri ATCC 55730 or a placebo to subjects with 
IBS. Following supplementation, an improvement in IBS symptoms was reported, however, a 
similar response occurred in the placebo group. This may demonstrate a strong placebo effect or the 
natural healing cycle of the disease with IBD and IBS patients frequently entering periods of 
remission. 
 
Taken together, the therapeutic effect of probiotics in humans supports other benefits of probiotics. 
While some effects are inconsistent, probiotics treatment appears to reduce symptoms of IBS, 
particularly abdominal pain, and restore the balance of pro and anti-inflammatory cytokines. 
Separation of IBS into sub-classifications of disease confirmed that some probiotic strains may have 
effects that are symptom-specific. Combining selected stains of probiotics into a single multi-strain 
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probiotic blend appears to provide greater efficacy compared to the single strains alone. Based on 
these findings, further research is required looking more specifically at the various effects of each 
probiotic when applied to different disease classifications and in combination. To overcome 
potential placebo effects or inconsistent results, emphasis should be placed on sample size. Future 
research is vital to help find how and why probiotics are effective in each specific disease state. 
This in turn may help map the aetiology of particular inflammatory conditions, thereby helping to 
develop a prophylactic or therapeutic intervention. 
 
1.7. CONCLUSION 
Inflammation is a necessary physiological response by body tissues to injury, chemical irritation or 
an assault by pathogenic bacteria. Once the insult is neutralised, normal physiological function 
needs to be restored. For example, in the gastrointestinal tract an inflammatory response is elicited 
to clear pathogenic bacteria. Probiotic bacteria can then subsequently reduce the inflammatory 
response, thereby promoting a ‘regulated’ pro–anti inflammatory state, and assist in reducing the 
symptoms of conditions such as irritable bowel syndrome. The clinical evidence for these benefits 
is equivocal, however. This review indicates that probiotics provide both a prophylactic and 
therapeutic benefit in improving IBD and IBS by regulating cytokine and cell signalling pathways. 
Cell culture studies investigating probiotics used a range of cell lines, probiotic doses and 
inflammatory stimulants. The majority of studies employed similar cell culture conditions relating 
to incubation periods and dosage of probiotics and inflammatory stimulants. The concentrations of 
probiotics applied to cell cultures are similar to those concentrations typically recommended for 
human consumption. The amount of probiotics applied was, however, greater than the amount of 
viable probiotics that reach the intestines.87-89 A number of methodological issues are worth 
considering for the design of future studies, and I briefly discuss these issues below. 
 
1.7.1. Cell culture studies 
The predominant cell lines reviewed were Caco-2 and T84 cells. With the exception of one study 
reporting that Caco-2 cells are a less stable model of inflammation36, similar results were seen 
between all the different cell lines used. Applying probiotic strains to the different cell lines gave 
varying results. The weight of the evidence indicates that probiotics were beneficial in preventing or 
reducing inflammation, however. A reduction in inflammation was achieved through a number of 
mechanisms, including maintaining a strong transepithelial resistance and cell membrane integrity. 
Maintaining the cell membrane integrity increased the transepithelial resistance by restoring ZO-1 
and ZO-2 to the cell membrane and PKC-ζ to the cytosol. Another inflammatory mediator strongly 
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affected by probiotic stimulation was the production of cytokines. Regulation of cytokine 
production strongly influences the development and progression of inflammation. Regulation of 
pro- and anti-inflammatory cytokine production varied greatly between studies. Overall, probiotics 
reduced or prevented the production of pro-inflammatory cytokines and increased or maintained the 
production of anti-inflammatory cytokines.  
 
The specific effects of a probiotic strain varied depending on the model and mode of inflammation, 
however. L. acidophilus applied to HT29,45, 46 Caco-2, 45, 46 Colo329,47 SW480,47 Raw264.7,52 
YAMC cells52 and splenocytes69 resulted in no effects52, 69 increased TER,45, 46 modulated protein 
expression,45 increased COX-2 activity and PGE247 secretion. These differences highlight the 
variable and specific effects of probiotics in different models of inflammation. One explanation for 
the differences may come from the different signalling pathways responsible for inflammation. 
Each strain of probiotic appears to have a specific ability to up- or down-regulate specific 
inflammatory pathways. For example, inflammation resulting from a dysregulated Nedd8 pathway 
may require different strains of probiotics to re-regulate inflammation compared with inflammation 
resulting from dysregulated cytokine production. Inflammation stemming from a cytokine 
imbalance (pro- or anti-inflammatory) may require different strains of probiotic again, depending 
on the specific cytokine profile. 
 
In summary, all the cell lines presented are suitable models for inducing inflammation of the GIT. 
More important is the cause of inflammation and identifying the dysregulated pathways. Identifying 
the cause of inflammation assists in selecting appropriate probiotics to counteract inflammation. 
More work is warranted to examine the efficacy of specific probiotics in different cell lines and 
models of inflammation. 
 
1.7.2. Animal studies 
Probiotic studies involving animals have largely been conducted in mice. The use of multiple 
strains of mice and variations in probiotic strains, combinations, concentrations and 
supplementation periods make comparisons difficult. Induction of experimental colitis increased the 
expression of pro-inflammatory mediators (e.g., IL-1β, IL-12, IFN-γ and TNF-α). Data from several 
studies indicates that when strains of Lactobacillus, Bifidobacterium and/or Streptococcus bacteria 
are administered, anti-inflammatory mediators (e.g., IL-2, IL-4, IL-10 and MyD88) are up 
regulated39, 51, 55, 66, 69, whereas pro-inflammatory mediators (e.g., IL-1β, IL-6, IL-12, TNF-α and 
IFN-γ) are down regulated.10, 22, 39, 51, 55, 72 
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The most common animal models used were BALB/c, IL-10 KO and C57 background mice.  These 
strains of mice appear to differ with respect to the progression of inflammation. Melgar and 
colleagues reported that BALB/c mice recovered from DSS-induced colitis within four weeks upon 
cessation of DSS, while C57 mice continued to developed chronic colitis following cessation of 
DSS.90 C57 background mice may be more appropriate to use when inducing inflammation with 
DSS. Using a model that maintains a degree of inflammation is critical to help eliminate natural 
recovery from the results. 
 
Similar to cell culture experiments, the effects of probiotics vary between different models of 
inflammation in animals. Inflammation in animals is initiated using DSS, TNBS, Bacteroides 
stercoris, and deleting the IL-10 gene. TNBS is applied rectally which requires that the animal is 
anesthetised. Anesthetizing an animal adds additional stress and the enema procedure itself has the 
inherent risk of adding ‘artificial’ inflammation by causing damage and even perforating the 
intestinal lining. This undue stress to the animal may alter cell signalling, giving false results. The 
invasive nature of TNBS also means that it is difficult to apply multiple low doses of TNBS over a 
short period. Accordingly, typically one large dose is applied. DSS is given to the animal in their 
drinking water or by gavage. Using DSS removes the need for anesthesia, and allows treatment with 
low doses over a set time (in the water). IL-10 KO mice spontaneously develop colitis from 20 
weeks of age. These mice continue to develop chronic colitis, but are expensive and eliminate one 
of the key targets for probiotic activity. 
 
1.7.3. Human studies 
Transferring results from an animal model to a human model of inflammation is difficult. Due to 
the invasive nature of procedures required to collect tissue for analysis of gastrointestinal effects, 
most human studies have assessed the efficacy of probiotics in humans by evaluating changes in the 
quality of life, disease symptoms and pain scores. Crohn’s disease and IBS patients have been 
treated with probiotics prophylactically (in remission) or therapeutically (active disease). The 
majority of studies involving humans have been conducted as randomised controlled trials in a 
double-blind fashion. A small number of the studies failed to show any benefit of probiotics 
consumption; one of these reported the lack of effect due to a strong placebo effect.78 Overall, 
results indicate that probiotics relieve IBS symptoms (abdominal pain, flatulence, bloating and 
bowel habits) and reduce the number of relapses that occur. Clinical trials on the efficacy of 
probiotics are limited by subject availability. The invasive nature and duration of some studies, 
combined with strict inclusion criteria, make patient recruitment difficult. The restrictions imposed 
in some studies resulted in only 11 subjects participating, with only five completing the trial.65 
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Other studies have recruited sufficient numbers of subjects, but achieving a homogenous group has 
been difficult. Some studies have adjusted for the different disease classifications within the 
groups,78, 79, 81 whereas others have not. Several disease classifications and levels of severity exist 
for both IBD and IBS. The different disease classifications and severities may represent different 
aetiologies, which may respond differently to probiotics.  
 
1.8. Future directions 
Future directions for research may involve exploring the optimal doses of probiotics, duration of 
treatment, the effects in different models and suitability as a prophylactic or therapeutic treatment. 
Probiotics reach the intestinal tract, but the percentage of ingested viable bacteria that reach the 
intestinal tract is not well known. Studies aimed at calculating the amount of viable bacteria that 
reaches the intestines may be useful. There is a clear lack of evidence on the effect probiotics have 
on patients with IBD. While alleviating the symptoms of IBD and IBS is clinically relevant, future 
research may also benefit from collecting colon tissue from Crohn’s disease and ulcerative colitis 
subjects for analysis of gastrointestinal inflammation and bacterial adhesion. This would provide a 
better understanding of the underlying mechanisms of each condition and possibly lead to better 
treatment strategies. Ultimately, probiotic research may also need to examine the synergistic 
benefits associated with individual strains that are currently used in commercially available 
probiotic mixtures. 
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1.9. Figures 
 
Figure 1.1: A single epithelial cell demonstrating inflammatory signalling pathways that involves: I) 
The NEDD8 pathway leading to binding of NEDD8 and cullin and subsequent activation of the NF-
κB pathway. II) Example of one of the cytokine pathways and its receptor. III) Activation of NF-κB 
via an imbalance in RONS. IV) MyD88 pathway activated by pathogens binding to TLR leading to 
the IKK complex and NF-κB pathway. V) Translocation of the p50 and p65 subunits results in 
changes to the cells function, which may provide positive or negative feedback to the extracellular 
space. NF-κB activation may result in the feedback changing the cytokine response to regulate the 
inflammatory response in a positive or negative way. In cases of IBD, one or more of these 
pathways can be dys–regulated leading to excessive inflammation due in part to an over production 
or lack of termination of pro-inflammatory cytokine signals. Probiotics may reduce or prevent the 
resulting inflammation by: 1) blocking or reducing the binding of NEDD8 to cullin via regulated 
production of ROS inactivating UBC12 and 2) Prevent or reduce the phosphorylation of IκB-α, 
preventing the translocation of the p50 and p65 subunits to the nucleus.   
[This figure was constructed from the published data of: Collier-Hyams et al 2005; Wu et al 2005; 
Kabelitz et al 2006; Kumar et al 2007; Ivison et al 2010;  Hooper and Macpherson 2010. 
[IL: interleukin; RONS: reactive oxygen and nitrogen species; TH: T-helper; TLR: toll like 
receptor; NEMO: NF-κB essential modulator] 
 
Figure 1.2: A diagrammatic representation of part of the epithelial barrier of the gastrointestinal 
tract. I) Tight junction and gap junction between two epithelial cells. ZO translocates away from the 
cell boundary towards the nucleus reducing the transepithelial resistance allowing pathogens to 
move between the cells and through the cell wall into the lamina propria. Once the pathogen enters 
the lamina propria it is able to move throughout the gastrointestinal system and systemic 
circulation causing sever inflammation. II) LPS mediated pathway of inflammation. III) RONS 
mediated induction of cytokine production and inflammation. IV) Antigens presenting on the 
epithelial surface may be detected and consumed by dendritic cells. The antigen is presented to TH0 
cells which enter the TH1 or TH2 pathway depending on the antigen. Probiotics help regulate and 
reduce inflammation by 1) preventing the translocation of ZO to the nucleus helping maintain the 
TER and the integrity of gap junctions preventing the migration of pathogens past the epithelial 
barrier and 2) by preventing the activation of NF-κB caused by pathogens and compounds like LPS 
and RONS. 
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[This figure was constructed from the published data of: Nunbhakdi-Craig  et al 2002; Schneeberger 
Lynch 2004; Parasol et al 2005; Zyrek et al 2007.  
[JAM–1: Junctional Adhesion Molecule LPS: Lipopolisaccharides]
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Table 1. Probiotic strains and their effects when administered with no inflammatory stimulants 
 
Strain/s Model Dose Supplementation Duration Findings Reference 
L. rhamnosus Caco-2, 
HeLA, T84 
(human) and 
IEC-6 (rat) 
cells 
 
MOI 1:1 1 hour Oxidation of thioredoxin-1 and 
glutathione, ↑ in the chemiluminescence 
of luminal, ↓ neddylation of Cul-1, loss 
of IκB-α ubiquination 
Kumar et al., 
2007 
L. rhamnosus Female 
BABL/c 
mice 
1 × 108 cfu by gavage Sacrificed after 30 
minutes 
Oxidative stress in the mucosa of the 
small bowel and loss of Cul-1 
neddylation in mucosal lysates. 
 
Kumar et al., 
2007 
L. reuteri Female 
BALB/c 
mice 
1 × 1010 cfu/mL daily On days 1-4 and again on 
days 21-24 
Enhanced mucosal TNF-α, IL-2 and IL-
1β producing cells 
Maassen, van 
Holten-Neelen 
et al. 2000 
 
L. brevis Female 
BALB/c 
mice 
1 × 1010 cfu/mL daily On days 1-4 and again on 
days 21-24 
Enhanced mucosal TNF-α and IL-2 
producing cells 
 
Maassen, van 
Holten-Neelen 
et al. 2000 
 
B. infantis Germ free 
WT & IL-10 
KO mice 
 
Monoassociated 
infection 
24 weeks No effects Moran, Walter 
et al. 2009 
B. bifidum Germ free 
WT & IL-10 
KO mice 
 
Monoassociated 
infection 
24 weeks No effects Moran, Walter 
et al. 2009 
B. animalis 
 
Germ free 
WT and IL-
Monoassociated 
infection 
24 weeks IL-10 KO mice had thickening of the 
duodena with cellular infiltration of 
mononuclear cells into the lamina 
Moran, Walter 
et al. 2009 
29 
 
10 KO mice 
 
propria. Mucosal ulceration localised to 
the duodenum and ↑ spontaneous 
release of IL-12/IL-23 p40 from colonic 
explants 
 
Abbreviations: L. = lactobacillus; B. = Bifidobacterium; TNF = tumour necrosis factor; IL = interleukin; cfu = colony forming units; WT = wild type; 
KO = knockout; ↑ = increase/improvement; ↓ = decrease/reduction; MOI = multiplicity of infection. 
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Table 2. Probiotic strains and their effects when applied simultaneously with inflammatory stimulants 
 
Strain/s Model Dose Supplementation 
Duration 
Findings Reference 
L. casei  T84 cells 1 × 106 cfu/mL 3 hours No effect on EPEC- induced ZO-1 alteration  
 
Parassol, Freitas 
et al. 2005 
 
L. casei T84 cells  1 × 107 & 1 × 
108 cfu/mL  
 
3 hours Maintained ZO-1 distribution  
 
Parassol, Freitas 
et al. 2005 
Escherichia coli 
strain Nissle 1917 
 
T84 and Caco-2 
cells 
MOI 100:1  
 
1 hour Maintained TER Zyrek, Cichon et 
al. 2007 
B. breve RAW264.7 3 × 108 bacteria 
cells/mL 
 
16 hours Attenuated increase in mRNA IL-1β & IL-
12p40. Inhibited IκB-α phosphorylation and ↑ 
mRNA levels of IL-10, SOCS1 and SOCS3 
 
Okada, Tsuzuki 
et al. 2009 
B. adolescentis RAW264.7 3 × 108 bacteria 
cells/mL 
16 hours Attenuated increase in IL-1β and TNF-α. 
Inhibited IκB-α phosphorylation and ↑ mRNA 
levels of SOCS1 and SOCS3 
 
Okada, Tsuzuki 
et al. 2009 
B. Longum RAW264.7 3 × 108 bacteria 
cells/mL 
16 hours Attenuated the IL-12p40 levels. Inhibited IκB-α 
phosphorylation and ↑ mRNA levels of SOCS1 
and SOCS3 
 
Okada, Tsuzuki 
et al. 2009 
B. Longum LPMCs derived 
from UC patients 
mucosal biopsies 
 
106 cfu/mL of 
medium 
 
24 hours Reduced tissue supernatant production of TNF-
α, IL-8, and NF-κB p65 
Bai, Ouyang et 
al. 2006 
L. Paracasei 
Caco-2 cells 
 
 
108 bacteria/mL 
 
20 hours Substantial IL-6, HSP70 and HSP 27 production, 
no effect on IL-8 
 
Reilly, Poylin et 
al. 2007 
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L. Plantarum 
Caco-2 cells 
 
108 bacteria/mL 20 hours Substantial IL-6, HSP70 and HSP 27 production, 
no effect on IL-8 
 
Reilly, Poylin et 
al. 2007 
L. rhamnosus GG CD4+ T cells from 
CD and HV 
1 × 106 cfu/mL 4 days ↓ IFN-γ production in HV cells  
 
Hvas, Kelsen et 
al. 2007 
 
L. rhamnosus GG 
and L. acidophilus 
 
CD4+ T cells from 
CD and HV 
1 × 106 cfu/mL 4 days ↓ IFN-γ production in HV cells  Hvas, Kelsen et 
al. 2007 
S. Boulardii male Sprague-
Dawley rats 
 
5 × 109 viable 
cells 
7 days restored the histological appearance and 
weight/length of the colon, abolished the TNBS 
down-regulation of mRNA PPAR-γ expression 
and up-regulation of IL-8, IL-1β, IL-6, IL-8R, 
TNF-α and iNOS mRNA in the colon tissue 
 
Lee et al., 2009b 
 
Escherichia coli 
strain Nissle 1917 
Female BALB/c 
mice 
1.5-2.0 × 108 
twice a day 
8 days Protected against intestinal barrier dysfunction, 
maintained a greater body mass and colon 
length. Up-regulation of ZO-1  
 
Ukena, Singh et 
al. 2007 
L. plantarum IL-10 gene KO 
mice 
 
1 × 109-10 
cfu/mL in 
drinking water 
(average 
5mL/day) 
 
4 weeks Reduced diarrhoea and spontaneous colonic 
mucosal IL-12 and IFN-γ production, improved 
colonic, rectal and cecal histology scores 
 
Schultz, 
Veltkamp et al. 
2002 
L. GG male Wistar rats 
 
1 × 108 cfu/mL 
 
3 days Improved colonic tissue architecture and small ↑ 
in the relative amounts of L. 
 
Amit-Romach, 
Uni et al. 2008 
S. thermophilus, L. 
acidophilus and B. 
lactis (YO-MIX™ 
male Wistar rats 
 
1 × 108 cfu /mL 
 
3 days elevated the Bifidobacteria population Amit-Romach, 
Uni et al. 2008 
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Y 109 FRO 1000) 
 
Abbreviations: L., B., TNF, IL, cfu, WT, KO, ↑, ↓, MOI - see table 1; S. = streptococcus; EPEC = enteropathogenic Escherichia coli; TER = 
transepithelial resistance; IκB = Ikappa B; NF-κB = nuclear factor kappa B; HSP = heat shock protein; LPMCs = lamina propria mononuclear cells; 
mRNA = messenger ribonucleic acid; CD = Crohn’s disease; UC = ulcerative colitis; HV = healthy volunteers; IFN = interferon; SOCS = suppressor 
of cytokine signalling. 
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Table 3. Probiotic strains and their prophylactic effects 
 
Strain/s Model Dose Supplementation 
Duration 
Findings Reference 
S. thermophilus HT29/cl.19A 
and Caco-2 cells 
 
MOI 10:1 
 
Up to 48 hours Only Prophylactic able to alter INF-γ or TNF-α 
effects 
Resta-Lenert and 
Barrett 2006 
L. acidophilus HT29/cl.19A 
and Caco-2 cells 
 
MOI 10:1 
 
Up to 48 hours Only Prophylactic able to alter INF-γ or TNF-α 
effects 
Resta-Lenert and 
Barrett 2006 
L. reuteri T84, HT-29 and 
Caco-2 cells 
1 × 109 cells 2 hours Inhibited TNF-α; ↑ IL-8 production  Ma, Forsythe et 
al. 2004 
 
S. thermophilus HT29/cl-19A 
and Caco-2 cells 
 
MOI 50:1 1 hour Increased TER  Resta-Lenert and 
Barrett 2003 
L. acidophilus HT29/cl-19A 
and Caco-2 cells 
 
MOI 50:1 1 hour Increased TER  
 
Resta-Lenert and 
Barrett 2003 
S. thermophilus 
and L. acidophilus 
HT29/cl-19A 
and Caco-2 cells 
MOI 50:1 1 hour Increased TER above single strains  Resta-Lenert and 
Barrett 2003 
 
S. Boulardii HT-29 cells 5-20 yeasts per 
cell 
 
24 hours ↑ mRNA expression of PPAR-γ and decreased 
IL-8 expression 
Lee et al., 2009b 
 
L. acidophilus Colo329 and 
SW480 cells 
1 × 106 cfu/mL 6 hours ↑ COX-2 promoter activity, COX-2 protein 
expression and PGE2 secretion  
 
Otte, Mahjurian-
Namari et al. 
2009 
 
VSL#3 Colo329 and 
SW480 cells 
1 × 106 cfu/mL 6 hours ↓ the gastrin and TNF-α induced COX-2 
expression and PGE2 secretion  
 
Otte, Mahjurian-
Namari et al. 
2009 
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Escherichia coli 
strain Nissle 1917 
Colo329 and 
SW480 cells 
1 × 106 cfu/mL 6 hours ↓ the gastrin and TNF-α induced COX-2 
expression and PGE2 secretion  
 
Otte, Mahjurian-
Namari et al. 
2009 
 
L. acidophilus murine RAW 
264.7 
macrophage and 
YAMC cells 
 
2 × 109 cfu/mL 
 
4 hours No effect Petrof, Claud et 
al. 2009 
L. Paracasei  
 
murine RAW 
264.7 
macrophage and 
YAMC cells 
 
2 × 109 cfu/mL 
 
4 hours No effect Petrof, Claud et 
al. 2009 
L. Plantarum 
murine RAW 
264.7 
macrophage and 
YAMC cells 
 
2 × 109 cfu/mL 
 
4 hours Inhibited TNF-α stimulated NF-κB activation and 
binding of the p50/p65 isoform. Attenuated the 
release of MCP-1 
 
Petrof, Claud et 
al. 2009 
L. fermentum Mice 1 × 109 cfu daily 
for two weeks 
prior to TNBS 
2 weeks Maintained a greater body weight and developed 
a milder form of colitis. ↑ PGE2, IL-2 and IL-4 
production in colon explant supernatants 
 
Mane, Loren et 
al. 2009 
L. fermentum Female Wistar 
rats 
 
5 × 108 cfu 
 
3 weeks Reduced diarrhoea, colonic damage scores, 
adhesions, colonic MPO activity and colonic 
secreted TNF-α levels 
 
Peran, Sierra et 
al. 2007 
B. infantis female Wistar 
rats 
5 × 108 cfu 
 
3 weeks Reduced levels of colonic secreted TNF-α Peran, Sierra et 
al. 2007 
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L. casei female Wistar 
rats 
 
5 × 108 cfu 
 
3 weeks Little or no effects Peran, Camuesco 
et al. 2007 
 
L. acidophilus female Wistar 
rats 
 
5 × 108 cfu 
 
3 weeks Lower colonic damage scores, adhesions, colonic 
MPO activity, colonic LTB4 production and 
expression of iNOS 
 
Peran, Camuesco 
et al. 2007 
B. longum male ICR mice 2 × 1010 cfu/kg 
body weight 
6 days Inhibited GAG degradation, prevented colon 
shortening and inflammation (protein expression 
of IL-1β and TNF-α, MPO activity and activation 
of NF-κB) 
  
Lee, Lee et al. 
2009a 
L. plantarum male ICR mice 2 × 1010 cfu/kg 
body weight 
6 days Inhibit GAG degradation, prevented colon 
shortening, inflammation (protein expression of 
IL-1β and TNF-α, MPO activity and activation of 
NF-κB)  
 
Lee, Lee et al. 
2009a 
L. salivarius IL-10 KO mice 
(develop colitis 
≥ week 20) 
1 × 109 cfu/mL 
in milk – 4-7 mL 
drank/day 
 
19 weeks Attenuated spontaneously developed colitis  McCarthy, 
O'Mahony et al. 
2003 
B. infantis IL-10 KO mice 
(develop colitis 
≥ week 20) 
1 × 108 cfu/mL 
in milk – 4-7 mL 
drank/day 
 
 19 weeks ↓ in vitro production of IFN-γ, TNF-α and IL-12 
in isolated lymphocytes 
McCarthy, 
O'Mahony et al. 
2003 
Escherichia coli 
Nissle 1917 
pathogen-free 
C57BL/6 
5 × 108 cfu/mL 
 
10 days Prevented weight loss, shortening and thickening 
of the colon. ↓ DAI score, ulceration and 
inflammatory cell infiltration 
 
Kamada, Inoue 
et al. 2005 
Escherichia coli IL-10 KO mice 5 × 108 cfu/mL 10 days ↓ colon weights, spontaneous production of IFN- Kamada, Inoue 
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Nissle 1917   γ and MIP-2 from total RNA extracted from 
LPMCs 
 
et al. 2005 
VSL#3 mononuclear 
cells from mice 
intestinal tissue 
 
11.25 × 109 
bacteria/day 
7 days Altered distribution of DC within the intestinal 
mucosa 
Wang, 
O'Gorman et al. 
2009 
L. acidophilus Bar 
13 and B. Longum 
Bar 33 
BALB/c mice 1 × 109 cfu of 
each strain 
3 weeks Prevented loss of body mass, ↓ 
CD4+subpopulation, ↓ serum concentrations of 
IL-12, IFN-γ, TNF-α, MCP-1 and IL-10 and ↓ 
inflammation 
 
Roselli, 
Finamore et al. 
2009 
L. plantarum Bar 
10, Streptococcus 
thermophilus Bar 
20 and B. animalis 
subspecies lactis 
Bar 30 
 
BALB/c mice 1 × 109 cfu of 
each strain 
 3 weeks  Prevented loss of body mass, serum TNF-α and 
MCP-1 concentrations and inflammation. ↑ 
serum IL-10  
Roselli, 
Finamore et al. 
2009 
Saccharomyces 
boulardii 
CD (n = 32) 1 g 6 months – open 
RCT 
Fewer patients clinically relapsed  Guslandi, Mezzi 
et al. 2000 
 
Abbreviations: VSL#3 = A multi-strain probiotic blend consisting of: B. breve, B. longum, B. infantis, L. acidophilus, L. plantarum, L. paracasei, L. 
bulgaricus and Streptococcus thermophilus. L., B., TNF, IL, cfu, ↑, ↓, MOI – see table 1; S., TER, NF-κB, LPMCs, CD, IFN – see table 2; YAMC = 
young adult mouse colon; MCP-1 = monocyte chemotactic protein-1; COX = cyclooxygenase; PGE2 = prostaglandin E2; TNBS = trinitobenzene 
sulfonic acid; MPO = myeloperoxidase; LTB4 = leukotriene B4; iNOS = inducible nitric oxide synthase; g = gram; kg = kilogram; GAG = 
glycosaminoglycan; DAI = disease activity score; MIP = macrophage inflammatory protein; RNA = ribonucleic acid; DC = dendritic cell; RCT = 
randomised controlled trial.   
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Table 4. Probiotic strains and their therapeutic effects 
 
Strain/s Model Dose Supplementation 
Duration 
Findings Reference 
B. breve monocytes 
purified from 
healthy blood 
donors 
 
Bacteria:host 
ratio 2:1, 10:1 
and 40:1 
24 hours ↑ TNF-α, IL-1β, IL-6, IL-10, IL-12 and IFN-γ  Latvala, Pietila 
et al. 2008 
L. rhamnosus monocytes 
purified from 
healthy blood 
donors 
 
Bacteria:host 
ratio 2:1, 10:1 
and 40:1 
24 hours Weak inducer of cytokine expression Latvala, Pietila 
et al. 2008 
B. animalis monocytes 
purified from 
healthy blood 
donors 
 
Bacteria:host 
ratio 2:1, 10:1 
and 40:1 
24 hours ↑ TNF-α, IL-1β, IL-6, IL-10, IL-12 and IFN-γ Latvala, Pietila 
et al. 2008 
L. mesenteroides monocytes 
purified from 
healthy blood 
donors 
 
Bacteria:host 
ratio 2:1, 10:1 
and 40:1 
24 hours Weak inducer of cytokine expression Latvala, Pietila 
et al. 2008 
B. bifidum Splenocytes 1 × 107 cells 72 hours Failed to alter IL-17 production Tanabe, Kinuta 
et al. 2008 
 
 colon tissue 1 × 105 cells 24 hours Suppressed IL-17 and eotaxin production Tanabe, Kinuta 
et al. 2008 
 
B. catenulatum Splenocytes 1 × 107 cells 72 hours Failed to alter IL-17 production Tanabe, Kinuta 
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et al. 2008 
 
 colon tissue 1 × 105 cells 24 hours Suppressed IL-17 and eotaxin production  Tanabe, Kinuta 
et al. 2008 
 
B. infantis Splenocytes 1 × 107 cells 72 hours Suppressed IL-17 and promoted IL-27, IL-5 and 
IL-12 production and ↑ IL-10  
 
Tanabe, Kinuta 
et al. 2008 
 colon tissue 1 × 105 cells 24 hours Suppressed IL-17 and eotaxin production and ↑ 
IL-10 
Tanabe, Kinuta 
et al. 2008 
 
L. bulgaricus Splenocytes 1 × 107 cells 72 hours Failed to significantly exert an effect on IL-17 
production  
 
Tanabe, Kinuta 
et al. 2008 
 colon tissue 1 × 105 cells 24 hours Suppressed IL-17 and eotaxin production Tanabe, Kinuta 
et al. 2008 
 
L. acidophilus Splenocytes 1 × 107 cells 72 hours Failed to significantly exert an effect on IL-17 
production 
Tanabe, Kinuta 
et al. 2008 
 
 colon tissue 1 × 105 cells 24 hours Suppressed IL-17 and eotaxin production Tanabe, Kinuta 
et al. 2008 
 
L. fermentum Mice 1 × 109 cfu daily  2 weeks ↓ colon histology scores and IL-6 production in 
colon explant supernatants, ↑ colonic MyD88 
staining  
 
Mane, Loren et 
al. 2009 
L. paracasei and 
L. reuteri 
L-10 KO mice ~1 × 109 cfu 2 days before and 
a third after 3 H. 
Hepaticus doses 
Attenuated TNF-α and IL-12p40 mRNA but not 
the IBD-like lesions  
Pena, Rogers et 
al. 2005 
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L. acidophilus BALB/c mice 
 
2 × 108 cfu daily 
 
12 days Prevented weight loss, ↓ DAI score, MPO 
activity and IL-1β mRNA levels and ↑ IL-4 
mRNA levels in the colon 
Chen, Wang et 
al. 2009 
B. adolescentis 
BALB/c mice 
 
2 × 108 cfu daily 
 
12 days Prevented weight loss, ↓ DAI score, MPO 
activity and IL-1β mRNA levels and ↑ IL-4 
mRNA levels in the colon  
 
Chen, Wang et 
al. 2009 
E. faecalis 
 
BALB/c mice 
 
2 × 108 cfu daily 
 
12 days Prevented weight loss, ↓ DAI score, MPO 
activity and IL-1β mRNA levels and ↑ IL-4 
mRNA levels in the colon  
 
Chen, Wang et 
al. 2009 
Clostridium 
butyricum 
BALB/c mice 
 
2 × 108 cfu daily 12 days Prevented weight loss, ↓ DAI score, MPO 
activity and IL-1β mRNA levels and ↑ IL-4 
mRNA levels in the colon 
 
Chen, Wang et 
al. 2009 
B. infantis IBS (n= 362) 1 × 106 cfu/mL 4 weeks – 
multicenter, 
double-blind RCT 
 
No change  Whorwell, 
Altringer et al. 
2006 
 IBS (n= 362) 1 × 108 cfu/mL 4 weeks – 
multicenter, 
double-blind RCT 
 
Relieved abdominal pain  Whorwell, 
Altringer et al. 
2006 
 IBS (n= 362) 1 × 1010 cfu/mL 4 weeks – 
multicenter, 
double-blind RCT 
 
Coagulated becoming resistant to acid and 
agitation 
 
Whorwell, 
Altringer et al. 
2006 
L. acidophilus IBS (n = 40) 2 × 109 cfu/mL 4 weeks – double-
blind RCT 
Relieved abdominal pain and associated 
symptoms 
Sinn, Song et al. 
2008 
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L. plantarum IBS (n = 40) 1 × 1010 cfu/day 4 weeks – double-
blind RCT 
Relieved pain, constipation and flatulence  Niedzielin, 
Kordecki et al. 
2001 
 
Saccharomyces 
boulardii 
CD (n = 34) 
 
1.2 × 109 
cells/day 
3 months – 
double-blind RCT 
↑ intestinal permeability  Garcia Vilela, 
De Lourdes De 
Abreu Ferrari et 
al. 2008 
 
B. infantis 35624 IBS (n= 77) 1 × 1010 live 
bacteria cells 
8 weeks – single 
blind RCT 
Lower composite score and restored in vitro 
production of IL-10 and IL-12 by PBMCs 
O'Mahony, 
McCarthy et al. 
2005 
 
L. salivarius 
UCC4331 
IBS (n= 77) 1 × 1010 live 
bacteria cells 
8 weeks – single 
blind RCT 
Lower composite score only at week 2 O'Mahony, 
McCarthy et al. 
2005 
 
Escherichia coli 
and E. faecalis 
IBS (n = 297) 3.0 to 9.0 × 107 
cfu/day 
8 weeks – double-
blind RCT 
 
Improved global symptom score and abdominal 
pain  
Enck, 
Zimmermann et 
al. 2008 
 
B. longum, L. 
acidophilus and S. 
thermophilus 
IBS (n = 116) 1 × 1010 cfu/day 4 weeks - double-
blind RCT 
Strong placebo effect but relieved abdominal 
pain  
 
Drouault-
Holowacz, 
Bieuvelet et al. 
2008 
 
S. thermophilus, L. 
bulgaricus, L. 
D-IBS (n = 42) 2.6 × 1010 
cfu/day 
4 weeks – single 
blind RCT 
Small bowel permeability ↓, improved IBS 
scores, abdominal pain and flatulence 
Zeng, Li et al. 
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acidophilus and B. 
longum 
 
 2008 
VSL#3 D-IBS (n = 25) 4.5 × 1011 
bacteria/day 
10 weeks - double-
blind RCT 
 
Relieved abdominal bloating  
 
Kim, Camilleri 
et al. 2003 
VSL#3 B-IBS (n = 48) 4.5 × 1011 
bacteria/day 
4 and 8 weeks – 
double-blind RCT 
Reduced flatulence scores and slowed colonic 
transit. Cytokines below detection level  
 
Kim, Vazquez 
Roque et al. 
2005 
 
VSL#3 IBS 4.5 or 9.0 × 1011 
bacteria/day 
 
6 weeks – double-
blind RCT cross 
over design 
 
↑ IBS symptoms, ↓ abdominal pain/discomfort, ↓ 
abdominal bloating/gassiness and ↓ disruption of 
family life 
Guandalini et al. 
L. rhamnosus GG, 
L. Rhamnosus 
Lc705, 
Propionibacterium 
freudenreichii ssp. 
Shermanii JS & B. 
Animalis ssp. 
Lactis Bb12 
 
IBS (n = 86) 4.8 × 109 cfu/day 5 months – 
double-blind RCT 
Improved IBS scores. Cytokines largely below 
level of detection 
Kajander, 
Myllyluoma et 
al. 2008 
L. reuteri IBS (n = 54) 2 × 108 cfu/day 6 months – 
double-blind RCT 
Improvement in IBS symptoms but also placebo 
effect  
 
Niv, Naftali et al. 
2005 
L. GG CD (n = 45) 1.2 × 1010 
cfu/day 
1 year – double-
blind RCT 
 
Unsuccessful in reducing the severity of CD Prantera, 
Scribano et al. 
2002 
 
42 
 
Abbreviations: L., B., cfu, ↑, ↓, TNF, IL, KO – see table 1; IFN, mRNA – see table 2; MPO, DAI, RCT – see table 3; H. = helicobacter; E. = 
enterococcus CD = Crohn’s disease; IBD = inflammatory bowel disease; IBS = irritable bowel syndrome; D-IBS = diarrhea predominant irritable 
bowel syndrome; PBMC = peripheral blood mononuclear cell.
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Chapter 2 
Publication 1 
A review of the pharmacobiotic regulation of gastrointestinal inflammation  
by probiotics, commensal bacteria and prebiotics
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Abstract   The  idea  that  microbes  induce  disease  has 
steered medical research toward the discovery of antibacte- 
rial products for the prevention and treatment of microbial 
infections. The twentieth century saw increasing depen- 
dency on antimicrobials as mainline therapy accentuating 
the notion that bacterial interactions with humans were to be 
avoided or desirably controlled. The last two decades, 
though, have seen a refocusing of thinking and research 
effort directed towards elucidating the critical inter-rela- 
tionships between the gut microbiome and its host that 
control health/wellness or disease. This research has rede- 
fined the interactions between gut microbes and vertebrates, 
now recognizing that the microbial active cohort and its 
mammalian host have shared co-evolutionary metabolic 
interactions that span millennia. Microbial interactions in the 
gastrointestinal tract provide the necessary cues for the 
development of regulated pro- and anti-inflammatory signals 
that promotes immunological tolerance, metabolic regula- 
tion and other factors which may then control local and extra- 
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intestinal inflammation. Pharmacobiotics, using nutritional 
and functional food additives to regulate the gut microbiome, 
will be an exciting growth area of therapeutics, developing 
alongside an increased scientific understanding of gut- 
microbiome symbiosis in health and disease. 
 
Keywords  Pharmacobiotics · Gastrointestinal · 
Inflammation · Probiotics · Commensal · Bacteria · 
Prebiotics · Symbiotics 
 
 
Introduction 
 
All body mucosal and extra-mucosal tissue sites that 
include the GIT, mouth, hair, nose, ears, vagina, lungs, and 
skin have their own unique microbiomes (Dominguez- 
Bello et al. 2010). There are purported to be thousands of 
bacterial species in the GIT and the number residing within 
the body of the average healthy adult human is estimated to 
out number human cells by a factor of 10 to 1 (O’Hara and 
Shanahan 2006). The microbiota within the human distal 
GIT are the largest body community and it provides an 
excellent millieu to investigate inflammatory processes. 
Recent evidence suggests that the bacterial load and the 
products of the intestinal microbiota might positively 
influence inflammatory disease pathogenesis (Wen et al. 
2008; Mazmanian et al. 2008). 
The bacteria that colonize the GIT perform a number of 
functions that include (1) regulating the normal develop- 
ment and function of the mucosal barriers (Xu and Gordon 
2003); (2) assisting the maturation of immunological tis- 
sues, which in turn promotes immunological tolerance to 
antigens from foods/environment or potentially pathogenic 
organisms (Berg and Savage 1975); (3) controlling nutri- 
ent  uptake  and  metabolism  (Mazmanian  et  al.  2005; 
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Rakoff-Nahoum et al. 2004), and (4) preventing the prop- 
agation of pathogenic micro-organisms (Tappenden and 
Deutsch 2007). Changes in the profile of resident GIT 
bacteria may reduce their beneficial functions and affect 
the regulation of GI immune and inflammatory responses. 
Hence, in addition to its inherited constitution of genes, the 
GIT microbiota and the effects of the environment may 
constitute prime factors in the causation of disease, as 
alluded to more than half a century ago (Pickering 1950). 
 
 
The GIT, immunological  tolerance  and the control 
of inflammation 
 
Pre-birth mammalian young are sterile in utero. Therefore, 
could a germ-free GIT be desirable and could it be con- 
ducive to better health outcomes, significantly reducing the 
risk of disease such as inflammatory bowel diseases or 
large bowel cancer? Although this notion may provide a 
useful  hypothesis  for  further  thought,  this  premise  is 
beyond the scope of this review. Given that mammals on 
this planet engage with bacterial species throughout a 
lifetime in vivo studies with germ-free animals tend to 
suggest otherwise (Cert-Bensussan and Gaboriau-Routhiau 
2010). Comparative studies between mice that were raised 
in conventional versus germ-free environments highlight 
the importance of the intestinal microbiota for the devel- 
opment of the peripheral immune system in immuno- 
competent hosts. Most notably, the spleens of germ-free 
mice contain fewer and smaller germinal centers (Bauer 
et al. 1963) and decreased numbers of memory CD4?   T 
cells, and cytokine production by these T cells shows a 
TH2-type profile (Mazmanian et al. 2005). Moreover, a 
balanced microbiome prevents the growth of disease- 
causing bacteria within the intestine. The GIT microbiota 
produce vitamins (e.g. vitamin K) and are also important 
for maintaining the muscular activity of the small intestine. 
The bacteria that colonize the adult human GIT hence 
functions collectively as a metabolic organ (Backhead et al. 
2007) and within this evolutionary paradigm, the devel- 
opment of an immune-metabolic-competent host may be a 
necessary response for survival. 
The  environmental/microbiological  picture,  hence,  is 
that from the time of birth, there is an assailment and 
colonization of all mucosal surfaces and the skin with 
bacteria that triggers the natural development and matu- 
ration of the immune system. Specifically studies reveal 
that the functions of the human GIT immune system are 
only partially encoded in the host’s genes and that cues are 
required from the symbiotic microbial cohort for its full 
development (Hooper 2004). The microbiota that colonize 
the human GIT exhibit a high phylogenetic diversity 
reflecting their immense metabolic potential. How bacteria 
colonize the GIT provides initial clues as to the cues the 
GIT needs to develop a regulated immuno-metabolic- 
competent profile. 
Up-regulated immune responses in an individual are nec- 
essary to clear the GIT of pathogenic cells. The immune 
system achieves this by initiating a pro-inflammatory 
response. The microbiota act partly in an immune-surveil- 
lance role by detecting pathogenic bacteria, stimulating the 
immune system and subsequently initiating an appropriate 
eradicative inflammatory response (Eckmann 2006). Once 
the pathogenic cells are cleared, anti-inflammatory signals are 
switched on to restore the pro-inflammatory response back to 
a normal level. Accordingly, the healthy gut is in a constant 
state of regulated inflammation. The role that microbiota play 
in triggering the anti-inflammatory response is still unclear. 
Failure to re-regulate inflammatory responses can increase the 
risk of developing inflammatory conditions of the host’s gut 
architecture such as inflammatory bowel diseases (IBD) or 
irritable bowel syndrome (IBS). 
Accumulating evidence indicates that the balance of 
commensal1 bacteria within the GIT may be associated with 
the development of some GI disorders (Swidsinski et al. 
2002). Patients IBD or IBS have been reported to present 
with increased pro-inflammatory or potentially pathogenic 
bacterial  species such as  Bacteroides  (Swidsinski et  al. 
2002), Escherichia coli (Mylonaki et al. 2005; Martin et al. 
2004), Enterococci and decreased bifidobacteria and lacto- 
bacilli species (Giaffer et al. 1991; Van de Merwe et al. 
1988). The etiology of IBD is not fully understood, but is 
considered to be a T-cell-driven inflammation resulting from 
a persistent preponderance of pro- over anti-inflammatory 
cytokine production (Hvas et al. 2007). 
Crohn’s disease (CD) and ulcerative colitis (UC) are the 
two main types of IBD. CD is driven by T-helper 1 (TH1) 
immune responses (Matsuoka et al. 2004; Fuss et al. 1996), 
and can affect any part of the GIT, i.e. from the mouth to 
the anus. By contrast, UC is T-helper 2 (TH2) driven, and 
is restricted to the mucosa of the colon and rectum (Heller 
et al. 2005; Fuss et al. 1996) (Fig. 1). IBS is a functional 
bowel disorder affecting mostly the large intestine with the 
prime symptoms including abdominal pain, diarrhoea and 
constipation. 
 
 
The hygiene hypothesis  and GIT inflammation 
 
The past six decades have seen a significant increase in the 
prevalence of autoimmune diseases (Mackay et al. 2001; 
Sironi and Clerici 2010). This was the catalyst that led to 
the formulation of the hygiene hypothesis. Over the passt 
two  decades,  the  hygiene  theory  has  been  tested  and 
 
1   Literally meaning eating at the same table. 
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Fig. 1  Inflammatory signalling pathways of a single epithelial cell. 
a The NEDD8 pathway leading to binding of NEDD8 and cullin and 
subsequent activation of the NF-jB pathway. b Example of one of the 
cytokine pathways and its receptor. c Activation of NF-jB via an 
imbalance in RONS. d MyD88 pathway activated by pathogens 
binding to TLR leading to the IKK complex and NF-jB  pathway. 
e Translocation of the p50 and p65 subunits results in changes to the 
cells function, which may provide positive or negative feedback to the 
extracellular space. NF-jB activation may result in the feedback 
changing the cytokine response to regulate the inflammatory response 
in a positive or negative way. In cases of IBD, one or more of these 
pathways can be dys-regulated leading to excessive inflammation due 
 
tweaked, expanded and extended (Sironi and Clerici 2010). 
This hypothesis provides a biologically plausible explana- 
tion for the trend that implicates diminished exposure in 
early childhood to those commensal infections that boost 
immune defenses. This deficit subsequently enhances the 
risk, for later life, of GIT inflammatory problems that 
disrupt normal/regulated GIT inflammatory responses and 
increases the susceptibility to developing autoimmune 
diseases (Bach 2002). The hypothesis proposed that there 
was reduced exposure to infections in early childhood owing 
to a combination of diminishing family size and better 
personal hygiene, which might then increase the risk of 
developing allergic diseases (Bach 2002). The interface of 
the microbial environment with the innate immune system 
could be significantly modulated so that its ability to impart 
instructions to adaptive/regulatory immune/ inflammatory 
responses would be adversely affected, par- ticularly when 
such interactions occurred in utero and/or were presaged in 
early life. Bach (2002) documented this in part to an over 
production or lack of termination of pro- inflammatory cytokine 
signals. Probiotics may reduce or prevent the resulting inflammation 
by: (1) blocking or reducing the binding of NEDD8  to  cullin  via  
regulated  production  of  ROS  inactivating UBC12 and (2) Prevent or 
reduce the phosphorylation of IjB-a, preventing the translocation of the 
p50 and p65 subunits to the nucleus. This figure was constructed from 
the published data of Collier-Hyams et al. 2005, Wu et al. 2005, 
Kabelitz et al. 2006, Kumar et al. 2007, Ivison et al. 2010, Hooper and 
Macpherson 2010). IL  interleukin,  RONS reactive  oxygen  and  
nitrogen  species,  TH T-helper, TLR toll-like receptor, NEMO NF-jB 
essential modulator 
 
 
trend highlighting that an epidemic of both GI autoimmune 
diseases in which the immune response was dominated by 
Th1 cells (such as type 1 diabetes mellitus, CD, multiple 
sclerosis) and allergic diseases in which the immune 
response was dominated by Th2 cells (such as asthma, 
allergic rhinitis, and atopic dermatitis) was becoming 
increasingly prevalent in Western communities. 
Evolution has naturally endowed the human species with 
immune/inflammatory regulatory mechanisms activated by 
the interactions with both the external and internal microbial 
environments (Ley et al. 2008). These then serve to fine-tune 
both Th1 and Th2 antigen-driven effector responses (Wills- 
Karp et al. 2001). The innate immune system senses the 
environment and accordingly modulates the T regulatory arm, 
the ultimate keeper of the balance between antigen tolerance 
and responsiveness. The efficiency of the regulatory interface 
in its current state would paradoxically be jeopardized by a 
decrease in the microbial burden that the immune system has 
co-evolved with (Wills-Karp et al. 2001). 
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Studies exploring the molecular mechanisms that might 
underpin the hygiene hypothesis have focused mostly on the 
interactions between bacterial products and Toll-like recep- 
tors (TLRs)—the main transducers of microbial signals to the 
innate immune system and critical regulators of CD4 T-cell 
activation and regulation (O’Neill 2006; Pasare and Medzhi- 
tov 2004). Therapeutically, a recent review has highlighted 
how in those individuals with chronic helminth infections 
there is often an association with a reduced prevalence of 
inflammatory disorders, including allergic diseases (Hussaarts 
et al. 2011). Mechanistically, it was reported that by inducing 
or expanding regulatory B cells with helminths may open 
novel avenues for the treatment of inflammatory diseases, 
such as allergic asthma (Hussaarts et al. 2011). 
 
 
Probiotics  and IBD 
 
Probiotics are living organisms in food and dietary sup- 
plements that upon ingestion can improve the health of the 
host beyond their inherent basic nutritional content (Fuller 
1989). CD and UC, collectively referred to as IBD, are 
chronic aggressive disorders with a prevalence of approx- 
imately 0.1–0.5% in Western countries. Probiotics may 
have a significant benefit in preventing and treating IBD. 
Environmental factors such as the composition and 
metabolic activity of the gut flora, immune system reac- 
tivity and genetic factors are all believed to play a role in 
the progression of IBD states (Lakatos et al. 2006). Clinical 
observations suggest that certain intestinal and extra- 
intestinal bacterial infections may perhaps precede or 
reactivate chronic intestinal inflammation. A number of 
microbial agents have been implicated as initiating factors 
in the pathogenesis of IBD, including Mycobacterium 
paratuberculosis, measles virus, Listeria monocytogenes, 
and adherent E. coli (Sartor 2005). However, results 
implicating any single micro-organism in the etiology of 
IBD are equivocal. Moreover, recently it was reported that 
subjects diagnosed with IBD were more likely to have been 
prescribed  antibiotics  2–5 years  before  their  diagnosis 
(Shaw et al. 2011). This then suggests that antibiotic 
administration may be implicated as a predisposing factor 
in IBD etiology. The plausible mechanism for causality is 
the disruption of the GIT microbiome. 
One mechanism by which pathogenic micro-organisms 
may drive intestinal inflammation in susceptible individuals 
is via disruption of the mucosal barrier. This could then lead 
to an increased uptake of luminal antigens or mimics of self- 
antigens and activate the mucosal immune system via 
modulation of transcription factors such as NFkB (Sartor 
2006) (Fig. 2) by sustaining an up-regulating activity. 
Data from in vitro studies, from experiments using 
animal models of intestinal inflammation, and clinical trials 
have all suggested a critical role for normal luminal bac- 
teria in the pathogenesis of IBD (Sartor 2006). 
The most compelling evidence for the interactive role of 
bacteria, immune system and genes has been derived from 
experimental animal models of both Crohn’s-like and 
colitis-like  disease (Duchmann et  al.  1999; Mow et  al. 
2004; Sartor 2006). There are more than 20 different 
spontaneously occurring or genetically engineered (either 
the knockout type or transgenic) animal models of IBD 
(Sartor 2006). Colonization with an enteric flora is required 
for full expression of disease. Thus, the normal flora is a 
common factor driving the inflammatory process irre- 
spective of the underlying genetic predisposition and 
immunological effector mechanism. A recent phenotype/ 
genotype investigation demonstrated that in a subset of 
patients with CD and UC, there was an altered intestinal- 
associated microbial compositions (Frank et al. 2011). 
Hence, it is possible that changes in the GIT microbiota/ 
microbiome profile in individuals with specific susceptible 
genotypes may lead to adverse inflammatory profiles. A 
recent review has documented the results of clinical trials 
that investigated the efficacy of probiotics (single, multiple 
strains and probiotic blends with prebiotics) (Table 1) in 
CD, UC and pouchitis (Mack 2011). The review concluded 
that there was little evidence for the benefit of currently 
used probiotic microbes in CD or associated conditions 
affecting extra-intestinal organs. However, the review also 
reported that clinical practice guidelines in Canada were 
now including a probiotic as an option for recurrent and 
relapsing antibiotic sensitive pouchitis. Further, the use of 
probiotics in mild UC was provocative and suggested a 
potential for benefit in selected patients (Mack 2011). 
Rescue of an disrupted GIT microbiome may depend on 
the introduction of multi-strain probiotics rather than single 
strains. Given the extensive array of micro-organisms that 
inhabit the GIT, probiotic mixtures may be a more bio- 
logically plausible therapeutic option in rescuing GIT 
microbiome functionality. Recently, it was reported that 
multi-strain probiotics are more effective against a wide 
range of end points (Chapman et al. 2011). Chapman et al. 
(2011) also reported that based on a limited number of 
studies, multi-strain probiotics may show greater efficacy 
than single strains, including strains that are components of 
the mixtures themselves. Altering the GIT microbiome/ 
microbiota through pharmacological or nutritional means 
has the potential to influence the onset, progression and 
recovery from inflammatory disorders of the GIT. 
 
 
Influence of probiotic  therapies 
 
A number of reports describe the influence of probiotic 
supplements on colitis in animal trials. In particular, the IL- 
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Table 1  Clinical studies reported for probiotics [adapted and updated from Vitetta and Sali (2008)] 
 
Probiotics 
 
Conditions and symptoms Probiotic supplement source and associated 
bacterial strains 
L = Lactobacillus strains 
B = Bifidobacterium strains 
 
Level of 
evidencea 
 
References 
 
Diarrhoea from antibiotic use for bacterial 
infections 
L. rhamnosus GG I Hawrelak et al. (2005) 
L. reuteri MM53 II de Vrese and Marteau (2007) 
L. reuteri ATCC 55730  Frohmader et al. (2010) 
VSL#3  Guandalini (2011) 
Hickson (2011) 
Cimperman et al. (2011) 
Johnston et al. (2011) 
Atopic eczema Kallioma¨ki et al. (2001, 2003); 
Kajander et al. (2008) 
Prevention L. rhamnosus GG I Giovannini et al. (2007) 
Treatment L. fermentum PCC II Kallioma¨ki et al. (2001, 2003, 
2007) 
II Betsi et al. (2008) 
Allergies   Majamaa and Isolauri (1997) 
Food allergy L. rhamnosus GG III Mukerji et al. (2009) 
Rhinosinusitis L. rhamnosus R0011 
Bacterial gastroenteritis Saavedra et al. (1994) 
Vancomycin resistant enterococci L. rhamnosus GG 
L. rhamnosus GG 
II 
III 
Shornikova et al. (1997) 
Lomax and Calder (2009) 
C. difficili   Rohde et al. (2009) 
Colic L. reuteri DSM17938 II Savino et al. (2007) 
Savino et al. (2010) 
Chronic fatigue syndrome L. paracasei  ssp. III Rao et al. (2009) 
L. paracasei  F19 IV Sullivan et al. (2009) 
L. acidophilus NCFB 1748 Lakhan and Kirchgessner (2010) 
B. lactis Bb12 
L. casei strain Shirota 
Constipation In adults: effective strains 
B. lactis DN-173 010, L. casei 
Chmielewska and Szajewska 
(2010) 
Shirota Escherichia coli Nissle 1917 Tabbers et al. (2009) 
Quigley (2011) 
In children: effective strains I/II 
L. casei rhamnosus Lcr35 II 
B. lactis DN-173 010 
Helicobacter pylori infection L. reuteri MM53 II Cremonini et al. (2002) 
L. acidophilus La5 III Lesbros-Pantoflickova et al. (2007) 
B. lactis Bb12 Francavilla et al. (2008) 
Mourad-Baars et al. (2010) 
(ineffective in children) 
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Table 1 continued 
 
Probiotics 
 
Conditions and symptoms Probiotic supplement source and associated 
bacterial strainsL = Lactobacillus 
strainsB = Bifidobacterium strains 
 
 
 
Level of 
evidencea 
 
 
 
References 
 
Irritable bowel syndrome L. acidophilus II Niedzielin et al. (2001) 
L. plantarum  II Madden and Hunter (2002) 
Whorwell et al. (2006) 
L. rhamnosus                                                                                   Drouault-Holowacz et al. (2008) 
B. breve B. lactis                                                                             Ki Cha et al. (2011) 
B. longum 
S. thermophilus 
Inflammatory bowel syndrome B. breve II Friedman and George (2000) 
B. bifidum II Gionchetti et al. (2000a, b) UC
 L. acidophilus II Fedorak and Dieleman (2008) 
CD L. acidophilus  Hammer (2011) 
Pouchitis L. paracasei  Mack (2011) 
L. bulgaricus                                                                                    (refer text forefficacy outcomes) 
B. breve 
B. longum 
B. infantis 
S. thermophilus 
L. fermentum PCC 
L. plantarum 299V 
VSL#3 
Immunity decreased—reducing 
rates of infections: 
Kontiokari et al. (2001) 
L. rhamnosus GG I Hatakka et al. (2001) 
URTIs L. rhamnosus GR-1 II Falagas et al. (2006) 
Candidiasis L. reuteri RC-14 II Forestier et al. (2008) 
HIV B. lactis HN019 III Hao et al. (2011) 
Day care infections in children L. acidophilus La5 Hummelen et al. (2011) 
L. plantarum CECT 7315 Man˜ e´ et al. (2011) 
ICU infections Davidson et al. (2011) 
Adjuvant to influenza 
Vaccine—improve efficacy 
Prevention of preterm necrotizing 
enterocolitis 
L. bifidus, I AlFaleh and Bassler (2010) 
S. thermophillus 
B. infantis 
Prevention of: Probitics—Yakult II Twetman and Stecksen-Blicks 
(2008) 
Na¨se et al. (2001) 
Dental caries L. rhamnosus GG III Slawik et al. (2011) 
Gingival inflammation   Koduganti et al. (2011) 
Periodontal disease 
Radiotherapy-induced diarrhoea VSL#3b II Delia et al. (2007) 
Chemotherapy— L. casei (Yakult Honsha) III Naito et al. (2008) 
Prevention of recurrence– F. prausnitzii I Prisciandaro et al. (2011) 
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Table 1 continued 
 
Probiotics 
 
Conditions and symptoms Probiotic supplement source and associated 
bacterial strainsL = Lactobacillus 
strainsB = Bifidobacterium strains 
 
 
 
Level of 
evidencea 
 
 
 
References 
 
Bladder cancer 
(combined with epirubicin) 
 
 
Chemotherapy-induced intestinal 
mucositis 
 
 
 
 
 
 
 
 
 
 
 
 
Ulcerative colitis 
L. plantarum 
B. bifidum Yakult 
B. breve Yakult 
S. boulardi 
B. infantis 
L. rhamnosus GG 
L. plantarum LP31 
L. plantarum 423 
L. johnsonii NCC533 Ecologic® 
641 
L. fermentum CECT571 
VSL#3 
L. acidophilus 
L. plantarum 299V 
Inducing remission VSL#3 III Friedman and George (2000) 
Maintenance/remission L. rhamnosus GG35/VSL#3 II/III Gionchetti et al. (2000a) 
Prevention VSL#3 II Gionchetti et al. (2003) 
Pouchitis L. rhamnosus GG36 III Mimura et al. (2004) 
Viral gastroenteritis L. casei Shirota II Lin et al. (2009) 
Prevention L rhamnosus GG II Nagata et al. (2011) 
Treatment B. lactis Bb12 I 
L. rhamnosus GG II 
L. reuteri MM53 
 
a   Level I: from a systematic review of all relevant randomised controlled trials—meta-analyses, Level II: from at least one properly designed 
randomised controlled clinical trial, Level III: from one or more well-designed pseudo-randomised controlled trials (alternate allocation or some 
other method), Level IV: opinions of respected authorities based on clinical experience, descriptive studies or reports of expert committees 
b   VSL#3, a multi-strain product composed of—B. longum, B. infantis, B. breve, L. acidophilus, L casei, L. plantarum,  L. delbruekii ssp. 
bulgaricus, S. thermophilus 
 
 
10 knockout mouse has been extensively studied because it 
develops colitis when colonized with a conventional flora 
but remains disease-free when maintained under germ-free 
conditions (Paul et al. 2011). 
Although it is unclear whether the abnormal composi- 
tion of the enteric flora contributes to the pathogenesis of 
IBD, evidence from clinical observations (e.g., from evi- 
dence that antibiotics are effective in certain patients) 
(Talley et al. 2011) has prompted the examination of a 
wide variety of probiotic strains in the treatment of IBD 
(Cain and Karpa 2011). 
Probiotics have also been used to treat patients with 
existing IBS (Cain and Karpa 2011). The efficacy was 
assessed by comparing abdominal pain and discomfort, 
symptom scores for bowel habit satisfaction, flatulence and 
production  of  C-reactive  protein  (CRP)  and  cytokines 
(IL-2, IL-4, IL-6, IL-10, IL-12, IFN-c and TNF-a,) before 
and after probiotics treatment (Lee and Bak 2011). 
One of the problems with probiotic therapy is finding 
and  administering  the  optimal  dose.  As  each  probiotic 
strain may require a different dose and the different disease 
aetiologies may require different doses, finding the ‘ideal’ 
dose is complex. Whorwell et al. (2006) investigated the 
effects  of  three  different  doses  of  B.  infantis  35624 
(1 9 106,  1 9 108   and 1 9 1010  cfu/ml) in treating pri- 
mary-care  IBS  patients.  The  dose  of  1 9 108  cfu/ml 
proved superior in relieving abdominal pain compared with 
the placebo and other doses. Further investigation of the 
highest dosage demonstrated that the probiotics ‘‘coagu- 
lated’’ into a firm glue-like mass making them resistant to 
acid and agitation. The lowest dose of probiotics may not 
have been effective because of the duration of the study, or 
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insufficient biological activity. These findings highlight the 
potential importance of how probiotics are administered to 
maximize bioavailability within the GIT. 
To assess the efficacy of probiotics, improvements in 
disease symptoms are monitored. Probiotics have been 
shown to reduce abdominal pain and discomfort and 
symptom scores such as when patients with IBS were 
administered L. acidophilus (Sinn et al. 2008), L. plan- 
tarum 299V (Niedzielin et al. 2001) or ProSymbioflor (a 
combination of E. coli DSM 17252 and E. faecalis DSM 
16640) (Enck et al. 2008) compared with a placebo. In 
contrast,  Drouault-Holowacz  et  al.  (2008)  found  that 
B. longum LA 101, L. acidophilus LA 102, L. lactis LA 
103 and S. thermophilus LA 104 were not superior to the 
placebo treatment for relieving disease symptoms, due to a 
strong placebo2  effect. Probiotic supplementats did, how- 
ever,  significantly  relieve  abdominal  pain  to  a  greater 
extent compared with placebo treatment. Further analysis 
of the IBS sub groups revealed that patients with changing 
bowel habits (alternations in bowel habits and short 
durations of symptom exacerbation and remission) repor- 
ted significantly less abdominal pain, and patients with 
constipation predominant IBS reported less constipation. 
These results indicate that different disease etiologies may 
exist between IBS sub groups and that some probiotics 
may be more efficient than others for treating symptoms 
within these sub groups. These findings also point to the 
need to further classify patients into relevant sub groups 
whenever   possible   for   assessing   the   efficacy   of   a 
probiotic. 
A number of studies investigating the effects of probi- 
otics within specific subgroups of IBS have shown the 
beneficial effects. Thus, Zeng et al. (2008) first separated 
patients with IBS into sub groups (those with increased 
small bowel permeability and those with increased colonic 
permeability), treating diarrhoea-predominant IBS patients 
with S. thermophilus, L. bulgaricus,  L. acidophilus  and 
B. longum. The proportion of patients with increased small 
bowel permeability (lactulose/mannitol ratio [0.025) 
decreased significantly (P \ 0.023) after treatment. These 
patients also showed improvements in their IBS score 
diminished abdominal pain and flatulence. Similarly, the 
symptoms were relieved after treatment with the probiotic 
VSL#3 in subjects with either diarrhoea-predominant IBS 
(Kim et al. 2005) or IBS with bloating (Kim et al. 2003). In 
subjects with IBS with bloating, the VSL#3 reduced flat- 
ulence scores and retarded colonic transit time, without 
altering bowel function. In patients with diarrhoea-pre- 
dominant   IBS,   the   VSL#3   only   relieved   abdominal 
 
 
2  A placebo is a substance containing no medication benefit and 
prescribed to reinforce a patient’s expectation of possibly attaining a 
beneficial effect. 
bloating, having no effect on mean transit measures, bowel 
function scores or satisfactory relief of symptoms. VSL#3 
has also been shown to be superior to a placebo in children 
with IBS. VSL#3 supplementation improved overall IBS 
symptoms as assessed by abdominal pain/discomfort, 
abdominal bloating/gassiness and on family life disruption 
(Guandalini et al. 2010). 
To date, monitoring disease symptoms has been usually 
used to assess the efficacy of probiotics in IBS and IBD 
patients. These subjective measures, usually self-assessed 
by the patients, have provided slight indications of the 
underlying mechanisms of probiotics or the disease etiol- 
ogy. In an attempt to understand the physiological actions 
of probiotics, Kajander et al. (2005) administered patients 
with IBS the mixture of probiotic supplements containing 
LGG, L. rhamnosus LC705, B. breve Bb99 and P. freud- 
enreichii  ssp.  shermanii  JS  (Kajander  et  al.  2005)  or 
L. rhamnosus GG, LGG, L. rhamnosus Lc705 (DSM 7061), 
P.  freudenreichii  ssp.  Shermanii  JS  (DSM  7067)  and 
B. animalis ssp. lactis Bb12 (Kajander et al. 2005). Serum 
CRP and pro-inflammatory and anti-inflammatory cytokine 
(IFN-c, TNF-a, IL-2, IL-4, IL-6 and IL-10) concentrations 
were generally below the limit of detection and, therefore, 
did not indicate any differences between the treatment 
groups (Kajander et al. 2008). Both studies did, however, 
report an improvement in the IBS scores from baseline, 
particularly for distention and abdominal pain. The IBS 
score had at 5 months decreased by 14 points (95% CI -19 
to -9) with the multispecies probiotic versus 3 points (95% 
CI -8  to 1) with placebo (P = 0.0083). Moreover, the 
study also reported that there was a stabilization of the 
microbiota. As the microbiota similarity index increased 
with the probiotic supplementation (1.9 ± 3.1), it decreased 
with placebo (-2.9 ± 1.7). 
In contrast to the benefits of probiotics for relieving IBS, 
symptoms other studies have found few or no beneficial 
effects of probiotics. O’Mahony et al. (2005) found dis- 
parate  effects  when  providing  L.  salivarius  UCC4331, 
B. infantis 35624 or a placebo to subjects with IBS and to 
healthy volunteers. Following supplementation, the com- 
posite score (weeks 1–8), pain/discomfort (at weeks 1, 2, 4, 
5, and 7), bloating/distention (at weeks 2, 5, and 6) and 
difficulty with bowel movements (at weeks 2, 3, 5, and 6) 
were generally lower in the B. infantis group than in the 
placebo (malted milk drink) group. Composite score was 
only lower in the L. salivarius group compared with the 
control group in the second week of supplementation, 
indicating that the effects of L. salivarius were short-lived 
and intermittent. In vitro production of IL-10 and IL-12 by 
isolated mononuclear cells [peripheral blood mononuclear 
cells (PBMC)] from whole blood was a pro-inflammatory 
profile at baseline in patients with IBS. Patients with IBS 
had low levels of IL-10 and high levels of IL-12 synthesis 
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compared with healthy volunteers. Notably, however, 
supplementation with B. infantis restored IL-10 and IL-12 
synthesis to levels similar to those observed in healthy 
volunteers. 
To understand the apparent lack of effect of probiotics 
in some clinical studies, it is essential that the placebo 
effect or natural healing cycle needs to be objectively 
investigated. Niv et al. (2005) provided L. reuteri ATCC 
55730 or a placebo to subjects with IBS. Following sup- 
plementation, an improvement in IBS symptoms was 
reported. However, a similar response occurred in the 
placebo group (treatment versus placebo P = 0.0714 and 
P = 0.0971, respectively). This may demonstrate a strong 
placebo effect or stimulation of the natural healing cycle of 
the disease allowing some IBD and IBS patients to more 
frequently enter periods of remission. 
Overall the therapeutic effect of probiotics in human 
studies supports additional benefits. While some results 
were inconsistent, probiotics treatment generally reduced 
symptoms  of   IBS,   particularly   abdominal   pain,   and 
restored the balance of pro- and anti-inflammatory cyto- 
kines. Separation of IBS into sub-classes of disease activity 
confirmed that some probiotic strains may have effects that 
are symptom-specific (Fedorak and Dieleman 2008; 
Hammer 2011). Based on these findings, further research is 
required to identify more specifically the various effects of 
each probiotic when applied to different disease classifi- 
cations. To overcome potential placebo effects and 
minimize inconsistent results, a greater emphasis should be 
placed on sample size. Future research is vital to help find 
how and why probiotics are effective in each specific dis- 
ease  state.  This,  then  may  further  assist  to  map  the 
aetiology of particular inflammatory conditions that serve 
to develop rationally designed prophylactic and therapeutic 
interventions. 
 
 
The symbiotic control  of GIT inflammation 
 
Inflammation  is  an  essential  physiological  response  by 
body tissues to injury, chemical irritation or an assault by 
generally pathogenic bacteria (Mazmanian et al. 2008). 
Once the insult is neutralized, normal physiological func- 
tion needs to be restored. In the GIT, an inflammatory 
response is elicited to clear pathogenic bacteria with 
adaptive responses by commensal and probiotic bacteria 
that can then subsequently reduce the inflammatory 
response. This, thereby promotes a regulated pro- or anti- 
inflammatory state, and assists in reducing the symptoms of 
conditions  such  as  IBS.  Figures 1  and  2  illustrate  dia- 
grammatically  the  complexity  exhibited  by  the  GIT  in 
the regulation of inflammation. Research (Parassol et al. 
2005; Zyrek et al. 2007) supports the notion that increased 
intestinal permeability resulting from the disruption of the 
epithelial tight junction may initiate or promote dys-regu- 
lated inflammation. Maintaining and protecting the tight 
junctions preserve barrier function (Nunbhakdi-Craig et al. 
2002; Schneeberger and Lynch 2004). It has been dem- 
onstrated in vitro that treatment of T84 and Caco-2 cells 
with probiotics restored or maintained tight junction com- 
plexes,  thereby  restoring  the  epithelial  barrier  function 
in  enteropathogenic  E.  coli-stimulated  cells.  Incubation 
with Escherichia coli Nissle 1917 or L. casei following or 
during enteropathogenic E. coli infection restored the 
integrity of the epithelial cell barrier (Parassol et al. 2005, 
Zyrek et al. 2007) (Fig. 2). 
Commensal bacteria and vertebrate immune systems 
form a symbiotic relationship and have a co-evolutionary 
profile (such that proper immune development and function 
rely on colonisation of the GIT by commensal bacteria and 
the maturation cues elicited by the bacterial cohort. 
Modification of the gut flora has strong therapeutic 
implications. The demonstration that commensal bacteria 
are not sequestered by the gut epithelium but are instead 
recognized by TLRs under normal steady-state conditions 
attests to this complexity. Indeed, the interaction of com- 
mensal bacterial products with host microbial pattern 
recognition receptors plays a crucial role in resistance to 
epithelial injury and promoting intestinal homeostasis 
(Rossi et al. 2011). Because mammalian TLRs recognize 
products of both pathogenic and commensal bacteria, they 
might have at least two distinct functions, namely: (1) 
protection from infection and (2) control of mucosal 
homeostasis, both of which are dependent on the recogni- 
tion of microorganisms—pathogens and commensals, 
respectively. This dual function might explain why some of 
the TLR-induced gene products, such as inflammatory 
cytokines and chemokines, are intricately involved in both 
host defense and tissue repair. 
Although the clinical evidence for the benefits of pro- 
biotics is equivocal, the data presented in this review 
indicate that probiotics provide both a prophylactic and 
therapeutic benefit by regulating cytokine and cell signal- 
ing pathways (Mencarelli et al. 2011). We have previously 
reviewed the published human studies of probiotics and of 
prebiotics (a nutritional supplement favoring the growth 
and increasing the lifespan of probiotic bacteria) and their 
effects on several clinical scenarios (Vitetta and Sali 2008). 
The  beneficial effects  of  probiotics  and  prebiotics  can 
occur when the internal human environment meets the 
enhanced  commensal/probiotic  environment  throughout 
the digestive tract. Understanding both the bacteria–bac- 
teria interactions and the bacteria–host interactions, 
especially in the distal GIT, will provide further opportu- 
nities  for  modulating  the  bacterial  flora for  therapeutic 
gain. Although the trials summarized in Tables 1 and 2 
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Fig. 2  Epithelial  cell  barrier of the  gastrointestinal tract.  a  Tight 
junction and gap junction between two epithelial cells. ZO translo- 
cates away from the cell boundary towards the nucleus reducing the 
transepithelial resistance allowing pathogens to move between the 
cells  and  through  the  cell  wall  into  the  lamina  propria.   Once 
the pathogen enters the lamina propria it is able to move throughout 
the gastrointestinal system and systemic circulation causing sever 
inflammation. b LPS-mediated pathway of inflammation. c RONS- 
mediated induction of cytokine production and inflammation. d Anti- 
gens presenting on the epithelial surface may be detected and 
consumed by dendritic cells. The antigen is presented to TH0 cells 
which enter the TH1 or TH2 pathway depending on the antigen. 
Probiotics help regulate and reduce inflammation by (1) preventing 
the translocation of ZO to the nucleus helping maintain the TER and 
the integrity of gap junctions preventing the migration of pathogens 
past the epithelial barrier and (2) by preventing the activation of NF- 
jB caused by pathogens and compounds like LPS and RONS. This 
figure was constructed from the published data of Nunbhakdi-Craig 
et al. (2002), Schneeberger and Lynch (2004), Parassol et al. (2005), 
Zyrek et al. (2007). ZO-1 and -2 zolulin occludin, JAM-1 junctional 
adhesion molecule, LPS Lipopolisaccharides 
 
indicate promising trends, the present consensus is that a 
number of larger controlled trials will be necessary before 
warranting the use of probiotic supplements as a routine 
medical treatment for numerous gastrointestinal conditions. 
There  is  considerable  public,  media  and  scientific 
interest in various natural products that include probiotics 
and prebiotics in modulating intestinal activities. Probiotic 
bacteria are becoming more important in the context of 
human nutrition, as scientific evidence continues to accu- 
mulate on the properties, functionality, and benefits of 
probiotics for promoting human health. Manipulating this 
most complex ecosystem is challenging. This is especially 
evident when therapeutic interventions aim to regulate the 
GIT flora for the effective treatment of diseases such as 
irritability  and  inflammation  of  the  GIT  and  possibly 
cancer of the large bowel. However, the promise is often 
admixed with the hype. We do not believe one probiotic 
will cure all diseases, but rather that probiotics are certainly 
an integral part of the integrative approach to health. 
 
 
Prebiotics  and synbiotics 
 
The  introduction  of  prebiotics  (Table 2)  in  Japan  and 
Europe as food additives justifies the need for controlled 
clinical studies, before prebiotics can be unequivocally 
recommended as a food additive for infant formulas and 
yogurts or as dietary supplements that should be consumed 
on a daily basis. No human studies have been conducted to 
confirm the suggested in vitro and animal study effects of 
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Table 2  Clinical studies reported for prebiotics and symbiotics [adapted and updated from Vitetta and Sali (2008)] 
 
Prebiotics and symbiotics 
 
Conditions and symptoms Type of prebiotic and (daily dose) Level of 
evidencea 
 
References 
 
Constipation in 
elderly adults 
Galacto-oligosaccharides (12 g/day) III Scheppach et al. (2001) 
Fructo-oligosaccharides (10 g) III Welters et al. (2002) 
Sairanen et al. (2007) 
Yen et al. (2011) 
Infant weight gain Symbiotic treatment II Chouraqui et al. (2008) 
B. longum BL999 (BL999) ? L. rhamnosus LPR, 
BL999 ? LPR ? 4 g/L of 90% galacto-oligosaccharide/10% 
short-chain fructo-oligosaccharide (GOS/SCFOS), or 
BL999 ? L. paracasei  ST11 (ST11) ? 4 g/L GOS/SCFOS 
IBD Dietary inulin 24 g/day III Welters et al. (2002) 
Active CD Symbiotic treatment II Furrie et al. (2005) 
Chronic pouchitis 
Active UC 
B. longum ? 6 g of synergy (inulin plus oligofructose mixture 
b.i.d. synergy 15 g/day) 
Lindsay et al. (2006) 
Prevention of atopic eczema Galacto-oligosaccharides and Fructo-oligosaccharides II Kukkonen et al. (2007) 
(infants on formula feeding 
regimens) 
Immunity decreased—reducing 
rates of infection 
(0.8 g/100 ml of formula) 
 
Fructo-oligosaccharides (2 g for infants) II Shadid et al. (2007) 
Enhanced calcium absorption       Fructo-oligosaccharides (8 g)                                                               II                 Scholz-Ahrens et al. (2007) 
 
Synbiotics are products that contain both a probiotic and prebiotic component (Bengmark and Martindale 2005; Scholz-Ahrens et al. 2007) 
a   Level I: from a systematic review of all relevant randomised controlled trials—meta-analyses, Level II: from at least one properly designed 
randomised controlled clinical trial, Level III: from one or more well-designed pseudo-randomised controlled trials (alternate allocation or some 
other method) 
 
prebiotics on carcinogenesis. Long-term trials with prebi- 
otics, perhaps among patients with chronic digestive 
diseases such as colon cancer-prone patients, would cer- 
tainly be useful (de Vrese and Schrezenmeir 2008). 
The efficacy of a synbiotic combination of combining 
prebiotics with probiotics needs to be further evaluated and 
quantified. Such studies could include investigations as to 
whether there is altered bacterial colonization in the gut 
following the ingestion of both prebiotics and probiotics. For 
example, by determining the natural adaptation of the gut to 
re-colonization with commensal bacteria and their growth- 
promoting nutrients (after pre/probiotic treatment) may 
establish how dietary factors could influence the pathogen- 
esis of inflammatory diseases of the digestive system. 
The  FAO/WHO  Expert  Consultation  and  Working 
Group on probiotics presented their recommendations to 
Codex (Pineiro and Stanton 2007) with the hope that these 
will be used for a science-based risk assessment process for 
managerial decisions concerning probiotics. These recom- 
mendations will have major implications by limiting future 
health claims that can be attributed to probiotics as thera- 
peutic preparations. 
The resolution of some human diseases does not reside 
solely within the host but rather could involve the host’s 
interface with the microbial environment. Manipulating the 
gut flora is a realistic therapeutic and prophylactic strategy 
for many infectious, inflammatory and neoplastic diseases 
within the gut. But the promise of pharmacobiotics (ther- 
apeutic exploitation of the commensal flora) is only likely 
to be fulfilled following greater understanding of the 
endogenous enteric microflora. The GIT flora is certainly a 
rich repository of metabolites that can be exploited for 
therapeutic benefit. Elucidating the molecular details of 
host–gut flora interactions is, therefore, a prerequisite for a 
bacteria derived metabolomic program of discovery that 
may provide novel metabolites for the control of GIT 
inflammation. Reports that have demonstrated that dietary 
fructo-oligosaccharide (neosugar) can significantly influ- 
ence the feacal flora and activities of reductive enzymes 
(Buddington et al. 1996) certainly warrant further study. 
Synbiotics are products that contain both probiotic and 
prebiotic components (Bengmark and Martindale 2005; 
Scholz-Ahrens et al. 2007). The rationale for such combi- 
nation products is that together the formulation enhances 
the survival of probiotic bacteria in transit through the 
proximal GIT, improves colonization of the probiotic in the 
large bowel and stimulates the growth of the endogenous 
flora as well (Bengmark and Martindale 2005). This effect 
may rescue the GIT from a dys-regulated inflammatory 
response that may increase risk of disease. 
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Future research 
 
Future directions for research may involve exploring the 
optimal doses of probiotics, duration of treatment, their effects 
in different models (in vitro and animal) of inflammatory 
disease and suitability as a prophylactic or therapeutic treat- 
ment. Probiotics and prebiotics can be delivered to the GIT but 
the proportion of ingested viable bacteria that reach the 
intestinal tract is not well characterized. Studies aimed at 
calculating the quantity of viable probiotic bacteria that 
reaches the upper and lower GIT may be useful. There is still a 
clear lack of evidence about the effect probiotics has on 
patients with IBD in terms of restoring the GIT microbiome 
profile. While alleviating the symptoms of IBD and IBS is 
clinically relevant, future research may also benefit from 
collecting colon tissue from CD and UC subjects for analysis 
of gastrointestinal inflammation, bacterial adhesion to normal 
epithelial cells and colonic crypts histology. This would cer- 
tainly provide a better understanding of the underlying 
mechanisms of each condition and possibly lead to better 
strategies for treatment. Ultimately, probiotic research may 
also need to examine the synergistic benefits associated with 
individual bacterial strains that are currently used to formulate 
commercially available probiotic mixtures. 
Mechanistically, the causal relationship between reac- 
tive oxygen species and the unbridled damage proposed to 
macromolecules has led to an over simplification of com- 
plex biological processes. We have previously reported that 
the formation of superoxide anion/hydrogen peroxide and 
nitric oxide does not conditionally lead to random macro- 
molecular damage; under normal physiological conditions, 
their production is actually regulated consistent with their 
second messenger roles (Linnane et al. 2007). As for the 
GIT, we would expect that it too would behave in a manner 
that sustains a redox regulated state. Intestinal cells that 
maintain a redox balance preserve the environment that 
supports physiological processes and orchestrates networks 
of enzymatic reactions whereby inflammation remains 
regulated. Furthermore, the innate immune system presents 
a wide array of different receptors that can recognize 
specific bacterial molecular patterns. Hence an enhanced 
understanding of the role played by individual probiotic 
molecular patterns becomes crucial to evolve the current 
complex area of live probiotic bacteria toward improved 
efficacious pharmacobiotic strategies (Caselli et al. 2011). 
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Abstract   The microbiome located in the human gastro- 
intestinal tract (GIT) comprises the largest community 
(diverse and dense) of bacteria, and in conjunction with a 
conducive internal milieu, promotes the development of 
regulated  pro-  and  anti-inflammatory signals  within  the 
GIT that promotes immunological and metabolic tolerance. 
In addition, host-microbial interactions govern GIT 
inflammation and provide cues for upholding metabolic 
regulation in both the host and microbes. Failure to regu- 
late inflammatory responses can increase the risk of 
developing inflammatory conditions in the GIT. Here, we 
review clinical studies regarding the efficacy of probiotics/ 
prebiotics and the role they may have in restoring host 
metabolic homeostasis by rescuing the inflammatory 
response. The clinical studies reviewed included functional 
constipation, antibiotic-associated diarrhoea, Clostridium 
difficile diarrhoea, infectious diarrhoea/gastroenteritis, 
irritable bowel syndrome, inflammatory bowel diseases and 
necrotizing enterocolitis. We have demonstrated that there 
was an overall reduction in risk when probiotics were 
administered over placebo in the majority of GIT inflam- 
matory   conditions.  The   effect   size   of   a   cumulative 
reduction in relative risk for the GIT conditions/diseases 
investigated was 0.65 (0.61–0.70) (z = 13.3); p \ 0.0001 
that is an average reduction in risk of 35 % in favour of 
probiotics. We  also progress a  hypothesis that  the  GIT 
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comprises numerous micro-axes (e.g. mucus secretion, 
Th1/Th2  balance)  that  are  in  operational  homeostasis; 
hence probiotics and prebiotics may have a significant 
pharmacobiotic regulatory role in maintaining host GIT 
homeostasis in disease states partially through reactive 
oxygen species signalling. 
 
Keywords    Microbiome · Clinical trials · 
Reactive oxygen species · Probiotics · Lactobacillus · 
Bifidobacteria · Prebiotics · Gastrointestinal tract · 
Inflammation · Internal environment · Nutrition 
 
 
Introduction 
 
Inflammatory reactions are defence mechanisms triggered 
by injury to tissues that can be prompted by either internal 
or external insults (Koch and Nusrat 2012). The functional 
interactions between the anatomical sub-structures of the 
gastrointestinal tract (GIT) (e.g. epithelial cell lining, 
mucosal tissues), the microbiota that inhabits this site and 
the milieu that ensues, lead to functional connections with 
complex metabolic outcomes. 
It is reported that the products of bacterial metabolism in 
the GIT act as signalling molecules that impact the host’s 
metabolic responses (Tremaroli and Ba¨ckhed 2012). 
Although contentious, the idea that humans in utero are 
germ-free may no longer be accurate, (Jime´nez et al. 2008) 
instead bacteria or bacterial antigen exposure at this 
developmental stage may occur indicating that signalling 
of mucosal development may actually commence in utero 
rather than in the neonatal stage. Furthermore, diet and 
medications (i.e. antibiotics) that a neonate is exposed to, 
in combination with the GIT microbiome in early life, may 
hold the key to aberrant molecular signals that predispose 
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to chronic inflammatory disease development in adulthood 
(Neuman and Nanau 2012). 
Recent analytical studies report that it is possible to 
classify humans into just three broad bacterial enterotypes 
(irrespective of whether chronic intestinal diseases are 
present or absent), hence these being dominated by three 
different genera, namely the Bacteroides and Prevotella 
(both belonging to the phylum Bacteroidetes) and Rumi- 
nococcus (Arumugam et al. 2011). Furthermore, it has been 
reported that this overall enterotype profile was conserved 
independently of gender, body mass index and geographi- 
cal region/nationality, while notwithstanding the significant 
differences that exist in the long-term dietary habits 
between people from Western countries and those from 
Asian countries. In another study that investigated what 
linkages may exist between long-term dietary patterns with 
GIT microbial enterotypes, it was reported that higher fat 
and lower fiber intakes were associated with specific en- 
terotypes (Wu et al. 2011). That is that the enterotypes 
seemed to be determined by the type of long-term diet 
exposure. Hence, the Bacteroides enterotype was positively 
related with animal protein and saturated fats, whereas the 
Prevotella enterotype was associated with a mostly plant- 
based dietary profile that consisted of high carbohydrates 
and low meat and dairy consumption. Further, a recent 
investigation demonstrated that short-term macronutrient 
changes in the diet, being either composed of entirely 
animal or plant products, substantially alter the microbial 
profile and microbial gene expression in humans (David 
et al. 2013). The authors reported that the animal-based diet 
increased the abundance of bile-tolerant microbes (Alisti- 
pes, Bilophila and Bacteroides) and decreased the levels of 
Firmicutes that metabolize dietary plant polysaccharides 
(Roseburia, Eubacterium rectale  and Ruminococcus bro- 
mii). The reverse was true for the plant-based diet. Whereas 
the animal-based diet increased the abundance and activity 
of Bilophila wadsworthia and altered faecal bile acid pro- 
files that are associated with IBD. 
The increased consumption of fat-to-fiber ratio that 
occurs in Western diets has been reported to be among the 
major triggering factors of metabolic impairments and gut 
dysbiosis that can lead to obesity and type II diabetes mellitus 
(T2DM) (Roberfroid 2007). A recent study in mice showed 
that the gut microbiota could be regarded as a stamp of the 
metabolic phenotypes that inhabit the GIT and that this was 
independent of differences in host genetic make-up and 
dietary profile (Serino et al. 2012). This then proposes the 
notion that there may be a co-operative microbial–host 
induction of metabolic adaptation. Consequently, modifying 
the gut microbiota by administering appropriate dietary 
changes together with probiotic species and prebiotic fibers 
may represent a promising strategy to control or prevent 
inflammatory metabolic diseases of the GIT. 
Methodology 
 
A systematic search of the literature was conducted using 
PubMed, the Cochrane Library, Science Direct, Scopus, 
EMBASE, MEDLINE and CINAHL. 
 
Search terms 
 
Articles were identified using the search terms, ‘‘Diet’’ OR 
‘‘Overweight’’  OR  ‘‘Obesity’’  AND  ‘‘Probiotics’’  OR 
‘‘Prebiotics’’ OR ‘‘Commensal Bacteria’’ AND ‘‘Gastro- 
intestinal Tract’’ and ‘‘Inflammation’’ AND ‘‘Crohn’s 
Disease’’ AND ‘Ulcerative colitis’’ AND ‘‘Irritable Bowel 
Syndrome’’ AND’’ Constipation’’ AND ‘‘Diarrhoea’’ AND 
‘‘Gastrointestinal Infections’’ AND ‘‘Necrotizing Entero- 
colitis.’’ The inclusion criteria for this review were: (1) an 
RCT and/or cross-over clinical trial that used either a 
placebo comparator or other as a control published on or 
after the year 2000, (2) human participants diagnosed with 
or without GIT inflammatory conditions, (3) other epide- 
miological observational and mechanistic studies, (4) the 
clinical study was published in English; and (5) the clinical 
study presented data in the form of a relative risk (RR) 
(95 % CI) reduction (test: probiotic with or without pre- 
biotics versus a placebo or appropriate comparator) or that 
 
 
356 Records identified from bibliographic databases 
 
 
 
Records excluded from further review 
188   Study design not eligible 
76   No relevant outcome 
10   No relevant study group 
 
 
82 Studies retrieved for relevant assessment 
 
 
1 study excluded due to 
repeat publication 
 
 
81 studies assessed qualitatively 
 
 
 
 
Of the 81 RCTs assessed these included… 
Clostridium difficile diarrhoea = 3 
Antibiotic Associated Diarrhoea =17 
Infectious Diarrhoea / Viral Gastroenteritis   =11 
Irritable Bowel Syndrome =21 
Crohn’s Disease = 5 
Ulcerative Colitis = 6 
Necrotizing Enterocolitis =10 
Constipation = 4 
Pouchitis = 4 
 
Fig. 1  Flow diagram of literature search for systematic review 
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Table 1  RCTs that administered probiotics with/without prebiotics reporting a benefit or otherwise for inflammatory conditions/diseases of the 
gastrointestinal tract as an effect size (risk ratio reduction and 95 % CI) 
 
Conditions/diseases 
references 
 
Strain(s), Dose regimen 
L. = Lactobacillus 
B. = Bifidobacterium 
S. = Streptococcus 
E. = Escherichia 
 
Effect size RR (95 % CI)*   Outcome 
 
Functional constipation 
Koebnick et al. 2003 L. casei (Shirota) 
Dose: 6.5 9 109  CFU/65 mL/day/ 
5 weeks 
Yang et al. 2008 B. lactis DN-173010 
Dose: 1.25 9 1010  CFU/100 g of 
fermented milk/day/2 weeks 
 
0.27 (0.1–0.72) Significant improvement in chronic 
constipation 
 
 
0.32 (0.23–0.43) Significant improvement in stool 
frequency by probiotic (71 %) over 
control (8.3 %) in 2-week study period 
Banaszkiewicz and 
Szajewska 2005 
L. rhamnosus GG 
Dose: 1 mL/kg/day of 70 % lactulose 
plus 109  CFU/day/24 weeks 
1.1 (0.58–1.9)* No significant difference between 
treatments 
Bu et al. 2007 Lcr35 8 9 108 CFU/day (250 mg/two 
capsules/b.i.d./4 weeks) 
Tabbers et al. 201117  B. lactis DN-173 010 
Dose: 4.25 9 109  CFU/125 g/pot/b.i.d./ 
3 weeks 
Mazlyn et al. 201314  L. casei strain Shirota 
Dose: 3 9 1010  CFU/80 mL/day/4 weeks 
 
 
Antibiotic-associated diarrhoea 
Surawicz et al. 2000 S. boulardii 
Dose: 1 g/day (administered as 2x250 mg 
capsules b.i.d./4 weeks 
 
Szajewska et al. 2001 L. rhamnosus GG 
Dose: 6 9 109  CFU/day/until discharged 
Thomas et al. 2001 L. rhamnosus GG 
Dose: 20 9 109  CFU/day/2 weeks 
 
 
Armuzzi et al. 2001 L. rhamnosus GG 
Dose: 6 9 109  CFU/b.i.d./2 weeks 
Cremonini et al. 2002 L. casei subsp. rhamnosus (GG) 6 9 109/ 
sachet 
Saccharomyces boulardii 5 9 109/sachet 
L. acidophilus and B. lactis 5 9 109/ 
sachet 
Dose: administered b.i.d./2 weeks 
Jirapinyo et al. 2002 L. acidophilus and B. infantis 
Dose: 108  CFU/b.i.d./2 weeks 
La Rosa et al. 2003 L. sporogens ? prebiotic of 
Fructo-oligosaccharides 
Dose : 107  CFU/t.i.d./2 weeks 
0.25 (0.1–0.61) Significant improvement with probiotic 
over placebo 
0.86 (0.70–1.10)* Non-significant :stool frequency over 
control 
 
 
0.71 (0.55–0.92) ;severity in constipation/significant only 
after 4 weeks (authors noted that a 
longer intervention was required to 
properly assess this study outcome) 
 
 
0.33 (0.11–1.06)* S. boulardii ? high-dose vancomycin 
non-significant :67 % efficacy 
prevention of CDD recurrences over 
high-dose vancomycin alone 
0.2 (0.1–0.66) Significant;nosocomial diarrhoea 
 
 
0.98 (0.68–1.4)* No statistically significant difference 
between probiotic and placebo in 
reducing antibiotic-associated 
diarrhoea 
0.01 (0.03–0.43) ;bloating ;diarrhoea ;taste disturbances 
 
 
0.17 (0.02–1.27)* ;diarrhoea—all probiotic combinations 
not significantly better than placebo 
 
 
 
 
 
0.47 (0.18–1.21)* Non-significant ;diarrhoea 
 
 
0.47 (0.29–0.77                     Non-significant;number of days and 
duration of events with antibiotic- 
induced diarrhoea 
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Table 1  continued 
 
Conditions/diseases 
references 
 
 
Strain(s), Dose regimen 
L. = Lactobacillus 
B. = Bifidobacterium 
S. = Streptococcus 
E. = Escherichia 
 
 
Effect size RR (95 % CI)*   Outcome 
 
Beniwal et al. 2003 Vanilla-flavored yogurt containing 106 
CFU/g of L. acidophilus, 
L. bulgaricus, and S. thermophilus 
combined 
Dose: 227 g/b.i.d./8 days 
Seki et al. 2003 Clostridium butyricum 
Dose: 107  CFU/g viable spores 
administered at 1–4 g/day/1 weeks 
Nista et al. 2004 Bacillus clausii 
Dose: 2 9 109  spores/t.d.s./2 weeks 
Pereg et al. 2005 L casei DN-114 001 
Dose: 100 mL of yogurt with 108  CFU/ 
mL/day/8 weeks (6 days/week) 
Correˆa et al. 2005 B. lactis S. thermophilus 
Dose: 107  and 106  CFU, respectively, of 
each/day/2 weeks 
Kotowska et al. 2005 S. boulardii 
Dose: 250 mg/b.i.d./duration of antibiotic 
treatment 
Wenus et al. 2008 L. rhamnosus GG 
L. acidophilus La-5 
B. lactis Bb-12 
Dose: 108  CFU/mL of LGG/Bb-12 and 
107  CFU/mL 
La-5 administered as 250 mL/day/ 
2 weeks 
Frohmader et al. 201019  S. thermophilus 
B. breve 
B. longum, 
B. infantis 
L. acidophilus, 
L. plantarum, 
L. paracasei, 
L. delbrueckii subsp. Bulgaricus 
Dose: 45 9 1010  multi–strain CFU/day/ 
2 weeks 
Song et al. 2010 L. rhamnosus R0011 
L. acidophilus R0052 
Dose: 2 9 109  CFU/capsule/b.i.d./ 
2 weeks 
Cimperman et al. 201120  L.reuteri ATCC 55730 
Dose: 1 9 108  CFU/day/4 weeks 
0.52 (0.28–0.97) Significantly reduced the incidence and 
duration of antibiotic-associated 
diarrhoea 
 
 
 
0.12 (0.05–0.28) Effective treatment and prophylaxis for 
antibiotic-associated diarrhoea 
 
 
0.88 (0.50–1.56)* A non-significant;prevalence of diarrhoea 
 
 
0.76 (0.49–1.17)* A non-significant trend for reduction of 
the incidence of diarrhoea was reported 
 
 
0.52 (0.21–1.23)* Non-significant :stool frequency and 
;stool consistency 
 
 
0.19 (0.07–0.55) Significant;prevalence of diarrhoea 
 
 
 
0.21 (0.05–0.93) Significant ;risk of antibiotic-associated 
diarrhoea 
 
 
 
 
 
 
0.50 (0.27–0.93) Significant;frequency of liquid stool 
 
 
 
 
 
 
 
 
 
 
 
0.54 (0.17–1.74)* Non-significant ;antibiotic-associated 
diarrhoea 
 
 
 
0.15 (0.02–1.11)* Non-significant;frequency of diarrhoea 
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Table 1  continued 
 
Conditions/diseases 
references 
 
 
Strain(s), Dose regimen 
L. = Lactobacillus 
B. = Bifidobacterium 
S. = Streptococcus 
E. = Escherichia 
 
 
Effect size RR (95 % CI)*   Outcome 
 
Clostridium Difficile diarrhoea 
Wullt et al. 2003 L. plantarum 299v 
Dose: metronidazole (400 mg t.i.d.) 
orally for 10 days in combination with 
either a fruit drink containing oats 
fermented with L. plantarum 299v 
(5 9 1010  CFU/d) or placebo (fruit 
drink with chemically acidified oats) 
once a day for 38 days. 
Plummer et al. 2004 L. acidophilus 
B. bifidum 
Dose: one capsule 2 9 1010 CFU/capsule/ 
day/3 weeks 
Lawrence et al. 2005 L. rhamnosus GG 
Dose: LGG 2.8 9 1011  CFU/capsule 
(40 mg lyophilized LGG and 320 mg 
inulin) or one placebo capsule (360 mg 
inulin)/t.i.d. adjunctively with anti-C. 
difficile antibiotics 
Infectious/traveller’s diarrhoea/gastroenteritis 
 
0.55 (0.22–1.35)* Although efficacy was not significant 
probiotic group had less symptom 
recurrence. 
 
 
 
 
 
 
0.33 (0.07–1.59)* Non-significant;diarrhoea events for test 
over control (NS) 
 
 
 
1.53(0.54–4.35)* No significant difference between 
treatments 
Guandalini et al. 2000 L. rhamnosus GG 
Dose: rehydration solution containing 
1010  CFU/250 mL/until diarrhoea 
resolved 
0.57 (0.34–0.81) 
0.35 (0.12–0.59) 
Significantly shorter duration of diarrhoea 
in retrovirus positive children 
Significantly reduced duration of 
diarrhoea 
Szajewska et al. 2001 L. rhamnosus GG 
Dose: 2.46 g powder at 6 9 109  CFU/ 
sachet b.i.d./for duration of hospital 
stay 
Chouraqui et al. 2004 B. lactis Bb 12 
Dose: 106  CFU/g powder resulting in 
1.5 9 108  CFU/L/day/on average 
approx. 20–21 weeks 
Salazar-Lindo et al. 2004 L. casei strain GG 
Dose: 109  CFU/mL in a milk formula of 
150 mL/kg/day—maximum 
administered 1,000 mL 
0.13 (0.02–0.79) Significant improvement of probiotic over 
control. 
 
 
 
0.94 (0.53–1.66)* No significant difference between groups 
 
 
 
 
1.01 (0.46–2.21)* No improvement in management of 
diarrhoea 
Weizman et al. 2005 B. lactis Bb-12 or L. reuteri SD 2112 
Dose: all at 1 9 107  CFU/g powder/day/ 
12 weeks 
0.39 (0.19–0.79) 0.05 
(0.01–0.34) 
Both strains effective in ;diarrhoea 
Margreiter et al. 2006 L. gasseri and B. longum versus 
Enterococcus faecium 
Dose: 25 mg of 2 9 107–2 9 108  CFU/ 
capsule/t.i.d. versus 75 9 106  CFU/ 
capsule/t.i.d. 
Grossi et al. 2010 L. paracasei  B 21060 ? prebiotic 
Dose: 7 g sachet dissolved in water/juice 
of symbiotic preparation administered 
at 1011  CFU/day/10 days 
1.9 (0.74–4.96)** This study reported equivalent therapeutic 
efficacy for the 2 treatment regimens. 
 
 
 
 
0.43 (0.12–1.62) No difference in acute diarrhoea 
incidence at the end of the study 
However, significant difference in 
duration of diarrhoea 
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Table 1  continued 
 
Conditions/diseases 
references 
 
 
Strain(s), Dose regimen 
L. = Lactobacillus 
B. = Bifidobacterium 
S. = Streptococcus 
E. = Escherichia 
 
 
Effect size RR (95 % CI)*   Outcome 
 
Nagata et al. 201141  L. casei Shirota 
Dose: 4 9 1010  CFU/80 mL bottle/day/ 
12 weeks 
 
 
Virk et al. 2013 Synbiotic containing: 4.5 9 109  CFU 
Enterococcus faecium, a probiotic 
yeast of 5 9 108  CFU S cerevisiae 
strain CNCM I 4444 and a prebiotic 
fructo–oligosaccharide 
Dose: 2 capsules/day. 
1.25 (0.88–1.79)* No difference in number of cases with 
viral gastroenteritis between groups 
;mean duration days of fever after 
onset significantly decreased by test 
over placebo 
1.13 (0.87–1.5)* No significant difference of test synbiotic 
over placebo 
Pouchitis 
Gionchetti et al. 200022  S. Thermophiles 
 B. breve 
B. longum, 
B. infantis 
L. acidophilus 
L. plantarum 
L. paracasei 
L. delbrueckii subsp. Bulgaricus 
Dose: 5 9 1011  multi-strain CFU/g/6 g/ 
day/36 weeks 
Gionchetti et al. 200323  S. Thermophiles 
B. breve 
B. longum 
B. infantis 
L. acidophilus 
L. plantarum 
L. paracasei 
L. delbrueckii subsp. Bulgaricus 
Dose: 9 9 1011  multi-strain CFU/day/ 
52 weeks 
Mimura et al. 200424  S. Thermophiles 
B. breve 
B. longum 
B. infantis 
L. acidophilus 
L. plantarum 
L. paracasei 
L. delbrueckii subsp. Bulgaricus 
Dose: 30 9 1011  CFU/g 9 3/day/ 
52 weeks 
 
 
0.85 (0.71–1.02) ;frequency of flare-ups of chronic 
pouchitis effective in maintaining 
remission 
 
 
 
 
 
 
 
 
 
0.25 (0.06–1.03) ;frequency of flare-ups of chronic 
pouchitis effective in maintaining 
remission 
 
 
 
 
 
 
 
 
 
0.16 (0.06–0.46) ;frequency of flare–ups of chronic 
pouchitis—effective in maintaining 
remission at 1 year 
Crohn’s disease 
Guslandi et al. 2000 S. boulardii 
Dose: mesalamine 1 g t.i.d. or 
mesalamine 1 g b.i.d. plus a 
preparation of S. boulardii 1 g/day/ 
24 weeks 
 
 
0.17 (0.02–1.8)* Relapse in the probiotic treatment group 
was 6.25 % as compared to the control 
37.5 %. The low participant numbers 
precluded significance 
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Table 1  continued 
 
Conditions/diseases 
references 
 
 
Strain(s), Dose regimen 
L. = Lactobacillus 
B. = Bifidobacterium 
S. = Streptococcus 
E. = Escherichia 
 
 
Effect size RR (95 % CI)*   Outcome 
 
Prantera et al. 2002 L. rhamnosus GG 
Dose: 2.46 g satchet of 6 9 109/b.i.d./ 
52 weeks 
Schultz et al. 2004 L. rhamnosus GG 
Dose: 2 9 109  CFU/day/24 weeks 
 
Marteau et al. 2006 L. johnsonii, LA1, Nestle0 
Dose: 2 9 109  CFU/day/24 weeks 
Van Gossum et al. 2007 L. johnsonii, LA1, Nestle0 
Dose: 1010  CFU/day/12 weeks 
1.50 (0.90–2.4)* No significant difference from placebo in 
disease remission or disease 
improvement 
 
1.2 (0.1–14.7)* No significant difference in remission 
between test and placebo groups. 
Groups with low numbers 
0.77 (0.53–1.11)* No difference in recurrence between test 
and placebo groups 
 
1.10 (0.27–4.4)* Post elective ileo-caecal resection 
recurrence 
Ulcerative Colitis 
Ishikawa et al. 2003 B. breve 
B. bifidum 
L. acidophilus 
Dose: fermented milk 100 mL of 109CFU/ 
day/52 weeks 
Kato et al. 2004 B. breve strain Yakult 
B. bifidum strain Yakult 
L. acidophilus 
Dose: 109  CFU/100 mL bottle/day/ 
12 weeks 
Kruis et al. 2004 E. coli of strain Nissle 1917 (serotype 
O6:K5:H1) 
Dose: 2.5–25 9 109  CFU/day/52 weeks 
Sood et al. 2009 S. Thermophiles 
B. breve 
B. longum 
B. infantis 
L. acidophilus 
L. plantarum 
L. paracasei 
L. delbrueckii subsp. Bulgaricus 
Dose: 3.6 9 1012  multi-strain CFU/b.i.d./ 
12 wks 
Matthes et al. 2010 Escherichia coli strain Nissle 1917 
Dose: regimes tested were 20 mL of 
4 9 109  versus 20 mL of 2 9 109 
versus 10 mL of 109  CFU versus 
placebo/day/8 weeks 
 
 
0.30 (0.11–0.81) Probiotic supplementation maintained 
remission 
 
 
 
 
0.43 (0.15–1.2)* While there was a greater response to the 
probiotic treatment the result was not 
significant highlighting the low 
participant numbers. 
 
 
1.06 (0.86–1.19)* Probiotic equal efficacy to pharmaceutical 
in maintaining remission 
 
 
0.68 (0.55–0.84) Significant;UC disease activity index and 
remission in the active treatment over 
placebo at 6 and 12 weeks 
 
 
 
 
 
 
 
 
 
0.87 (0.54–1.4)* Re: in the intention to treat 
analysis…time to remission was 
shorter in the 40 mL administered 
group. The result was not significant 
highlighting the low participant 
  numbers   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
68 
 
Table 1  continued 
 
Conditions/diseases 
references 
 
 
Strain(s), Dose regimen 
L. = Lactobacillus 
B. = Bifidobacterium 
S. = Streptococcus 
E. = Escherichia 
 
 
Effect size RR (95 % CI)*   Outcome 
 
Tursi et al. 2010 S. thermophiles 
B. breve 
B. longum 
B. infantis 
L. acidophilus 
L. plantarum 
L. paracasei 
L. delbrueckii subsp. Bulgaricus 
Dose: 3.6 9 1012  multi-strain CFU/b.i.d./ 
8 weeks 
0.66 (0.45–0.97) ;UC disease activity index 
Irritable bowel syndrome 
Nobaek et al. 2000 L. plantarum (DSM9843) 
Dose: 400 mL of 5 9 107  CFU/mL/day/ 
4 weeks 
Niedzielin et al. 200129  L. plantarum 299 V 
Dose: 400 mL of 5 9 107  CFU/mL/day/ 
4 weeks 
Kim et al. 2003 S. thermophiles 
B. breve 
B. longum 
B. infantis 
L. acidophilus 
L. plantarum 
L. paracasei 
L. delbrueckii subsp. Bulgaricus 
Dose: 45 9 1011  multi-strain CFU/b.i.d./ 
8 weeks 
Kim et al. 2005 S. thermophiles 
B. breve 
B. longum 
B. infantis 
L. acidophilus 
L. plantarum 
L. paracasei 
L. delbrueckii subsp. Bulgaricus 
Dose: 45 9 1011  multi-strain CFU/b.i.d./ 
8 weeks 
Kajander et al. 2005 L. rhamnosus GG (ATCC 53103, LGG) 
L. rhamnosus Lc705 (DSM 7061), 
P. freudenreichii ssp. Shermanii JS (DSM 
7067) 
B. animalis ssp. Lactis Bb12 (DSM15954) 
Dose: ONE cap all at 8–9 9 109  multi- 
strain CFU/day/24 weeks 
 
 
 
 
 
 
 
0.59 (0.38–0.92) A non-significant;abdominal pain and 
flatulence 
 
 
0.10 (0.01–0.40) Significant;abdominal pain and overall 
IBS symptomatology normalisation of 
stools frequency test versus placebo 
 
1.1 (0.6–1.95)* A non-significant;bloating stool-related 
symptoms in diarrhoea-associated IBS 
 
 
 
 
 
 
 
 
 
 
0.77 (0.42–1.4)* A non-significant improvement in overall 
symptomatology of IBS 
 
 
 
 
 
 
 
 
 
 
0.42 (0.23–0.77) Significant change in total IBS symptom 
score including ;abdominal pain ? 
;bloating/distension ? ;flatulence ? 
;borborygmi 
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Table 1  continued 
 
Conditions/diseases 
references 
 
 
Strain(s), Dose regimen 
L. = Lactobacillus 
B. = Bifidobacterium 
S. = Streptococcus 
E. = Escherichia 
 
 
Effect size RR (95 % CI)*   Outcome 
 
Whorwell et al. 200633  B. infantis 35624 
Note 3 dose regimens were investigated 
and reported 
Dose 1: 1 9 106  CFU/day/4 weeks 
Dose 2: 1 9 108  CFU/day/4 weeks 
Dose 3: 1 9 1010  CFU/day/4 weeks 
Overall RR reduction: 
0.96 (0.72–1.30)* 0.88 
(0.69–1.11)* 1.16 
(0.90–1.50)* 0.90 
(0.76–1.10)* 
Combined variable of scores for 
abdominal pain/discomfort, bloating, 
and bowel habit satisfaction Non- 
significant improvements ;abdominal 
pain ;bloating ;bowel dysfunction 
Guyonnet et al. 2007 B. animalis DN-173 010 
Dose: 1.25 9 1010  CFU/day/6 weeks 
 
Gawronska et al. 2007 L. rhamnosus GG 
Dose: 3 9 109  CFU/day/4 weeks 
0.88 (0.66–1.75)* Non-significant improvement in 
constipation—predominant IBS and 
health-related quality of life 
0.70 (0.50–0.99) Significant improvements in pain 
frequency and severity 
Drouault-Holowacz et al. 
200835 
L. rhamnosus GG 
Dose: 1 9 1010  CFU/day/4 weeks 
0.98 (0.69–1.37)* ;abdominal pain borderline significance 
(p \ 0.048) trend toward lower 
abdominal pain score (p [ 0.05) 
Enck et al. 200837  E. coli (DSM 17252) 
E. faecalis (DSM 16440) 
Dose: 3–9 9 107  CFU/day/8 weeks 
0.51 (0.39–0.66) Significant;abdominal pain ;global 
symptom score 
Andriulli et al. 2008 Symbiotic formulation each 7 g sachet 
contains 
L. paracasei  B21060 [5 9 109  CFU 
xylo-oligosaccharides (700 mg) 
glutamine (500 mg) 
arabinogalactone (1,243 mg) 
Dose: 7 g in 100 mL of water/b.i.d./ 
12 weeks 
0.93 (0.68–1.3)* 0.46 
(0.24–0.89) 
Overall IBS symptomatology not 
significantly different between groups 
Significant ; in diarrhoea between 
groups in favour of the test 
Hong et al. 2009 B. bifidum BGN4 
B. lactis AD011 
L. acidophilus AD031; 
L. casei IBS041 
Dose: 20 9 109  CFU/sachet/b.i.d./ 
8 weeks 
Simre´n et al. 2010 L. paracasei,  ssp 
L. paracasei  F19, 
L. acidophilus La5, 
B. lactis B1. 
Dose: 400 mL of fermented milk of 
5 9 107  CFU/day/8 weeks 
Cui and Hu 2012 No clear information given re species or 
dose. 
Test: 2 Bifid triple viable capsules 
administered t.i.d./4 weeks 
Placebo: 200 mg of placebo administered 
t.i.d./4 weeks 
 
 
 
 
0.89 (0.54–1.46)* No significant change between groups in 
overall IBS symptomatology 
 
 
 
 
 
0.85 (0.62–1.7)* No significant treatment effect between 
active and control. 
 
 
 
 
 
0.51 (0.30–0.85) Significant difference trend of overall 
management of IBS symptomatology 
of test probiotic over placebo 
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Table 1  continued 
 
Conditions/diseases 
references 
 
 
Strain(s), Dose regimen 
L. = Lactobacillus 
B. = Bifidobacterium 
S. = Streptococcus 
E. = Escherichia 
 
 
Effect size RR (95 % CI)*   Outcome 
 
Ki Cha et al. 201239  S. thermophiles 
B. breve 
B. longum 
B. infantis 
L. acidophilus 
L. plantarum 
L. paracasei 
L. delbrueckii subsp. 
Bulgaricus 
Dose: 1 9 1010  multi-strain CFU/day/ 
8 weeks 
Kruis et al. 2012 E. coli Nissle 1917 
Dose: 2.5–25 9 109  CFU/day/12 weeks 
 
 
Ducrotte´ et al. 2012 L. plantarum 299v (DSM 9843) 
Dose: 1 9 1010  CFU/capsule/day/ 
4 weeks 
0.59 (0.4–0.89) ;abdominal pain ;bloating 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.81 (0.57–1.17)* No difference between groups response to 
treatment was significant in the 
probiotic group versus placebo in a 
subgroup prior to IBS development 
0.24 (0.17–0.35)                    Significant effective symptom relief, 
particularly of abdominal pain and 
bloating 
Dapoigny et al. 2012 L. casei rhamnosus Lcr35 
Dose: 6 9 108  CFU/day/4 weeks 
 
 
Roberts et al. 2013 B. lactis (strain I-2494 DN-173 010) 
S. thermophiles (CNCM strain I-1630) 
L. bulgaricus (CNCM strain I-1632 and 
I-1519) 
Dose: 1.25 9 1010  CFU B. lactis and 
1.2 9 109  CFU/cup of S. thermophiles 
and L. bulgaricus/day/4 weeks and 
8 weeks 
Capello et al. 2013 Symbiotic preparation contains 
thermophile bacteria: 
5 9 109  L. plantarum 
2 9 109  L. casei subp. Rhamnosus 
2 9 109  L. gasseri 
1 9 109  B. infantis 
1 9 109  B. longum 
1 9 109  L. acidophilus 
1 9 109  L. salivarus 
1 9 109  L. sporogenes 
5 9 109  S. thermophiles 
Prebiotic inulin 2.2 g 
1.3 g of tapioca-resistant starch 
Dose: 5 g sachet/b.i.d./4 weeks 
 
 
 
 1.20 (0.8–1.80) 0.64 (0.44–0.93) 
 
 
0.92 (0.6–1.54)* 5.4 (2.1–13.8) 
 
 
 
 
 
 
 
0.71 (0.46–1.16)* 0.80 (0.52–1.24)* 0.84 
(0.6– 
1.19)*Overall IBS symptomatology 
improved in placebo over test with 
significant ;in diarrhoea sub analysis in 
test over placebo 
4 weeks no difference between groups 
8 weeks placebo more significantly 
effective (p = 0.001) 
 
 
 
 
 
 
Symbiotic preparation demonstrated a 
non-significant beneficial effect in ; 
flatulence and bloating severity in IBS. 
Overall RR reduction not significant 
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Table 1  continued 
 
Conditions/diseases 
references 
 
 
Strain(s), Dose regimen 
L. = Lactobacillus 
B. = Bifidobacterium 
S. = Streptococcus 
E. = Escherichia 
 
 
Effect size RR (95 % CI)*   Outcome 
 
Yoon et al. 2014                   B. longum 
B. bifidum 
B. lactis 
L. acidophilus 
L. rhamnosus 
S. thermophiles 
Dose: all at 5 9 10 CFU/capsule 
(500 mg)/b.i.d./4 weeks 
0.51 (0.27–0.98) Significant difference between test 
probiotic multi-strain and placebo 
groups re overall improvement in IBS 
symptomrtology
Necrotizing Enterocolitis 
Dani et al. 2002 L. rhamnosus GG 
Dose: 6 9 109  CFU/day/1 week 
Costalos et al. 2003 Saccharomyces boulardii 
Dose: 50 mg/kg every 12 h 
Bin-Nun et al. 2005 B. infantis 
S. thermophilus 
B. bifidus 
Dose: 109  CFU/day/until discharged 
Lin et al. 2005 L. acidophilus 
B. infantis 
125 mg/kg/dose/b.i.d. with breast milk 
until discharged 
Mohan et al. 2006 B. lactis Bb12 
Dose: 1.6 9 109  CFU/day 1–3 and 
4.8 9 109  CFU/4–21 days 
Manzoni et al. 2006 L. casei subspecies rhamnosus 
Dose 6 9 109  CFU/day/6 weeks 
maximum 
Lin et al. 2008 L. acidophilus NCDO 1748 
B. bifidum NCDO 1453 
Dose: added to breast milk or mixed 
feeding all at 1 9 109 CFU/125 mg/kg/ 
b.i.d./6 weeks 
Rouge´ et al. 2009 L. rhamnosus GG 
B. longum BB536 
Dose:108  CFU/day/until discharged 
Samanta et al. 2009              B. infantis 
B. bifidum 
B. longum 
L. acidophilus 
Dose: each at 2.5 9 1010  CFU (125 g/kg) 
with expressed breast milk/b.i.d./till 
discharged 
 
 
0.49 (0.15–1.61)* No effective reduction in incidence 
 
 
0.59 (0.19–1.78)* No improvement 
 
 
0.1 (0.01–0.77) Significant reduction in incidence and 
severity and with no deaths from 
necrotizing enterocolitis 
 
 
0.21 (0.05–0.94) Significant reduction in incidence and 
severity 
 
 
 
1.62 (0.16–16.4)* No improvement in reduction of 
antibiotic resistant organisms 
 
 
1.0 (0.71–1.40) Significant reduction in gut fungal 
(candida) colonization 
 
 
0.35 (0.4–3.23) Significant reduction in incidence and 
severity and death 
 
 
 
 
2.18 (0.2–23.2)* No improvement in gastrointestinal 
tolerance to enteral feeding 
 
 
0.35 (0.13–0.92) Enteral administration significantly 
reduced morbidity due to necrotizing 
enterocolitis 
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Table 1  continued 
 
Conditions/diseases 
references 
 
 
Strain(s), Dose regimen 
L. = Lactobacillus 
B. = Bifidobacterium 
S. = Streptococcus 
E. = Escherichia 
 
 
Effect size RR (95 % CI)*   Outcome 
 
Ferna´ndez-Carrocera et al. 
2013 
L. acidophilus 1.0 9 109  CFU/g 
L. rhamnosus 4.4 9 108  CFU/g 
L. casei 1.0 9 109  CFU/g 
L. plantarum 1.76 9 108  CFU/g 
B. infantis 2.76 9 107  CFU/g 
S. thermophilus 6.6 9 105  CFU/g 
Dose: 1 g pack/day/until discharged 
0.50 (0.20–1.26) Post-hoc analysis showed significant risk 
reduction for necrotizing enterocolitis 
or death 
 
* p [ 0.05 b.i.d. = twice per day, t.i.d. = three times per day 
** This study not included in the final overall analysis due to equivalent efficacy between the two treatments 
 
the data allowed for the calculation of a RR (95 % CI). A 
flow diagram of the literature search for articles included in 
this systematic review is presented in Fig. 1. 
 
Probiotics, prebiotics and inflammatory git conditions 
 
Numerous  clinical  studies  suggest  probiotics  can 
improve health outcomes in various end-organs (Vitetta 
and  Sali  2008;  Vitetta  et  al.  2012).  Hence,  probiotics 
have been profiled accordingly, and that is that upon 
administration can improve the health of the host beyond 
their intrinsic and basic nutritional content (Fuller 1989). 
Hence it was noted that probiotic bacteria employed in 
clinical trials investigated in this review have included 
organisms from different genera (i.e. Bifidobacteria, 
Lactobacilli); different species from a specified genera 
(i.e. Lactobacillus acidophilus; Lactobacillus bulgaricus, 
Lactobacillus  rhamnosus);  as  well  as  those  organisms 
from different strains within a species (i.e. Lactobacillus 
acidophilus   La–1,   Lactobacillus   acidophilus   NCFM) 
whilst  administered  as  single-  or  multi-strain  prepara- 
tions  as  well  as  symbiotics (preparations of  probiotics 
and   prebiotic   mixtures).   This   hierarchical   profiling 
serving to highlight that different strains from the same 
species vary and hence may have the capacity to elab- 
orate different physiological functions within the GIT as 
demonstrated by the different effects on different 
inflammatory GIT conditions/diseases. 
Bifidobacteria and Lactobacilli have been the predom- 
inant genera studied and have demonstrated significant 
clinical efficacy in a number of health GIT conditions 
(Table 1). High level evidence-based studies have reported 
significant efficacy with specific probiotic strains in GIT 
inflammatory conditions such as constipation (in adults and 
children),  diarrhoea  (in  adults  and  children),  Crohn’s 
disease (CD), ulcerative colitis (UC), irritable bowel syn- 
drome (IBS) viral gastroenteritis, pouchitis and necrotizing 
enterocolitis. 
The demonstrated efficacy in this critical review has 
been presented as an effect size of relative risk reduction 
with the administration of a probiotic versus a comparator. 
The effect sizes as a relative risk reduction (95 % CI) for 
probiotics over a placebo/comparator for the GIT condi- 
tions  reviewed  (Fig. 2)  were  significant  for  antibiotic- 
associated   diarrhoea   [0.72   (0.62–0.84);   p \ 0.0001]; 
infectious    diarrhoea/gastroenteritis   [0.68    (0.55–0.84); 
p \ 0.0001]; IBS [0.71 (0.65–0.77); p \ 0.0001]; ulcera- 
tive  colitis  [0.63  (0.53–0.76);  p \ 0.0001];  necrotizing 
enterocolitis  [0.4  (0.27–0.59);  p \ 0.0001];  constipation 
[0.59    (0.5–0.68);    p \ 0001]    and    pouchitis    [0.19 
(0.11–0.32); p \ 0.0001]. Whereas, and although the trend 
was in favour of probiotics the effect size relative risk 
reduction was not significant for clostridium difficile diar- 
rhoea [0.70 (0.32–1.55); p = 0.38; and for Crohn’s disease 
[0.86 (0.63–1.16); p = 0.30. This latter result, possibly a 
reflection of the few studies included in this review. Others 
have reported significant risk reductions in these GIT 
conditions (Ritchie and Romanuk 2012). The overall effect 
size relative risk reduction for the administration of pro- 
biotics versus a placebo/comparator was statistically 
significant  for  probiotics  0.65  (0.61–0.70)  (z = 13.3); 
p \ 0.0001, reflecting a clinical risk reduction of 35 %. 
 
Manipulating metabolic changes in the GIT—a 
mechanistic overview 
 
The commensal microbiome contribution 
 
Microbiota that colonizes the human GIT exhibits a high 
phylogenetic  diversity,  reflecting  their  vast  metabolic 
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Fig. 2  Effect size [risk ratio (95 
% CI)] for the effect of 
probiotics over placebo/ 
comparator in the prevention 
and treatment of gastrointestinal 
tract inflammatory diseases/ 
conditions 
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potential. The environmental/microbiological picture is one 
that continues throughout life to functionally co-operate 
with the host which first initiated from the interactions first 
disseminated from the time of birth and possibly even in 
utero. Germ-free mice studies have shown that triggering 
natural development and maturation of the immune system 
are only partially encoded in the host’s genes, demon- 
strating that fundamental cues are required from the 
symbiotic microbial cohort for homeostatic development 
(Hooper 2004). How bacteria colonize the GIT provides 
initial clues as to the signals required by the GIT to develop 
a  regulated  immune–metabolic–inflammatory competent 
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profile. Up-regulated immune responses in an individual 
are necessary to protect the GIT from pathogenic cells. The 
immune system achieves this by initiating a pro-inflam- 
matory response. The microbiota, act partly in an immune- 
surveillance role by detecting pathogenic bacteria and 
stimulating the immune system, subsequently initiating an 
appropriate eradicative inflammatory response (Eckmann 
2006). Once the pathogenic cells have been cleared, the 
requisite is for an anti-inflammatory signal response that 
restores the balance between pro-and anti-inflammatory 
reactions. Accordingly, the healthy gut may be seen as one 
that is in a constant state of regulated inflammation. The 
role that commensal bacteria play in promoting an anti- 
inflammatory response is not well understood but is 
reported to be in part accomplished by the interaction of 
the bacteria with the intestinal epithelial cells that not only 
provide a physical barrier but also facilitate the interactions 
between GIT bacteria and host immune cells to achieve 
mucosal  immunological  equilibrium  (Goto  and  Ivanov 
2013). Failure to re-regulate inflammatory responses can 
increase the risk of developing inflammatory conditions of 
the host’s gut architecture such as IBD or IBS. Accumu- 
lating evidence indicates that the balance of commensal 
bacteria within the GIT may be associated with the 
development  of  some  GIT  disorders  (Swidsinski  et  al. 
2002). Patients with IBD or IBS are reported to present 
with increased pro-inflammatory or potentially pathogenic 
bacterial species with the Bacteroides, (Swidsinski et al. 
2002) Escherichia coli (Mylonaki et al. 2005; Martin et al. 
2004) and Enterococci genera together with decreased 
Bifidobacteria  and  Lactobacilli  species  (Van  de  Merwe 
et al. 1988). The etiology of IBD is not fully understood, 
but is considered to be T cell-driven inflammation resulting 
from a persistent preponderance of pro- over anti-inflam- 
matory cytokine production (Hvas et al. 2007). 
 
Nutrition/supplementation contribution 
 
GIT commensal bacteria metabolize food components that 
typically serve as energy sources. Additional factors such 
as sanitary conditions, birth delivery mode or antibiotic use 
drive the fluctuations of the microbial community during 
the first year or two of life (Adlerberth 2008). Furthermore, 
select studies clearly show that the specific consumption of 
foods  that  contain  bioactive  compounds  may  enhance 
health or increase the risk of disease. Such as is the case 
with human milk oligosaccharides that constitute the third 
most abundant class of molecules in breast milk optimizing 
the GIT microbial composition (Li et al. 2009). Other 
studies show that at least part of the protective effect of 
cruciferous vegetables is due to their relatively high con- 
tent of fiber and phytochemicals such as glucosinolates 
(Marcobal and  Sonnenburg 2012). Dietary fiber can  be 
fermented by gut bacteria, to yield short chain fatty acids 
and other metabolites that may go on to suppress adverse 
inflammatory conditions. Additional studies that report the 
specific consumption of dietary compounds such as phy- 
toestrogens show that metabolites elaborated by the GIT 
microbiome can then provide specific health benefits such 
as enhanced bone health (Chiang and Pan 2013). 
Recent findings suggest that a high-fat diet interacts with 
GIT bacteria to promote early inflammatory changes in the 
gut  that  contribute  to  the  development  of  obesity  and 
insulin resistance (Ding and Lund 2011). The innate 
immune system recognizes and responds to the structural 
components of gram-negative bacteria (e.g. lipopolysac- 
charide), resulting in inflammation. Toll-like receptors 
(TLRs) are pattern recognition receptors that have a central 
role in innate immunity (O’Neill et al. 2013). Lipopoly- 
saccharide (LPS) is a component of the outer membrane of 
Gram-negative bacteria. LPS binding to the host receptor, 
TLR4, triggers an inflammatory reaction characterised by 
the release of large number of inflammatory mediators that 
allow the host to respond to the invading pathogen (Mon- 
tero Vega and de Andre´s Martı´n 2008). The mechanism 
that drives this response is partly through the activation of 
transcriptional factors such as NF-jB via the balanced 
action of constitutively expressed nitric oxide/inducible 
nitric oxide synthase to maintain homeostasis. 
Mice fed diets high in saturated fats (72 % energy as fat) 
for 4 weeks reported an endotoxemia characterised by sig- 
nificant increases in plasma endotoxin levels i.e. LPS 
(Burcelin et al. 2008). This then shown to be a risk for 
inducing innate immune responses through the activation of 
TLR4 leading to inflammation by secreting pro-inflamma- 
tory cytokines and chemokines. Moreover, dietary fats and 
carbohydrates appear to be involved in inflammation through 
TLR4 activation. Free saturated fatty acids aggravate the 
expression and activity of TLR4 that is induced by high 
glucose in human monocytes along with increased signalling 
molecules such as superoxide generation that increase NF- 
jB activity leading to increased pro-inflammatory signals 
such as IL-6. But are these signals fundamentally adverse? It 
is further postulated that as a consequence, chronic activa- 
tion of the immune system is associated with the 
development of obesity, insulin-resistance and T2DM 
through LPS, free fatty acid and products from dying cells 
that can bind TLR4 at the surface of innate immune cells and 
activate inflammatory pathways implicated in the patho- 
genesis of chronic diseases (Nakamura and Omaye 2012). 
Tien et al. (2006) have reported that the anti-inflam- 
matory activity demonstrated by probiotics within the GIT, 
in particular Lactobacillus casei, is modulated by their 
targeting the stability of I-jba, the specific NF-jB inhib- 
itor, resulting in the mitigation of this major pro- 
inflammatory pathway. Therefore, they have hypothesized 
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that  certain  commensal  microbiota  has  the  ability  to 
actively influence the homeostatic control of intestinal 
inflammation, inhibiting NF-jB activation, even in the 
presence of pro-inflammatory pathogenic and commensal 
microorganisms. This data would tend to suggest that 
increased calorie consumption increases certain bacterial 
species that promote pro-inflammatory GIT profiles by 
influencing NF-jB activation that then increases the risk of 
metabolic diseases. Alternatively, a diet that promotes a 
healthy GIT milieu such as vegetarian, Palaeolithic or 
Mediterranean diets encourages optimum ratios of bacterial 
species by re-regulating pre- and pro-inflammatory signals 
that reduce the risk of metabolic disease development (Kim 
et al. 2013; Scoditti et al. 2012). The overall requisite is the 
regulated control of these intracellular molecular respon- 
ses. It seems plausible to posit that reactive oxygen species 
(ROS) may be the upstream early signal that provides an 
overall message to regulate the response that controls GIT 
inflammation. 
 
Probiotics as signal transducers in the GIT 
 
Over the last few decades, the role of oxidative stress has 
been proposed to play a major role in the development of 
diseases such as  inflammatory bowel disease (Abdullah 
et al. 2013). This inference further nurtures support for the 
administration of antioxidant therapies. We assert that this 
is incorrect and further that there are no reported clinical 
trials that support this conclusion. 
ROS are known to play a major role in maintaining 
normal physiological function (Linnane et al. 2007). The 
investigations on protein albumin thiol oxidations and 
serum protein carbonyl formations overemphasize the 
molecular damage that is attributed to ROS activity. These 
assertions have been previously considered and have 
challenged the commonly held view that proteins are ran- 
domly oxidized in an uncontrolled process by superoxide 
anion, hydrogen peroxide, nitric oxide and peroxynitrite, 
thereby contributing directly to the development of 
inflammatory conditions. This concept is untenable, mis- 
representing stringently regulated cellular redox metabolic 
processes. Elsewhere we have discussed the oxidation of 
protein amino acid residues (Linnane et al. 2007) and 
scientifically contended that oxidatively modified proteins 
do not simply arise as the result of random oxidative 
damage (e.g. hydroxylation of various amino acid residues, 
sulphoxidation of methionines and nitrosylation of sul- 
phydryl groups). 
Probiotic bacteria have been reported to promote a range of 
GIT physiological functions that include a regulated control 
over immune responses, epithelial barrier function and 
cellular proliferation (Bermudez-Brito et al. 2012). The 
mechanism  proposed  for  the  GIT  control  of  pathogens 
involves (a) direct anti-microbial activity through the 
production of bacteriocins or other inhibitors of pathogenic 
bacteria gene expression, (b) competitive exclusion of 
pathogenic bacteria by competing for binding sites or 
stimulation of epithelial barrier function, (c) stimulation of 
immune responses via increases of sIgA and anti-inflam- 
matory cytokine factors and the rescue and regulation of pro-
inflammatory cytokines, and (d) inhibition of virulence 
gene(s) or protein expression in gastrointestinal pathogenic 
bacteria (Amalaradjou and Bhunia 2012). The active 
mechanism that induces this complex control of pathogenic 
activity implicates ROS. 
Recent important advances in cellular signalling have 
demonstrated that some genera of human commensal GIT 
bacteria can induce a rapid increase of ROS that then elicit 
a strong physiological response through the activation of 
epithelial  NADPH  oxidase-1  (Nox1)  (Neish  2013;  Lin 
et al. 2009). In addition, reports site in vitro experiments 
with epithelial cells that, when co-cultured with specific 
probiotic bacteria, show an increased and rapid oxidation 
reaction of soluble redox sinks, namely glutathione and 
thioredoxin (Neish 2013; Lin et al. 2009). This very much 
indicates the presence of a regulated process. This effect 
was demonstrated as an increase in the oxido-reductase 
reaction of transcriptional factor activations such as NF- 
jB, NrF2 and the antioxidant response element, reflecting a 
cellular response to increased ROS production that is reg- 
ulated (Neish 2013; Lin et al. 2009). This effect must be 
decisive to elicit a restrained anti-infective response with a 
minimal chance of pro-inflammatory damage to the tissue. 
These reactions define potent regulatory effects on host 
physiological functions that include immune function and 
intracellular signalling. 
The reported mechanisms of action for probiotics are 
similarly aligned acting to enhance the epithelial barrier, 
increase bacterial adhesion to the intestinal mucosa with an 
attendant inhibition of pathogen adhesion to the competi- 
tive exclusion of pathogenic microorganisms (Neish 2013; 
Lin et al. 2009; Lee 2008). Furthermore, probiotic strains 
have also been reported to generate a range of anti- 
microbial substances and to positively affect and modulate 
immune system function. Lee (2008) has reported that the 
enteric commensal bacteria, by rapidly generating ROS, 
negotiate an acceptance by the GIT epithelia. Different 
strains of commensal bacteria can elicit markedly different 
levels of ROS from contacted cells. Lactobacilli are 
especially potent inducers of ROS generation in cultured 
cells and in vivo, though all bacteria tested have some 
ability to alter the intracellular oxido-reductase environ- 
ment. Yan et al. (2007) has reported that there are soluble 
factors that are produced by strains of lactobacilli that are 
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capable of mediating beneficial effects in in vivo inflam- matory models. This result expands our understanding that 
 
there are ROS-stimulating bacteria that possess effective 
specific membrane components and/or secreted factors that 
activate cellular ROS production to maintain homeostasis. 
It has been reported that redox signalling by microbial 
ROS formation is in response to microbial signals via 
formyl peptide receptors and the gut epithelial Nox1 (Lin 
et al. 2009). As we have previously documented (Linnane 
et al. 2007) ROS generated by Nox enzymes have been 
shown to function as essential second messengers in mul- 
tiple signal transduction metabolic pathways through the 
rapid and transient oxidative inactivation of a distinct class 
of sensor proteins bearing oxidant-sensitive thiol groups. 
These redox sensitive proteins include tyrosine phospha- 
tases that attend as regulators of the MAP kinase pathways 
(Linnane et al. 2007; Lin et al. 2009). These reports focus 
our understanding on the importance of second messenger 
functionality for the maintenance of homeostasis and bring 
into serious question the elimination of ROS by antioxidant 
supplements for the amelioration of GIT inflammatory 
diseases such as IBD. The established importance of recent 
investigations regarding probiotic/microbial-elicited ROS 
clarifies that stimulated cellular proliferation and motility is 
strictly controlled and is a regulated signalling process for 
proper innate immunity and gut barrier function (Lin et al. 
2009; Collier-Hyams et al. 2006; Neish et al. 2000). The 
observations that the vertebrate epithelia of the intestinal 
tract, supports a tolerable low-level inflammatory response 
toward the GIT microflora, can be viewed as an adaptive 
activity that maintains homeostasis. 
 
 
Discussion 
 
It has become clear from numerous studies derived from 
different experimental model systems that enteric bacteria 
are a critical component in the maintenance of health as 
well as in the initiation and dys-regulation of gastrointes- 
tinal   inflammation   that   may   lead   to   dysbiosis   and 
ultimately GIT disease (Howarth and Wang 2013). Also an 
enhanced understanding of the molecular mechanisms 
underlying bacterial signalling and tolerance in the small 
and large bowel may provide clues to the localized 
microbiotic-controlled axis that operates within the GIT to 
maintain homeostasis, such as in the secretion of mucus. 
Mucus production has been reported to be stimulated by 
high-fiber diets, confirming that under in vivo physiologi- 
cal conditions, an adaptive GIT-derived feedback micro- 
axis mechanism is in place for sensing and responding to 
normally induced mechanical stress with an increase in 
lubrication of the GIT lumen (Enss et al. 1994; Schmidt- 
Wittig et al. 1996). A more recent study (Miyake et al. 
2006) has demonstrated that lubrication in the GIT can be 
rapidly  and  precisely  fine-tuned  to  widely  fluctuating 
dietary-dependent levels of mechanical stress. This further 
supports our contention that feedback GIT micro-axes that 
are associated with mucus secretion, Th1/Th2 modulation or 
the secretion of proteins (e.g. secretin) that regulate GIT 
homeostasis which are  fundamentally influenced by  the 
GIT microbiome. The value of ROS signalling, rather than 
leading to macromolecular damage, has been relatively 
undervalued. We suggest that proper commensal bacterial 
signalling is of utmost importance in maintaining GIT 
homeostasis. 
Furthermore, this critical review has highlighted the sig- 
nificant pharmacobiotic importance of certain probiotic 
genera/strains that can exert a significant health benefit by 
rescuing a dysbiotic GIT microbiota profile. The microbial 
community composition is governed by the host’s age, diet 
and internal environment and bacterial phylogeny influenc- 
ing immunological tolerance and inflammatory responses 
within individuals (Vitetta et al. 2013). Prudent dietary 
practices with perhaps regular probiotic/prebiotic supple- 
mentation that achieve and preserve the internal milieu may 
be the rationale for health maintenance and GIT inflamma- 
tory disease prevention. Clearly, the number of human 
intervention studies assessing the effect of probiotics in 
inflammatory diseases of the GIT supports this contention. 
Although overall, the connection between the gut mic- 
robiota, energy homeostasis, inflammation and its role in 
the pathogenesis of GIT inflammatory conditions are 
increasingly recognized, further studies are required to 
confirm probiotic, prebiotic and symbiotic relevance, bio- 
logical acceptability, mode of action and the long-term 
effects of these supplements. The challenge is for clinical 
trials with robust designs and sharp end-points. 
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3.1. Abstract 
Objective Obesity is a predisposing factor for chronic diseases. Current research efforts with 
probiotic bacteria have reported improvement in gastrointestinal tract low–level inflammation 
and metabolic syndrome associated markers that positively affect energy balance. 
Aim We have investigated a multi–strain probiotic preparation containing a combination of 
probiotic strains including Bifidobacteria and Lactobacilli species and a Streptococcus 
species in a mouse model of high fat diet/obesity induced liver steatosis.  
Methods Three groups of C57B1/6J mice fed either a standard chow or high fat diet (HFD) 
for 20 weeks and a third group fed a HFD for 10 weeks and then concomitantly administered 
probiotics for a further 10 weeks.  At sacrifice all animals were weighed and serum, liver and 
large bowel samples collected for analysis.  
Results A multi-strain probiotic administered with a HFD significantly maintained tight 
junction protein ZO-1 (0.24±0.04 vs. 0.01±0.01) and ZO-2 (0.44±0.12 vs. 0.17±0.08) 
expression compared to the HFD group only.  However probiotics were unable to restore ZO-
1 or ZO-2 expression to levels seen in chow fed mice (0.38±0.08 and 0.81±0.19 
respectively).  Final body mass (33.6g ± 1.91 [chow] vs. 46.5g ± 4.07 [HFD−probiotics] and 
45.5g ± 4.75 [HFD+probiotics]; p<0.001) was significantly increased with the high fat diet ± 
probiotics compared to chow controls as were liver (1.72g ± 0.33, 2.40g ± 0.74, 2.73g ± 1.2; 
p <0.05) and fat pad mass (0.90 ± 0.33, 2.60 ± 0.47 and 2.14 ± 0.56; p <0.01) respectively. 
Compared to chow fed mice, HFD ± probiotics elevated hepatic triglycerides (p<0.001), 
serum glucose (p<0.05), cholesterol (p<0.01), Alanine transaminase (ALT) (p<0.001) and 
Aspartate aminotransferase (AST) (p<005) while reducing serum triglycerides (p<0.05).  
Conclusions The reduced progression of HFD induced steatosis by the administration of a 
multi–strain probiotic formulation further supports the posit that probiotics may assist with 
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lipid disposal from a HFD by reducing the accumulation of fat deposits in the liver consistent 
with reduced steatosis. 
Key words: Steatosis, Non –Alcoholic Fatty Liver Disease, High Fat Diet, Probiotics. 
3.2. Introduction 
Non-alcoholic fatty liver disease (NAFLD) is more commonly diagnosed than alcoholic liver 
disease, owing to the rapid and increased prevalence and burden of obesity.91-93  The 
prevalence of NAFLD is almost proportional to the global increase in obesity and T2DM.  
Furthermore, NAFLD is the most commonly diagnosed cause of abnormal liver function 
tests.94  NAFLD is caused by fat deposited (steatosis) in the liver that is not due to excess 
alcohol consumption. Disruption of the normal mechanisms for synthesis, transport and 
removal of fatty acids (LCFA)95 and triglycerides (TG)96 underpins the basic mechanism for 
the development of NAFLD.97, 98    
Furthermore, the progressive form of NAFLD is designated as non–alcoholic steatohepatitis 
(NASH). NASH is the progression of steatosis to chronic inflammation of the liver with fat 
accumulation (steatohepatitis), previously thought to be only associated with alcoholic liver 
disease (ALD). The progression from NAFLD to NASH may lead to cirrhosis and end stage 
liver disease that is adverse to health and associated with morbidity.  Not all those that 
develop NAFLD progress to NASH leading to the second hit theory.98 Day and James98 have 
reported that different pathogenic factors can lead firstly to NAFLD and secondly to NASH. 
NASH is increasingly recognized as the leading form of liver dysfunction and cirrhosis in 
non-alcoholic liver disease, viral hepatitis negative population currently accounting for 5% of 
all liver transplants.99 
The major risk factor for NAFLD is over consumption of calorie dense foods and the 
resulting consequences, namely obesity (abdominal visceral obesity), dyslipidemia, insulin 
resistance and T2DM.100, 101  Diets comprising high amounts of saturated fats or 
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carbohydrates have been associated with increased liver inflammation.102, 103 Currently, 
NAFLD has been estimated to affect as much as 34%104, 105 and NASH between 2–5% of the 
population. 106  Dividing the population into lean and obese groups further highlights the 
correlation with obesity. NAFLD has been found in 16% of lean individuals, opposed to 76% 
of obese individuals.107 With childhood obesity rates increasing, the prevalence of NAFLD 
and NASH is expected to rise, increasing the burden of fatty liver disease. 
A link between ALD and NAFLD that may help explain the similar pathogenesis between the 
diseases may be ethanol concentrations. Ethanol production has been linked with bacterial 
overgrowth and obese mice have been shown to produce greater amounts of ethanol than lean 
mice.108 Bacterial overgrowth has been associated with liver disease and found in NASH 
patients.109, 110 The usually low levels of bacteria colonizing the small intestine increase 
several fold small intestinal bacterial overgrowth (SIBO) and naturally produce elevated 
levels of ethanol via fermentative processes. In order to metabolise ethanol in the liver there 
is a high energy demand that leads to increased oxygen consumption. There is then a 
subsequent requisite for an increase in hepatic blood flow. If the supply of oxygen does not 
match the demand, however, a state of hypoxia can be induced that may contribute to liver 
damage.111 Ethanol also increases the production of ROS, mediating lipid peroxidation that 
has been postulated to promote liver damage.112 This however can be alternatively interpreted 
as increased cell signalling by oxidized lipids that interact with the mitochondria.113   
Excess ethanol can lead to increased intestinal permeability, increased exposure to pathogenic 
bacteria (and bacterial products such as lipopolysaccharides), to immune surveillance cells 
and increased passage of undigested macromolecules into the bloodstream. These actions can 
then activate the immune system resulting in dysregulated inflammation.114, 115 
The treatment options for NAFLD include weight management, medications, various 
supplements and recently the administration of probiotics. While probiotics are traditionally 
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recommended for individuals with gastrointestinal tract (GIT) disorders, it is emerging that 
probiotics may have an overarching role via the GIT influencing end–organ physiology (e.g., 
the liver, kidneys).116 Probiotics may help increase liver function by re–regulating cytokine 
productions, particularly pro–inflammatory cytokines that affect the liver (i.e., TNF–α, IL–6 
and TGF–β).117, 118 TGF–β in particular, may activate hepatic stellate cells leading to 
fibrogenesis.119  Probiotics may also help reduce the inflammatory response via a ROS 
dependent signalling120 mechanism reducing lipid peroxidation and preventing the 
progression of NAFLD and NASH. 
The link between liver disease and gastrointestinal bacteria (commensal or pathogenic) may 
appear abstract, however animal studies correlate pathogenic bacterial overgrowth with the 
development of liver disease.121 Subsequent administration of antibiotics reduced the liver 
damage incurred by gastrointestinal pathogenic bacteria overgrowth by reducing and in some 
cases eradicating bacteria.121 Probiotics defined as live bacterial cultures that when consumed 
in foods (e.g., yoghurts) and dietary supplements can improve the health of the host beyond 
their inherent basic nutritional content.122 As such probiotic bacteria have been posited to 
prevent or treat NAFLD by positively influencing the gastrointestinal microbiome through 
cytokine productions and regulating immuno-inflammatory responses.  
A mechanistic overview postulates that probiotics may reduce inflammation by reducing 
gastrointestinal epithelial cell permeability, preventing the passage of pathogens (or bacterial 
by-products such as lipopolysaccharides) from passing across the GIT epithelial barrier. 
Probiotics have been reported to reduce intestinal permeability by maintaining or increasing 
the concentration of tight junction proteins (ZO-1, ZO-2, PKC-ζ) at the cell membrane.35, 36 
This study hypothesized that the administration of a multi–strain probiotic preparation 
consisting of a mixture of Bifidobacteria and Lactobacilli strains and a Streptococcus strain 
could mitigate the adverse effects of a HFD on the liver and hence offer new insights into the 
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cellular mechanisms behind NAFLD.   Furthermore the aim of this study was to establish 
what        beneficial effects probiotic bacteria could provide in a mouse model of NAFLD and 
what GIT cellular mechanism (attenuation of gut dysbiosis) may be contributing to exert their 
effect on the liver. 
3.3. Methods 
Study design 
Mice were fed either a standard chow diet or a HFD for a total of 20 weeks. At the end of 
week 10, the HFD group of mice were divided into 2 groups and probiotics were added to the 
drinking water for the remaining 10 weeks for one group of mice.  At the end of week 20 all 
mice were euthanized, dissected and samples stored for later analysis. 
Animals 
Young wild type (WT) mice on a C57B1/6J background were randomly divided into one of 
three groups: 1) a control group, receiving a standard diet (n=10); 2) a HFD fed group 
(n=10); and 3) HFD fed group supplemented with probiotics (n=10; 1 × 108-9 Colony 
Forming Units (CFU)/mL). All animals were housed in a SPF facility maintained at 20°C on 
a 12 hour light/dark cycle with access to clean water and food.  
Ethics Statement 
All procedures were carried out in accordance and with approval from The University of 
Queensland and Queensland Institute of Medical Research (QIMR) ethics committees. 
Bacterial Strains 
Nine strains of probiotics represented here as percentages of total CFU/mL (Lactobacillus 
rhamnosus / Lactobacillus casei / Lactobacillus acidophilus / Lactbacillus plantarum / 
Lactobacillus fermentum comprising 87% of the total colony forming units; Bifidobacterium 
lactis / Bifidobacterium breve / Bifidobacterium bifidum comprised 13% of the total colony 
forming units; and Streptococcus thermophilus comprising 5% of the total colony forming 
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units were used as a multi–strain probiotic blend.  All strains were lyophilized, water soluble 
and added to the drinking water as a combination probiotic. The total concentration of 
probiotic blend added to the drinking water was 1 × 108-9 CFU/mL. This dosage was chosen 
as it represents a dose per kilogram of body mass equivalent for a human.  
Diet 
The standard chow and HFD were purchased from Specialty Feeds (WA, Australia; HFD 
product no. SF03-020). The chow diet contained 4.8% total fat (mono unsaturated fat 2%, 
polyunsaturated fat 1.77% and saturated fat 0.74%) providing 14 MJ/Kg of energy while the 
HFD contained 23% total fat (mono unsaturated fat 7.59%, polyunsaturated fat 2.04% and 
saturated fat 12.6%) providing 20 MJ/Kg of energy. 
Dissection 
At the end of week 20, mice were anaesthetized using an intraperitoneal injection of 
pentobarbital and xylene. Once anaesthetized, blood was collected using a cardiac puncture 
and allowed to clot at room temperature before serum was removed and stored. Tissue was 
collected by first removing the pancreas followed by the liver, fat pads, thigh muscle, small 
intestine, large intestine, spleen and the heart. The mass of the liver and fat pads was 
recorded. Tissue samples from the different sites were snap frozen in liquid nitrogen, fixed in 
OCT fluid or placed in formalin for histology. Tissue placed in formalin for fixing was 
transferred to a 70% ethanol solution after 24 hrs.  
Large Intestine / Swiss Roll 
The large intestine was cut longitudinally from the caecum to the rectum and opened. The 
intestinal tract was cleared of faecal matter using a cotton bud and cut longitudinally down 
the center again providing two separate longitudinal segments. One segment was carefully 
rolled on a wooden toothpick starting from the colon end with the mucosa on the outside of 
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the roll. The resulting roll was then carefully placed in formalin for histology. The second 
segment was cut into two or three pieces and frozen in liquid nitrogen. 
Blood Biochemistry 
Serum was analysed spectrophotometrically for alanine transaminase (ALT), aspartate 
transaminase (AST), albumin, glucose, cholesterol and triglycerides. Analysis was performed 
using a Cobas Integra 400, reagents and calibrators supplied by Roche Diagnostics (NSW, 
Australia). 
Hepatic Triglycerides Quantification 
Liver tissue was homogenized in a 1.5% potassium chloride solution (2.3 g KCl in 200 mL 
water). 500 µl of homogenate was extracted using a 2:1 chloroform/methanol mixture. 
Extracts were dried and stored at -80°C until analysis. For analysis, samples were 
reconstituted using 2% triton-x with the aid of sonication. Samples were further diluted with 
2% triton-x for a final concentration of 1:6 ready for analysis. Samples were measured 
spectrophotometrically (Cobas Mira, Roche Diagnostics, Australia) using a kit and calibrators 
supplied by Novachem (Victoria, Australia). 
Protein Quantification 
Proteins were measured as per manufacturer’s direction using a Pierce BCA protein assay kit 
supplied by Thermo Scientific (Victoria, Australia) 
Tight Junction Proteins – ZO-1, ZO-2 
Tight junction protein ZO-1 and ZO-2 rabbit anti-human polyclonal antibodies were 
purchased from Lifespan Biosciences (WA, USA). A polymer HRP anti-rabbit secondary 
antibody was purchased from Daco (Vic, Australia). ZO-1 and ZO-2 were analysed on large 
intestine swiss roll histology slides as per manufacturer’s direction. Optimisation of the 
antibodies gave optimal concentrations of 2.5 μg/ml and 10 μg/ml for ZO-1 and ZO-2 
respectively.  
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Histological Scoring 
Histology was blindly scored on large intestinal swiss roll sections with ZO-1 and ZO-2 
staining and liver sections with H and E and oil red O staining. Swiss rolls were scored for 
the expression of ZO-1 and ZO-2. Liver sections were scored for diagnosis, NAFLD activity 
score, steatosis grade and percentage, portal inflammation, lobular inflammation and 
ballooning, mallory’s hyaline, fibrosis stage, portal score and centrilobular score.   
Statistical analysis 
All data is presented as mean ± standard deviation unless otherwise stated. Data was tested 
for normality of the distribution, and analysis was performed with the statistical software 
GraphPad Prism. Comparison between groups was carried out using a 1-way analysis of 
variance with a Tukey’s multiple comparison post hoc test or a Kruskal-Wallis test for non-
parametric data with a Dunn’s multiple comparisons post hoc test of significance between 
individual groups. Differences were considered significant when P was less than 0.05 (* = P 
< 0.05; # = p < 0.01; § = p < 0.001). All significant differences between groups were 
determined using the HFD group as the reference group. 
 
3.4. Results 
Histological examination of the large intestine Swiss rolls for tight junction proteins ZO-1 
and ZO-2 showed mice fed a HFD had reduced expression for ZO-1(0.01±0.01 vs. 
0.38±0.08) and ZO-2 (0.17±0.08 vs. 0.81±0.19) compared to the chow group. Mice fed a 
HFD and supplemented with probiotics showed significant recovery in ZO-1 (0.24±0.04 vs. 
0.01±0.01) and ZO-2 (0.44±0.12 vs. 0.17±0.08) compared to high fat fed mice (Figure 1). 
Histological examination of livers from HFD mice demonstrated the development of steatosis 
with large fat droplets present. Chow fed mice showed no steatosis development (Table 1) or 
fat droplet accumulation. Compared to mice fed a HFD, mice fed a HFD and supplemented 
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with probiotics showed a non-significant reduction in steatosis grade (2.44 ± 0.73 and 2.00 ± 
1.25 respectively; p = 0.50) and steatosis percentage (72.78% ± 27.17 & 59.2% ± 38.74; p = 
0.9) respectively (Table 1) and visible reductions in fat droplets (Figure 2A-C).  
Confirming liver histology scores and observation, mice supplemented with probiotics had a 
two and a half fold reduction in hepatic triglyceride concentrations compared to HFD mice 
(Figure 3; p<0.001). Hepatic triglyceride concentrations of the HFD fed mice supplemented 
with probiotics remained elevated by threefold compared to chow fed mice (Figure 3; 
p<0.001). HFD feeding also decreased serum triglyceride concentrations (Figure 4). 
Probiotics supplementation was unable to attenuate these effects of the HFD. Chow fed mice 
showed increased serum triglycerides as hepatic triglycerides increased. HFD fed mice 
showed a reduction in serum triglycerides as hepatic triglycerides increased (Figure 5). 
Serum ALT, AST, glucose and cholesterol were elevated in HFD fed mice compared to chow 
fed mice (figure 6 & figure 4). Probiotics supplementation was unable to attenuate the effects 
of the HFD. When outliers were removed (>2 SD) probiotics supplementation significantly 
reduced ALT and AST concentrations compared to HFD fed mice (Figure 7; p<0.05).  
There was no difference in initial body mass of the chow, HFD or HFD plus probiotics 
groups (23.87g ± 0.95, 24.76g ± 0.72, 24.48g ± 0.84 respectively; p = 0.9). Body mass gain 
of the experimental groups paralleled the mass gain of the experimental group for the first 
seven weeks. At week eight, compared to chow fed mice, mice fed a high fat diet or 
supplemented with probiotics were 4.1% and 7.7% heavier (31.3g ± 1.22 vs. 32.6g ± 2.55 and 
33.7g ± 3.49; p<0.05) respectively. By the end of the 20th week, compared to chow fed mice 
the HFD fed mice and probiotics supplemented mice were 27.7% and 26.2% heavier (33.6g ± 
1.91 vs. 46.5g ± 4.07 and 45.5g ± 4.75; p<0.001; Figure 8) respectively. Compared to chow 
fed mice, mice fed a HFD or supplemented with probiotics also had heavier livers (1.72g ± 
0.33 vs. 2.40g ± 0.74 and 2.73g ± 1.2; p<0.05; Figure 9). Plotting liver mass against body 
 
 
91 
 
mass showed a steady increase in liver mass in relation to body mass. Once the body mass 
reached 45 – 47 g, the liver mass increased sharply (Figure 10). Above 45g, 50 – 100% of the 
body mass increase can be attributed to increased liver mass. 
3.5. Discussion 
The results from this study showed that mice fed a HFD followed by the administration of a 
multi-strain probiotic formulation maintained tight junction proteins (i.e., decreased intestinal 
epithelial cell permeability) and reduced hepatic triglyceride concentrations compared to 
mice fed a HFD alone.  Furthermore, the study demonstrated that supplementation with a 
multi-strain probiotic preparation non–significantly reduced the effects of a HFD by 
attenuating the progression of steatosis / NAFLD as evidenced in part from liver tissue 
histology showing visible reductions in fat droplets.  
Increased consumption of calorie dense foods / diets that are high in fat, particularly saturated 
fat, is a major contributor to obesity and its comorbidities. NAFLD is such an outcome. 
Despite the increasing prevalence of NAFLD, the pathogenesis remains poorly understood.     
NAFLD may have a benign asymptomatic course with a lack of definitive evidence about 
effective interventions.  NAFLD is typically first suspected when the results of liver function 
tests, measured as part of routine testing are moderately abnormal.123 The usual observed 
biochemical pattern in hepatic steatosis due to NAFLD is of increased levels of 
transaminases, with alanine aminotransferase (ALT) levels exceeding those of aspartate 
aminotransferase (AST).123 
While this study did not investigate the profile of the GIT microbiome with and without a 
HFD, we nevertheless postulated that the development of NAFLD could in part be associated 
with a dysbiotic GIT (a gut barrier abnormality).  In this study we combined a major 
contributor to the development of NAFLD, that is the over consumption of a high fat diet and 
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posited that induced changes in TJP expression would follow, that could then be preserved by 
the administration of probiotic bacteria.   
Maintaining the integrity of the GIT and epithelial permeability is one of the most important 
physiological defenses against pathogenic bacteria and exogenous pathogens. A reduction in 
TJP, in particular a reduction in TJP at the cell membrane leads to increased intestinal 
permeability. This in turn can lead to increased inflammatory responses and the translocation 
of pathobionts across the protective intestinal epithelial barrier. With the liver receiving 70% 
of its blood supply from the GIT124, pathobiont interactions across the epithelial barrier can 
trigger inflammatory responses that can then significantly and adversely influence end–organ 
physiology.[25] Such inflammatory responses mechanistically can in part lead to the 
development and progression of NAFLD.   Histological analysis of the large intestine showed 
that the administration of probiotics partly preserved the HFD induced sub-optimal 
expression of tight junction protein ZO-1 and ZO-2.   By maintaining the integrity of the GIT 
epithelial layer through the administration of probiotics, the liver seems to have been sparred 
further development / progression of NAFLD.   Hence it is possible to hypothesise that this is 
in part the result of reducing the inflammatory response that a HFD triggered dysbiotic GIT 
would promote from the effects of exogenous pathogens / pathobiont and by–product 
translocations across the epithelial gut barrier.  
While cellular mechanisms responsible for the observed lipid clearance from the liver were 
not found, the study showed physiological responses that may lead to the further elucidation 
of cellular mechanisms involved in the increased deposition of lipids in the liver.   Moreover 
the results also showed that in the chow fed mice as the liver triglyceride concentration 
increased, the serum triglyceride concentration also was observed increased.  In the HFD fed 
mice however, the observed increase in liver triglycerides was accompanied with decreased 
serum triglycerides (Figure 5).  This result may be due to altered liver lipid mobilisation and 
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metabolism. Experimental studies have reported that under regulated conditions, as liver 
triglyceride concentrations increase, there is an adaptation response that may increase or 
decrease cell signalling (reactive oxygen species dependent) mechanisms in order to increase 
the mobilisation of fat to clear it from the liver.125 
Further, an additional mechanism may be the activation and deactivation of hepatic stellate 
cells (HSC).  HSC have been shown to aid in the mobilisation of lipids. Lu126 showed that 
HSC activation can be modified by exposure to triglycerides.  Triglycerides at a 
concentration of 400 mg/L had an inhibiting effect on HSC activation, whereas a 
concentration of 12.5 mg/L of triglycerides promote HSC activation while concentrations in 
between had no effect on HSC activation.  HSC are also involved in liver fibrosis in response 
to liver damage. Therefore increased HSC activation may remove triglycerides from the liver 
but also increase fibrosis. Over activation of HSC may therefore lead to the development of 
cirrhosis. Under normal physiological conditions, HSC activation is regulated to maintain a 
balance between lipid mobilisation and lipid accumulation. Increased HSC activation from 
lipid accumulation may potentially result in liver damage and cirrhosis. Therefore it would 
seem that reducing HSC activity with a subsequent decrease in triglyceride mobilisation, can 
lead to the prevention of liver cirrhosis.  
The results of increased liver mass in the HFD mice provided a physiological response that 
posits the presence of a body mass threshold.   Mice fed a HFD consistently gained body 
mass for the duration of the 20 weeks (Figure 8).  A linear relationship was evident between 
body mass gained and liver mass increase that peaked around 45–47 g of body mass. The 
mass of the liver was observed to markedly increase, doubling to tripling in mass.   
Currently this study suggests that once the body mass of the mice reached 45 g, there was 
accumulation of most of the additional fat mass in the liver.  This could be due to exposing 
the liver to high levels of triglycerides and to lowered HSC activity, followed by a plausible 
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reduction in triglyceride mobilisation rather than leading to accumulation of triglycerides in 
the liver.  The reduced liver triglycerides whilst maintaining liver mass following the 
administration of probiotics, is indicative of a liver–gut axis that in part may be under 
operational control by the gastrointestinal microbiome.116 It is possible that the administration 
of probiotics influenced liver physiology by generating additional liver tissue that replaced 
that possibly damaged by the excessive accumulation of fat.  This result may aid in lipid 
mobilisation with the increased regenerated liver tissue capable of producing cell signalling 
molecules and essential fatty acids. Whether activation of HSC is increased with probiotics 
administration is not known at this stage and is of interest for future research. 
Despite the beneficial effects demonstrated by the administration of probiotics, these bacteria 
cannot be deemed a panacea to a high calorie diet.  In this study, 30% of the mice (n=3) 
showed little effect from the administration of probiotics, consequently additional factors that 
vary the gastrointestinal microbiome could also be important considerations.  Colonization of 
the GIT is not a uniform event and begins post birth as the newborn is exposed to maternal 
and environmental microbes.127   Therefore, it is plausible that animal housing differences, 
variable bacterial colonisation of the GIT and disease development could have attributed to 
the observed variation in probiotic effects.  Certainly a weakness of this study in this regard 
was the lack of GIT microbiome studies before and after probiotic administration and in the 
different groups of animals.   
This study clearly proposes that probiotics are not a panacea for an over consumption of 
calorie dense foods through a high saturated fat diet in the hope of down–regulating GIT 
inflammation and or liver fatty acid metabolism.  Rather, probiotics may help reduce the 
severity and or rate of progression of NAFLD to cirrhosis or hepatocellular carcinoma, 
resulting from the consumption and salvage of a high caloric / fat diets, by modulating the 
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gastrointestinal microbiome, host energy metabolism, gut permeability and inflammatory 
responses.  
Future Research Directions 
Further studies should investigate the role of multi-strain probiotics in the modulation of the 
GIT microbiome, gut dysbiosis and the effect on the gut-liver axis. Moreover investigate the 
prophylactic effect probiotics would have on NAFLD.  Studies have shown that probiotics 
may have a greater effect when administered prophylactically.  Exercise may also have a 
dramatic effect on NAFLD outcomes. The mice in this study were housed in cages with no 
exercise wheels and so were considered sedentary. With exercise the development of NAFLD 
may be further attenuated with the administration of probiotics that we postulate may have an 
additive positive effect.   
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3.6. Figures 
Figure 3.1: Swiss Roll Staining of the large intestine for ZO-1 A) Chow fed mouse showing 
normal ZO-1; B) HFD fed mouse with reduced ZO-1; C) Mouse fed HFD and supplemented 
with probiotics with increased ZO-1 staining compared to HFD alone.  
Figure 3.2: Liver histology for lipid deposits A) Mouse fed a standard chow diet with very 
little fat deposits; B) Mouse fed a HFD with large fat droplets; C) Mouse fed a HFD with 
probiotics supplementation showing significant reduction in fat droplets.  
Figure 3.3: Hepatic triglyceride concentrations 
Figure 3.4: Serum biochemical data A: glucose; B: cholesterol; C: triglycerides 
Figure 3.5: Liver triglycerides against serum triglycerides. An inverse relationship between 
serum and liver triglycerides was observed when a HFD was consumed with or without 
probiotics. 
Figure 3.6: Serum biochemical data A: ALT; B: AST; C: Albumin 
Figure 3.7: Serum biochemical data with three outliers removed A: ALT; B: AST 
Figure 3.8: Body mass increase over the 20 weeks 
Figure 3.9: A: Fat pad mass; B: Liver mass; C: Liver mass with outliers removed 
Figure 3.10: Liver mass plotted against body mass showing at approximately 45 grams in 
body mass a “liver mass threshold” appeared to occur. At this point the majority of body 
mass increase is largely due to an increase in liver mass. 
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Figures 
       
A       B           C 
 
 
 
Figure 3.1 
Table 3.1: Liver histology grading. 
  
Chow  
(n=9) 
HFD  
(n=9) 
HFD + 
probiotics 
(n=10) 
Steatosis Grade 0.0 ± 0.0 2.4 ± 0.7* 2.0 ± 1.3* 
Steatosis % 0.1 ± 0.3 72.8 ± 27.2* 59.2 ± 38.7* 
Portal 
Inflammation 0.0 ± 0.0 0.2 ± 0.4 0.0 ± 0.0 
Lobular 
Inflammation 0.6 ± 0.7 1.9 ± 1.0* 1.7 ± 1.2 
Ballooning 0.2 ± 0.4 1.3 ± 0.7* 
 
1.1 ± 0.6* 
 
Data are mean ± SD. * = p<0.05 
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Chapter 4  
The effects of probiotics supplementation on a high fat diet in a high iron 
environment 
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4.1 Abstract 
Obesity and non-alcoholic fatty liver disease (NAFLD) are associated with increased 
extracellular iron concentrations and mutations to the HFE gene, whereas increased 
extracellular iron alters the microbiome within the gastrointestinal tract. Probiotics have been 
advanced as a potential therapeutic option that may rescue a dysbiotic gastrointestinal tract by 
readjusting the local commensal bacterial cohort and its environment. Few studies have 
investigated the effects of probiotic supplementation on NAFLD in a high iron milieu. Aim: 
This study investigated the effects of a multi-strain probiotic blend on lipid metabolism and 
liver function in mice with high extracellular iron and fed a high fat diet so as to induce 
NAFLD. Methods: Hemochromatosis protein knock out (hfe-/-) mice were fed one of three 
diets: (i) a chow diet, (ii) a high fat diet for 20 weeks, or (iii) a high fat diet (10 weeks) and 
supplementation with multi-strain probiotics (predominantly Lactobacillus and 
Bifidobacterium) for another 10 weeks. Hepatic enzymes, triglycerides, cholesterol and 
histology were analysed, along with gene analysis of markers of liver function, lipid 
metabolism and inflammation. Results: Compared with HFD mice, the liver enzyme activity 
of alanine transaminase and aspartate transaminase, together with histology scoring for portal 
inflammation, Mallory’s hyaline and steatosis were lower in mice fed a high fat diet with 
probiotics supplementation. Conversely, the expression of genes involved in lipid metabolism 
(e.g., peroxisome proliferator-activated receptor alpha and carnitine palmitoyltransferase 1) 
and proteins involved in iron uptake (e.g., transferring receptors 1 and 2) were higher in mice 
fed a high fat diet with probiotics supplementation compared with high fat fed mice. 
Probiotics supplementation also restored gene expression of liver fatty acid-binding protein 
(L-FABP) to a level similar to chow fed mice. Conclusion: Probiotics supplementation 
shows potential for protecting against NAFLD by increasing lipid metabolism and iron 
uptake and reducing fat deposits within the liver of mice fed a high fat diet. 
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4.2 Introduction 
Non-alcoholic fatty liver disease is one of the most prevalent liver diseases in developed 
countries.128, 129 Increased consumption of fat is among the major triggering factors of 
metabolic impairments and gut dysbiosis that can lead to obesity and NAFLD.130, 131 A 
commonly accepted experimental model for studying NAFLD is to feed mice a high fat diet. 
If left untreated, progression of NAFLD to non-alcoholic steatohepatitis (NASH) may result 
in cirrhosis of the liver. The liver receives 70% of its blood supply from the gastrointestinal 
tract.124 Consequently, disruption of the gastrointestinal tract can lead to increased 
inflammation of the liver, resulting in the development and/or progression of diseases such as 
NAFLD and NASH.124, 132, 133 The functional interactions between the gastrointestinal tract 
and its microbiota lead to complex metabolic outcomes. Rescuing the gastrointestinal tract 
microbiome and its associated milieu is proposed to help re-regulate inflammation, attenuate 
intestinal permeability, and reduce the adverse effects resulting from pathogenic bacterial 
toxicity.134, 135  
 
Mutation in the HFE gene is common in patients with NAFLD.136, 137 This mutation disrupts 
iron absorption, resulting in increased extracellular iron.138, 139 Iron is an essential element for 
all bacteria, with a few exceptions such as B. burgdorferi140 (implicated in Lyme disease), 
and some lactic acid bacteria.141 Elevated levels of extracellular iron may result in increased 
gastrointestinal tract pathogen toxicity142 resulting in increased intestinal permeability and 
inflammation.143-145 One of the body’s first defenses for maintaining gastrointestinal tract 
health in the presence of invading pathogens is to withhold nutrients.146, 147 One such  
involves transferrin preferentially binding extracellular iron to prevent pathogenic bacteria 
from accessing iron.148 Transferrin is predominantly produced in the liver and is decreased in 
inflammation.149 Inflammation is prevalent with NAFLD, which may limit transferrin 
production. NAFLD patients often present with iron overload and transferrin saturation.138 
This indicates an inability to bind extracellular iron adequately, which may allow pathogenic 
bacteria to prosper and associated inflammation to occur. 
 
A commonly accepted model for studying hemochromatosis (iron overload) is the hfe-/- 
mouse model. The high iron environment created in hfe-/- mice increases the virulence of 
numerous pathogens in animal models.147 The normal flora are unable to thrive in an 
environment high in iron, because they are ‘out-competed’ by the bacterial overgrowth of 
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pathogenic bacteria.150, 151 The overgrowth of bacteria leads to increased intestinal 
inflammation and subsequently intestinal permeability152, 153, which may in turn allow 
pathogens to reach the liver where they can initiate inflammation and NAFLD. Restoring the 
gastrointestinal tract environment may allow the natural gastrointestinal tract microbiome to 
prosper and restrict the growth of pathogenic bacteria.  
 
Probiotics supplementation is touted as a possible therapy for rescuing the gastrointestinal 
tract environment.154, 155 The implementation of a multi-strain probiotic blend, combining 
lactic acid bacteria (Lactobacillus and Streptococcus) with gram positive bacteria 
(Bifidobacteria) aimed to establish a gastrointestinal tract environment where the commensal 
microflora would favourably compete with pathogenic bacteria. By combining the hfe-/- 
mouse model with a high fat diet so as to induce NAFLD, it is possible to investigate the 
potential effects extracellular iron on NAFLD. Using this model, I investigated the effects of 
a multi-strain probiotic blend combining strains of Bifidobacteria, Lactobacilli and 
Streptococcus on inflammation and lipid metabolism in the gastrointestinal tract and liver in 
hfe-/- fed a high fat diet. I hypothesised that in an environment high in iron, the administration 
of a multi-strain probiotic would enable the resultant gastrointestinal tract microbial cohort to 
function better in the presence of high iron. 
 
4.3 Method 
Study Design 
Mice were fed either a chow diet or a HFD for a total of 20 weeks. At the end of week 10, 
one HFD group were supplemented with probiotics in their drinking water for the remaining 
10 weeks. At the end of week 20 all mice were euthanized, dissected and blood and tissue 
samples were stored for later analysis. 
 
Animals 
Four-week old hfe-/- mice (on a C57BL/6J background, originally supplied by Professor 
William Sly, St Louis University, MO) were randomly distributed into one of three groups: 1) 
a control group receiving a standard chow diet (n=9) for 20 weeks; 2) a group fed a high fat 
diet (HFD) (n=9) for 20 weeks; and 3) a HFD group for 10 weeks supplemented with 
probiotics (n=9; 1 × 108-9 CFU/mL) for another 10 weeks. All animals were housed in a SPF 
facility maintained at 20°C on a 12 hour light/dark cycle with access to clean water and food. 
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All procedures were carried out in accordance and with approval from The University of 
Queensland and Queensland Institute of Medical Research (QIMR) ethics committees. 
 
Diet 
The chow diet and HFD were purchased from Specialty Feeds (WA, Australia; HFD product 
no. SF03-020). The chow diet contained 4.8% total fat (monounsaturated fat 2%, 
polyunsaturated fat 1.8% and saturated fat 0.7%), providing 14 MJ/kg of energy. The HFD 
contained 23% total fat (monounsaturated fat 7.6%, polyunsaturated fat 2.0% and saturated 
fat 12.6%), providing 20 MJ/kg of energy. 
 
Bacterial Strains 
Nine strains of probiotics (L. rhamnosus – 34.5%, Lactobacillus casei – 21%, Lactobacillus 
acidophilus – 16.5%, L. plantarum – 7%, Lactobacillus fermentum – 3%, Bifidobacterium 
lactis – 9%, Bifidobacterium breve – 3%, B. bifidum – 1%, S. thermophilus – 5%), were 
kindly donated by Fit BioCeuticals (NSW, Australia). All strains were lyophilised, water 
soluble and added to the drinking water as a combination probiotic. Probiotics were added to 
fresh water every second day. The total concentration of probiotics added to the drinking 
water was 1 × 108-9 CFU/mL. This dosage was chosen because it represents a dose per 
kilogram of body mass equivalent for a human (65 kg) and the amount of water consumed (5 
mL) by an average-sized mouse (25 g) per day. 
 
 
Dissection 
At the conclusion of week 20, all mice were anaesthetised using an intraperitoneal injection 
of pentobarbital and xylene. Once the mice were anaesthetised, blood was removed by 
cardiac puncture, and it was left to clot at room temperature before it was centrifuged to 
remove and store serum. The liver was removed and the mass was recorded before pieces 
(~50-100 mg) of liver tissue were snap frozen in liquid nitrogen or placed in formalin for 
histology. Tissue placed in formalin for fixing was transferred to a 70% ethanol solution after 
24 hours.  
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Blood Biochemistry 
Serum was analysed spectrophotometrically for the activity of the liver enzymes alanine 
transaminase (ALT) and aspartate transaminase (AST), and the concentrations of albumin, 
glucose, total cholesterol and triglycerides. Analysis was performed using a Cobas Integra 
400 auto-analyser, with reagents and calibrators supplied by Roche Diagnostics (NSW, 
Australia). 
 
Hepatic Triglycerides 
Prior to analysis, liver tissue was homogenised in a 1.5% potassium chloride solution (2.3 g 
KCl in 200 mL water). The homogenate (500 µl) was extracted using a 2:1 
chloroform/methanol mixture. Extracts were dried and stored at -80°C until analysis. For 
analysis, samples were reconstituted using 2% triton-x with the aid of sonication. Samples 
were further diluted with 2% triton-x to a final concentration of 1:6 for analysis. 
Triglycerides were measured spectrophotometrically (Cobas Mira, Roche Diagnostics, 
Australia) using a kit and calibrators supplied by Novachem (Victoria, Australia). 
 
Hepatic Isoprostanes 
Isoprostanes were extracted from liver tissue using a previously reported method.156 (Chapter 
6, published in J. Pharmacology and Biomedical Analysis)  
 
Hepatic Iron Concentration 
Hepatic iron concentration (HIC) was measured as previously described.157 Briefly, paraffin-
embedded samples were deparaffinised, washed, dried, weighed and acid digested. HIC was 
measured using an atomic absorption spectrophotometer (Varian AAS 4) at a wavelength of 
248.3 nm.    
Protein 
Liver protein concentration was measured as per the manufacturer’s direction using a Pierce 
BCA protein assay kit supplied by Thermo Scientific (Victoria, Australia). 
 
Histological Scoring 
Histology was scored blindly on liver sections with H and E and oil red O staining. Sections 
were scored for diagnosis, NAFLD activity score, steatosis grade and percentage, portal 
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inflammation, lobular inflammation and ballooning, Mallory’s hyaline (resulting from 
hepatocyte injury), fibrosis stage, portal score and centrilobular score.  
 
RNA extraction and Quantitative Real-time RT-PCR 
Total RNA was extracted using TRIzol reagent (Invitrogen, Mount Waverley, Victoria, 
Australia), and then subjected to deoxyribonuclease I digestion and transcribed into cDNA 
using Superscript III according to the manufacturer’s instructions (Invitrogen, Mount 
Waverley, Victoria, Australia). Quantitative gene expression was performed by real-time 
polymerase chain reaction (RT-PCR) (ViiATM 7, Applied Biosystems, Life Technologies 
Corporation, Carlsbad, California, USA) using Quantifast SYBR green as per the 
manufacturer’s conditions (Qiagen, Chadstone Centre Victoria, Australia). Genes involved in 
lipid metabolism were assessed (Table 4.1), including liver fatty acid-binding protein (L-
FABD), proliferator-activated receptor alpha and gamma (Ppar-α and Ppar-γ), carnitine 
palmitoyltransferase 1 (Cpt1A), adiponectin receptor 2 (AdipoR2), cluster of differentiation 
36 (CD36), low-density lipoprotein receptor (LDLR), and acetyl-CoA carboxylase (ACC1). 
The expression of individual genes was normalised to the geometric mean of three house-
keeper genes: basic transcription factor 3 (Btf-3), Glyceraldehyde 3-phosphate 
dehydrogenase (Gapdh) and β2-microglobulin (B2M).  Oligonucleotides were custom 
synthesised by Sigma Genosys (Castle Hill, NSW, Australia).   
 
Genes Forward (5′→3′) Reverse (5′→3′) 
L-FABP AAGTCAAGCCAGTCGTCAAGCT TGAGTTCAGTCACGGACTTTATG 
Ppar-α CATGTGAAGGCTGTAAGGGCTT TCTTGCAGCTCCGATCACACT 
Ppar-γ CATTGAGTGCCGAGTCTGTG GCTTCAATCGGATGGTTCTT 
Cpt1A AGACCGTGAGGAACTCAAACCTA TGAAGAGTCGCTCCCACT 
AdipoR2 TACACACAGAGACGGGCAAC TGGCTCCCAAGAAGAACAAG 
CD36 ACAGACGCAGCCTCCTTTC CAGATCCGAACACAGCGTAG 
LDLR GGACCTCAAGATTGGCTCTG TGTAGCTGCCTTCCAGGTTC 
ACC1 TGAAGACCTTAAAGCCAATGC GTTGTTGTTGGGTCCTCCA 
Reference Genes Forward (5′→3′) Reverse (5′→3′) 
Btf3 TGGCAGCAAACACCTTCACC AGCTTCAGCCAGTCTCCTTAAAC 
 
 
109 
 
B2M CTGATACATACGCCTGCAGAGTTAA ATGAATCTTCAGAGCATCATGAT 
Gapdh TCCTGCACCACCAACTGCTTAGC GCCTGCTTCACCACCTTCTTGAT 
  Table 4.1: qRT-PCR gene primers. 
 
Western blots 
Supernatant or protein extracts (30 μg) from liver and isolated gut cell homogenates were 
electrophoresed in sodium dodecyl sulfate-10% polyacrylamide gel for 30 min at 100 V and 
blotted onto polyvinylidene fluoride membranes (Biorad, Hercules, CA). Following 
incubation with 5% skim milk to block nonspecific sites, membranes were immunostained 
with primary antibodies for transferrin receptor 1 (TfR1) and transferrin receptor 1 (TfR2; 
Zymed, life technologies, Vic, AUS). A horseradish peroxidase-labeled goat anti-rabbit 
immunoglobulin G (Santa Cruz) secondary antibody was added, and protein bands were 
visualised using a standard chemiluminescent kit (Supersignal West Femto, Thermo 
Scientific).  
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Statistical analysis 
All data are presented as mean ± standard deviation, unless otherwise stated. Data were tested 
for normality of the distribution, and analysis was performed with the statistical software 
GraphPad Prism 6. Comparison between groups was carried out using either a 1-way analysis 
of variance with a Tukey’s multiple comparison post hoc test or a Kruskal-Wallis test for 
non-parametric data with a Dunn’s multiple comparisons post hoc test of significance 
between individual groups. Differences were considered significant when P was less than 
0.05. Unless stated otherwise, all significant differences between groups were determined 
using the HFD group as the reference group. 
 
4.4 Results 
There were no significant differences in the initial body mass of the three groups (chow 23.4 
± 1.0 g; HFD 25.9 ± 1.0 g; HFD+Probiotics 24.6 ± 2.1 g) (p = 0.9). By week 20, the body 
mass of both HFD groups were ∼25% greater than the chow group (chow 34.9 ± 2.7 g; HFD 
46.8 ± 2.9 g; HFD+Probiotics 45.6 ± 3.2 g; p<0.001; Figure 4.1). Liver mass was also greater 
in the HFD groups  (chow 1.7 ± 0.2 g; HFD 3.1 ± 0.8 g; HFD+Probiotics 2.6 ± 0.8 g; p<0.05; 
Figure 4.1). Histological examination of livers from HFD group showed steatosis with large 
fat droplets present. Chow fed mice showed no steatosis (Table 4.2) or fat accumulation.   
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Table 4.2: Liver histology grading 
  
Chow  
(n=9) 
HFD  
(n=9) 
HFD+Probiotics 
(n=10) 
NAS 
 
0.0§ ± 0.0 
 
6.1 ± 0.9 
 
5.5 ± 2.0 
 
Steatosis Grade 0.0§ ± 0.0 3.0 ± 0.0 2.6 ± 1.1 
Steatosis % 0.0§ ± 0.0 95.5 ± 6.4 84.0 ± 32.5 
Portal 
Inflammation 0.0* ± 0.0 0.44 ± 0.53 0.25 ± 0.38* 
 
Lobular 
Inflammation 0.0§ ± 0.0 1.6 ± 0.5 1.5 ± 0.6 
Ballooning 0.0§ ± 0.0 1.5 ± 0.5 1.4 ± 0.6 
 
Mallory’s Hyaline 0.0§ ± 0.0 1.6 ± 0.5 0.00§ ± 0.0 
Data are mean ± SD. * = p<0.05; § = p<0.001; NAS – NAFLD activity score 
 
Compared with the chow fed group, serum cholesterol concentration (Figure 4.3) and ALT 
and AST activity (Figure 4.2; p<0.001) were higher, whereas serum triglycerides (Figure 4.3; 
p<0.001) were lower in the HFD groups. Hepatic triglycerides (p<0.05) and hepatic protein 
(p<0.001) were also higher, whereas hepatic iron concentrations were lower (Figure 4.4 & 8; 
p<0.01) in the HFD groups compared with the chow fed group. Gene expression of PPAR- γ 
(p<0.01), CD36 (p<0.001) and L-FABP (p<0.01) were higher (Figures 5 & 6), whereas gene 
expression of LDLr (Figure 4.6; p<0.05) and AdiopR2 (Figure 4.7; p<0.001) and protein 
expression of TFR-1 (Figure 4.8; p<0.001) was lower in the HFD groups compared with the 
chow fed group. 
 
Compared with the HFD group, serum triglyceride concentration was higher (p<0.05; Figure 
4.3), whereas serum ALT and AST activity was lower (p<0.05; Figure 4.2) in the 
HFD+Probiotics group. The gene expression for PPAR-α, CPT1 and AdipoR2 was higher 
(p<0.05; Figures 5-7), whereas L-FABP gene expression was lower (p<0.05; Figure 4.6) in 
the HFD+Probiotics group compared with the HFD group. Lastly, hepatic isoprostanes 
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content (p<0.05; Figure 4.4) and protein expression of TFR-1 and TFR-2 (p<0.001; Figure 
4.8) were higher in the HFD+Probiotics group compared with the HFD group. 
 
4.5 Discussion 
 
The aim of this study was to investigate the effects of a multi-strain probiotic blend 
combining strains of Bifidobacteria, Lactobacilli and a Streptococcus on inflammation and 
lipid metabolism in the gastrointestinal tract and liver in the hfe-/- mice fed a high fat diet.  
These results demonstrate that compared with the high fat diet group, a multi–strain probiotic 
blend increased the expression of genes that regulate lipid metabolism (PPAR-α, Cpt1A and 
AdipoR2) and improved liver function, as indicated by lower activity of the liver enzymes 
alanine transaminase and aspartate transaminase. These changes with probiotics 
supplementation were associated with partial reductions in portal inflammation and Mallory’s 
hyaline, and increased expression of iron transport proteins. The results of this study suggest 
that probiotics may be beneficial for people with iron overload (e.g. haemochromatosis), 
dysregulated lipid metabolism and/or NAFLD. 
 
Probiotic supplementation was effective for increasing liver enzyme activity, and reducing 
portal inflammation and Mallory’s hyaline compared with the high fat diet group. Probiotics 
did not restore liver enzyme activity and inflammation to the same levels in the chow fed 
group. Nevertheless, these improvements suggest that probiotics improve liver function and 
reduce NAFLD resulting from a HFD. Although, improvements in steatosis grade and 
percentage in the probiotics group were not statistically significant, these variables showed a 
trend toward improvement. When non-responders (n=3) were removed, treatment with 
probiotics significantly improved steatosis grade and percentage. If the mice had been treated 
with probiotics earlier (i.e., after less than 10 weeks), then steatosis grade and percentage may 
have improved to a greater extent. 
 
The availability of iron in the gastrointestinal tract directly affects the composition and 
metabolic state of the gut microbiota.158, 159 This may partly explain how different dietary 
regimens (fat vs. protein vs. carbohydrate) alter the gut microbial phyla,160, 161 In the present 
study, probiotics supplementation may not have reduced inflammation entirely because 
extracellular iron was already elevated and may have promoted pathogenic bacterial 
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toxicity.150, 151 Compared with wild type mice, the faecal microbiota in hfe-/- mice has a 
greater proportion of Enterococcus faecium and species similar to Olsenella.158 Changes to 
the microbiota milieu may lead to changes in epithelial cell functions and permeability162 that 
in turn alter nutrient absorption and gastrointestinal tract inflammation.163  
 
In humans, 80-95% of iron consumed in the diet passes through the gastrointestinal tract and 
is not absorbed.164 This leaves high amounts of iron available for the pathogenic bacteria 
within the gastrointestinal tract. The amount of iron that is absorbed changes with different 
age, sex and strains (C57BL/6, DBA/2J, BALB/c & AKR) of mice.165, 166 Changes to the 
amount of iron absorbed as humans age167 may partially explain why the gut microbiota 
composition changes with age.168 Reductions to the amount of iron absorbed with aging167 
makes more free iron available in the gastrointestinal tract for bacterial growth. This can alter 
the microbiota composition and concentration.158 One mechanism that alters the amount of 
extracellular iron, is changes to receptors for transferrin bound iron. In the present study, 
HFD feeding reduced hepatic TFR-1 and TFR-2 protein expression compared with chow fed 
mice (Figure 4.8). TFR-1 and TFR-2 are required for iron delivery from transferrin, and 
mediate cellular uptake of transferrin-bound iron.169 Probiotics supplementation partially 
increased TFR-1 protein expression, whereas it increased TFR-2 protein expression above 
that in chow fed mice. Increased TFR-1 and TFR-2 may reduce extracellular iron by 
increasing iron delivery for cell metabolism through the release of transferrin-bound iron. As 
evidence of increased cellular iron uptake, hepatic iron concentration was higher in mice 
supplemented with probiotics compared with the high fat diet group (Figure 4.8). A reduction 
in extracellular iron would further allow the natural microbiota to return to a regulated state.  
 
Liver isoprostane content was lower in hfe-/- mice fed chow when compared wild type mice 
(Chapter 5). By contrast, probiotics increased liver isoprostane content (p<0.05) in hfe-/- mice 
to similar levels of chow fed mice (Chapter 5). Iron protects human endothelial cells against 
hydrogen peroxide-induced reductions in prostaglandin synthesis, possibly by initiating an 
extracellular reduction of free electrons available to reach the intracellular space (Fenton 
reaction).170 In the presence of an overload with iron, free radicals may be neutralised, 
thereby blocking lipid peroxidation/redox signalling. In turn, this may alter cellular lipid 
metabolism. My data suggest that probiotics supplementation may increase/regulate lipid 
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peroxidation in the presence of high extracellular iron. Probiotics may exert these effects by 
reducing extracellular iron through increasing cell iron delivery transferrin receptor proteins. 
 
Probiotic supplementation increased PPAR-α gene expression (Figure 4.5) compared to HFD 
and chow fed mice. This may serve to aid in fatty acid transport and lipid and glucose 
metabolism. Under normal circumstances PPAR-α and PPAR-γ gene expression is 
maintained in a regulated state, but in the presence of fatty acids, expression is increased.171, 
172 This may serve to mobilise fatty acids and prevent glucose accumulation / type II diabetes 
mellitus.173 Consumption of a HFD also reduced AdipoR2 gene expression, whereas 
probiotics partially reversed this response (Figure 4.7). One potential explanation for why 
PPAR-α gene expression increased following probiotics supplementation, is that probiotics 
partially blocked the decrease in AdipoR2 gene expression that occurred in response to high 
fat feeding. Enhancement of AdipoR2 has been shown to improve NASH,174 while a 
reduction in AdipoR2 results in reduced PPAR-α signalling.174, 175  
 
Gene expression of CD36 (Figure 4.5) was increased with HFD feeding. In HFD fed mice, 
elevated CD36 gene expression may indicate dysregulated intestinal inflammation176 and 
lipid accumulation177 propagating NAFLD.178-180 HFD also reduced LDLr gene expression 
(Figure 4.6), potentially resulting in accumulation of low-density lipoproteins and advancing 
NAFLD. However, Cpt1A gene expression was up regulated with probiotics supplementation 
(Figure 4.6), which may promote the transport and metabolism of long-chain fatty acids 
across cell membranes. The up-regulation of Cpt1A may therefore partially compensate for 
the down-regulation of LDLr. Probiotics also restored liver fatty acid-binding protein (L-
FABP) gene expression to a similar level to that in chow fed mice (Figure 4.6). Probiotics 
supplementation increased lipid metabolism/signalling pathways (Cpt1A and PPAR-α) that 
may reduce lipids accumulating in the liver. This restored L-FABP expression to similar 
levels as in chow fed mice. Lipid metabolism may also be affected by changes in the 
expression of ACC1. There was no significant difference between the three groups for ACC1 
gene expression. However, ACC1 gene expression tended to be lower following the high fat 
diet (p=0.2; Figure 4.7), which could have reduced fatty acid metabolism. By contrast, ACC1 
gene expression tended to be higher following probiotics supplementation (p=0.4). These 
findings provide tentative evidence that probiotics may help to reverse (at least in part) the 
detrimental metabolic effects of high fat feeding. 
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In summary, probiotic supplementation reduced liver enzyme activity, liver histology scores 
for portal inflammation and Mallory’s hyaline, whereas it increased the expression PPAR-α 
and Cpt1A genes and TFR-2 protein. By contrast, probiotics supplementation did not alter 
gene expression of CD36 or LDLr. The results of this study have beneficial implications for 
people with haemochromatosis, dysregulated lipid metabolism and/or reducing the 
progression of NAFLD alike. Future studies could investigate the effects of prophylactic 
treatment with probiotics over a longer period. 
 
4.6 Figures 
Figure 4.1: Body mass. HFD resulted in increased A) body mass and B) liver mass. 
Probiotics were able to partially prevent the liver mass gain. 
 
Figure 4.2: Serum data. HFD feeding increased A) ALT and B) AST. Probiotics rescued this 
effect in part. 
 
Figure 4.3: Serum data. A) Cholesterol was increased in both HFD groups B) Triglycerides 
was increased in the chow group C) Glucose was increased in the probiotics groups 
 
Figure 4.4: Hepatic data. A) Isoprostanes were significantly increased in mice supplemented 
with probiotics. B) Triglycerides were elevated and C) protein reduced in both HFD groups. 
 
Figure 4.5: RNA. A) Probiotics increased PPAR-alpha compared to chow fed mice. B) 
PPAR-gamma and C) CD36 levels were elevated in both groups of HFD fed mice. 
 
Figure 4.6: RNA. A) LDLr was reduced in both HFD fed groups. B) Cpt1 was elevated 
compared to both HFD and chow fed mice. C) Lfabp was elevated in HFD fed mice, 
probiotics rescued this effect. 
 
Figure 4.7: RNA. A) Acc1 B) AdipoR2 significantly reduced in HFD fed mice. Probiotics 
partially rescued this effect. 
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Figure 4.8: RNA. A) Tfr1 was significantly reduced in both HFD groups. B) Tfr2 was 
increased with probiotics supplementation. C) HICs was decreased in both HFD fed groups. 
Probiotics in part rescued this effect. 
 
 
Figure 4.1 
 
Figure 4.2 
 
Figure 4.3 
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Figure 4.4  
 
Figure 4.5 
 
Figure 4.6 
 
Figure 4.7 
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Figure 4.8  
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Chapter 5  
 
The data presented in this chapter is a continuation of the data collected from mice in chapter 
3. This data was intended to support the posit that probiotics could mitigate the adverse 
effects of a HFD on the liver. It was hypothesised that this data would show probiotics 
capable of preventing excessive oxidation of hepatic lipids. However because the findings 
were opposite to what was expected, the data did not fit with the structure or theme of chapter 
3. Rather these findings require a standalone chapter to explain the interesting findings. 
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5.1. ABSTRACT 
Quantification of lipid peroxidation has been a long–standing measure of cellular oxidative 
damage. Isoprostanes are formed through a reactive oxygen species reaction that is 
characterised by the oxidative degradation of arachidonic acid. Isoprostanes are currently 
considered the “gold standard” marker of oxidative damage. Whether the gastrointestinal 
tract and probiotics supplementation can affect lipid peroxidation is still unknown. Aim: 
Investigate the effects of a high fat diet +/- probiotics on lipid peroxidation in the liver. 
Methods: Mice were fed either a chow diet, high fat diet or a high fat diet with probiotics for 
20 weeks. At sacrifice, all animals were weighed and liver samples were collected for lipid 
peroxidation analysis. Results: Isoprostanes and malondialdehyde content of the liver was 
significantly lower in mice fed a high fat diet for 20 weeks compared with chow fed mice. 
Isoprostanes content correlated with malondialdehyde content and fat pad weight in the chow 
fed group. Malondialdehyde correlated weakly with fat pad weight in all groups. Probiotics 
supplementation had no effect on lipid peroxidation. Conclusion: Probiotics supplementation 
proved ineffective at altering lipid peroxidation in mice fed a HFD. Reduced isoprostanes and 
malondialdehyde concentrations following a HFD may indicate a potential role of lipid 
peroxidation in lipid metabolism and accumulation. 
 
5.2. INTRODUCTION 
Reactive oxygen species (ROS) and their role in the development / progression of chronic 
diseases and aging have had a long theoretical history.181, 182   The production of ROS is not 
spontaneous as is widely published183, but instead is part of a regulated process.184  Recently 
it has been posited and scientifically supported that intracellular generation of ROS are 
important signalling molecules essential for the normal functioning of the human 
metabolome183, 185, 186 and have beneficial immune functions that protect against infective 
agents.179, 182 However, dysregulation of ROS production can cause tissue damage. Under 
normal, healthy conditions, several enzymatic mechanisms prevent this event from 
occurring183. 184, 187 
 
Lipid peroxidation is thought to be an important factor in the pathophysiology of a number of 
diseases181 and has gained interest as a marker for quantifying the purported damage due to 
ROS. F2-isoprostanes have been established as an accurate and stable marker for measuring 
 
 
121 
 
lipid peroxidation in vivo.188, 189  F2-isoprostanes are produced from the oxidative degradation 
of arachidonic acid, and are considered the “gold standard” marker of lipid peroxidation. 
Quantification of F2-isoprostanes in biological samples is difficult however. Increasing 
evidence supports the notion that isoprostanes have strong biological effects.188, 190, 191 The 
pathophysiological role isoprostanes and other lipid peroxidation compounds have in certain 
diseases still remains relatively unknown. 
 
In recent decades, a number of molecular mechanisms have been found to contribute to the 
development of NAFLD and its progression to non-alcoholic steatohepatitis (NASH). Studies 
have reported that the pathogenesis of NAFLD and NASH is due to the “two hit” hypothesis. 
This depicts a state where one physiological mechanism is responsible for the initial 
development of NAFLD, and a second mechanism is responsible for the progression of the 
disease to NASH. Within the two hit theory, oxidative damage, dysregulated cytokine 
production and other inflammatory mediators may each play a role, with lipid peroxidation 
promoted as a leading causative factor.192, 193  Hence, ROS are extensively reported to 
promote lipid peroxidation, leading to detrimental effects on hepatocytes and other hepatic 
cells.192 ROS are also reported to increase cellular production of pro-inflammatory cytokines, 
promoting cell death, inflammation and fibrosis.194 
 
It has been reported that there is a differential effect on ROS activity with diets comprised 
predominantly of fat over a balanced diet.195-198 Also diets rich in saturated fat content can be 
very stable to oxidation, whereas diets rich in polyunsaturated fatty acids (PUFAs), 
specifically 18:2n-6, are prone to oxidation.199  There is also published literature on how diet 
can alter the composition of the intestinal microbiota.200-204 Diets rich in carbohydrate, fat or 
protein alters the microbiota population to favour a specific enterotype (Bacteroides, 
Prevotella or Ruminococcus).205-207 Changes to the gastrointestinal microbiota as a result of 
an unbalanced diet can promote dysbiosis increasing the risk inflammatory diseases.160, 161 
 
The aim of this study was to investigate the effects of lipid peroxidation in response to a high 
fat diet with a secondary aim to examine whether probiotics altered this response. I 
hypothesised that a diet high in fat would cause increased lipid peroxidation and that 
probiotics could rescue the altered lipid peroxidation by modifying the gut microbiota and re-
regulating the gut-liver-axis.  
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5.3. METHODS 
Study design 
Mice were fed either a chow diet or a HFD for a total of 20 weeks. At the end of week 10, 
probiotics were added to the drinking water of one group for the remaining 10 weeks. At the 
end of week 20 all mice were euthanized, dissected and samples stored for later analysis. 
 
Animals 
Eight week old C57B1/6J mice (Animal Resources Centre, Perth, WA, Australia) were 
randomly assigned into one of three groups: 1) a control group, receiving a standard 
laboratory chow diet (chow; n=9); 2) a high fat diet group (HFD) (n=10); and 3) HFD fed 
group supplemented with probiotics (probiotics; n=10; 1 × 108-9 CFU/mL). All animals were 
housed in a SPF facility with ad libitum access to clean food and water. Housing conditions 
were maintained at 19°C to 23°C with 50% humidity on a 12 hour light/dark cycle. All 
animals received humane care under the guidelines and approval of the Queensland Institute 
of Medical Research and the University of Queensland Animal Ethics Committees. 
 
Bacterial strains 
Nine strains of probiotics (L. rhamnosus – 34.5%, Lactobacillus casei – 21%, Lactobacillus 
acidophilus – 16.5%, L. plantarum – 7%, Lactobacillus fermentum – 3%, Bifidobacterium 
lactis – 9%, Bifidobacterium breve – 3%, B. bifidum – 1%, S. thermophilus – 5%), were 
kindly donated by Fit BioCeuticals (NSW, Australia). All strains were lyophilised, water 
soluble and added to the drinking water as a combination probiotic. The total concentration of 
probiotics added to the drinking water was 1 × 108-9 CFU/mL. This dosage was chosen 
because it represents a dose per kilogram of body mass equivalent for a human (65 kg) and 
the amount of water consumed (5 mL) by an average-sized mouse (25 g) per day. 
 
Diet 
The standard laboratory chow and HFD were purchased from Specialty Feeds (WA, 
Australia; HFD product SF03-020). The chow diet contained 4.8% total fat (mono 
unsaturated fat 2.0%, polyunsaturated fat 1.8% and saturated fat 0.7%) providing 14MJ/Kg of 
energy while the HFD contained 23% total fat (mono unsaturated fat 7.6%, polyunsaturated 
fat 2.0% and saturated fat 12.6%) providing 20MJ/Kg of energy. 
 
 
 
123 
 
Dissection 
At the conclusion of week 20, mice were anaesthetised using an intraperitoneal injection of 
pentobarbital and xylene. Once anaesthetised, animals were killed via cardiac puncture for 
blood collection. The blood was allowed to clot at room temperature before serum was 
removed and stored at -80°C. The liver was removed, weighed, cut into small pieces and snap 
frozen in liquid nitrogen for determination of oxidative compounds as detailed below. 
 
Isoprostanes 
Tissue extraction 
Isoprostanes were extracted from liver tissue using a previously published method.156 
Samples were weighed and 1mL of methanolic NaOH added. Samples were incubated at 42 
°C for 30 minutes, homogenised and 400 µl transferred to a screw-capped glass tube. A 
further 400 µl of methanolic NaOH was added together with 800 µl of distilled water and 
spiked with 400 pg/mL of 8-iso-PGF2α-d4 internal standard (Cayman Chemicals, USA). The 
resulting solution was vortex mixed, capped and incubated at 42°C for 60 minutes. 
Once removed from incubation, samples were placed on ice for 10 minutes then acidified to 
pH 3 with 450 µl of 3 M hydrochloric acid and vortex mixed. Hexane was added (3.0 mL), 
gently rotated for 10 minutes and centrifuged at 3000 × g; hexane supernatant was removed 
and discarded. The remaining solution was then extracted with ethyl acetate (3.0 mL); with 
extracts transferred to a clean tube and dried under nitrogen. Once dry, the samples were 
reconstituted with 200 µl of acetonitrile, vortex mixed, transferred into 400µl silinised glass 
inserts and dried for derivatization. 
 
Using a derivatization method based on that by Mori and colleagues208, 40 µl 
pentafluorobenzylbromide (PFBBr, 10% in acetonitrile) and 20 µl Diisopropylethylamine 
(DIPEA, 10% in acetonitrile) were added to the dried extract, which was then incubated at 
room temperature for 30 minutes. Samples were then dried under nitrogen and treated with 
10 µl of Pyridine and 20 µl of Bis(trimethylsilyl)trifluoroacetamide + Trimethylchlorosilane 
(BSTFA + TMCS 99:1) and incubated at 45°C for 20 minutes. Following incubation, 60 µl of 
hexane was added to each sample, mixed and placed on the auto sampler. Samples were 
analysed using a Varian 320 MS/MS with a Varian 450 gas chromatograph (Varian, 
Australia). The compounds analysed were m/z 569.3/299.3 and m/z 573.3/303.3 for 
isoprostanes and its internal standard, respectively. 
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Malondialdehyde (MDA) 
HPLC was used to determine plasma malondialdehyde (MDA) using the method of Sim et al. 
(2003). The principle of this method is that malondialdehyde contained in plasma is 
derivatised with 2,4-dinitrophenylhydrazine, which forms stable hydrazones that can be 
easily separated by HPLC using diode array detection (Shimadzu, Kyoto, Japan). 
 
Protein 
Protein was measured as per manufacturer’s direction using a Pierce BCA protein assay kit 
supplied by Thermo Scientific (Victoria, Australia) 
 
Statistical analysis 
All data are presented as mean ± standard deviation unless otherwise stated. Data were tested 
for normality of the distribution, and analysis was performed with the statistical software 
GraphPad Prism 6. Comparison between groups was carried out using a 1-way analysis of 
variance with a post hoc test of significance between individual groups. Differences were 
considered significant when p was less than 0.05. All significant differences between groups 
were determined using the HFD group as the reference group. 
 
5.4. RESULTS 
Ingestion of a high fat diet reduced the formation of liver isoprostanes and MDA compared to 
the chow fed group (Figure 5.1). No differences in MDA or isoprostanes concentrations were 
evident between the HFD and HFD + probiotics groups. Isoprostanes concentration 
correlated with MDA levels in the chow fed group only (R2 = 0.605; Figure 5.2). In the chow 
group, MDA and isoprostanes showed positive correlations with fat pad mass (Figure 5.3 & 
5.4) and isoprostanes negatively correlated with liver protein concentration (Figure 5.5). 
There was no correlation between MDA or isoprostanes with either liver mass (Figure 5.6) or 
body mass (Figure 5.7). The chow group weighed less than both the HFD groups (p<0.01; 
data not shown), but there was no difference in body mass between two HFD groups (data 
presented in chapter 3, Figures 9 and 10). 
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5.5. DISCUSSION 
Lipid peroxidation has long been postulated as a marker of oxidative damage. Accumulation 
of lipid peroxidation compounds is a sign of dysregulated lipid peroxidation that can lead to 
the development or progression of diseases. I hypothesised that mice fed a high fat diet would 
increase lipid peroxidation indicated by increased accumulation of isoprostanes and MDA in 
the liver, and that probiotics would reduce this lipid peroxidation. On the contrary, however, 
high fat feeding actually reduced lipid peroxidation in the liver (Figure 5.1), while probiotics 
did not alter this response. These findings challenge the popular notion that high fat feeding 
and obesity cause increased ROS production and lipid peroxidation.184, 187 
 
The findings of this study were unexpected. Other literature has reported that lipid 
peroxidation increases in mice fed a high fat diet.209, 210 One factor that may account for this 
disparity is the fat composition of diets.211, 212. A diet high in polyunsaturated fat may cause 
differing degrees of lipid peroxidation compared with a diet that is high in saturated fat. The 
high fat diet used in the present study was predominantly saturated fat (12.6%), which is less 
susceptible to oxidation.213 Studies investigating the effects of mono unsaturated, 
polyunsaturated and saturated fat on NAFLD, lipid peroxidation and fat accumulation should 
be considered for future studies.214-216 
 
The reduction in lipid peroxidation may be a protective response to help prevent cirrhosis of 
the liver. The amount and type of lipid the tissue is exposed to may also play an important 
factor in the disease state. Lu126 demonstrated that hepatic stellate cells exposed to varying 
concentrations of triglycerides or VLDL, had modified activation of stellate cells. A high 
dose of triglycerides (400 mg/L) inhibited stellate cell activation, while a low dose of 
triglycerides (12.5 mg/L) and high levels of VLDL (50 – 100 mg/L) promoted activation. 
This supports the importance of the type and amount of lipids the liver is exposed to and may 
help explain why some people progress from NAFLD to NASH. In the presence of increased 
triglycerides, if the stellate cells continue to be activated it may lead to cirrhosis of the liver.  
 
Reduced lipid peroxidation in HFD fed mice may be a response to prevent cirrhosis of the 
liver through deactivation of stellate cells. Stellate cell activation, rather than lipid 
peroxidation, may be the second hit in the ‘2-hit theory’ that defines whether an individual 
progresses from NAFLD to NASH. If this pathway is dysregulated, stellate cells may remain 
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activated, causing excessive fibrosis progressing to cirrhosis and NKT cells to activate. 
Hepatic stellate cells and hepatocytes are also necessary for lipid mobilization.217, 218 While 
the liver may prevent cirrhosis by reducing stellate cell activation, it also prevents 
mobilisation of the lipids. Whether lipid peroxidation has a roll in this effect is not known. 
Lipid peroxidation has been linked with hepatic stellate cell proliferation.219-221 Montosi222 
demonstrated that oxidative compounds anticipate stellate cell activation. As stellate cells are 
deactivated, so too oxidative compounds reduce. I speculate that exposure to high levels of 
triglycerides prevents the activation of stellate cells and subsequent lipid peroxidation and 
lipid metabolism. 
 
Another difference between results reported are the assays used. ELISA based assays for 
determination of lipid peroxide compounds are not selective enough often over estimating 
concentrations and having poor reproducibility.223, 224 The length of the study may also be an 
important factor. I fed my mice a HFD for 20 weeks allowing NAFLD to develop. Shorter 
feeding periods may not reach the same disease state where certain metabolic changes take 
effect.225, 226 Shorter feeding periods may not allow the liver sufficient time to accumulate the 
required lipids to deactivate the stellate cells and oxidative compound formation. Gaemers226 
demonstrated that the effects of the diet can fluctuate over the course of a study. Possible 
future work may involve measurement of the lipid content, hepatic stellate cell activation and 
lipid peroxide accumulation at regular intervals over a 20 week period. 
 
These results do not exclude isoprostanes and MDA as a measure of oxidative damage. 
However, it may be necessary to consider the population and / or individual when 
interpreting data for isoprostanes and MDA. High levels of isoprostanes and MDA may still 
indicate oxidative damage, but only above certain concentrations. Another point to consider 
when looking at these results is that isoprostanes are typically measured in plasma or serum. 
Due to the sample volume required it was not possible to measure serum isoprostanes in this 
study. As a substitute, liver isoprostanes were measured as a direct indicator of lipid 
peroxidation within the liver as opposed to systemic production of isoprostanes. This creates 
another question, does the liver concentration and plasma concentration of isoprostanes 
correlate? The present data show for the first time that liver isoprostanes and MDA are 
correlated, but only in chow fed mice. The lack of correlation in the HFD groups appears to 
be due to the small amount of isoprostanes and MDA produced in HFD mice. 
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The mice were housed in a SPF facility with a tightly controlled pathogen population. 
Housing animals in an environment exposed to more or different bacteria may influence the 
microbiota population and subsequently the gastrointestinal health and disease formation. 
The microbiota has been shown to have a dramatic effect on disease formation.227-229 If mice 
are exposed to different pathogens that alter the gut-liver axis, this may alter lipid 
peroxidation and fat metabolism.  
 
Probiotics were proposed to re-regulate fat-induced changes to the microbiota population and 
subsequent changes to lipid peroxidation. The lack of effect may be due to a number of 
reasons. The dose of probiotics may have been too low. Despite administering a dose based 
on body mass and the recommended dose for humans, the amount administered may have 
been too low to account for the changes caused by the high fat diet. Under the extreme 
circumstances, a higher dose may be required to rescue lipid peroxidation. The duration 
supplementation may have been too short, or were introduced too late into the study. By 
administering the probiotics 10 weeks into the study, the disease state may already be too 
established for short term supplementation to be effective. Administering the probiotics 
earlier, possibly as a prophylactic, may alter the results. Despite probiotics having little effect 
on lipid peroxidation, it is possible supplementation had beneficial effects elsewhere. As a 
consequence, it could be that a multi-strain probiotic administered in sufficient doses or as a 
prophylactic can rescue a dysbiotic gastrointestinal tract microbiome and in turn affect fat 
metabolism in the liver thereby possibly reducing its progression to fatty liver disease. Future 
studies will investigate other possible benefits of probiotics supplementation within a high fat 
feeding model as well as investigate signalling pathways that reduce lipid peroxidation. 
 
In summary, lipid peroxidation as determined by isoprostanes and MDA concentrations were 
reduced in mice fed a HFD for 20 weeks. Reduced lipid peroxidation in HFD fed mice may 
be a response to prevent cirrhosis of the liver via stellate cell deactivation. Stellate cell 
activation, rather than lipid peroxidation, may be the second hit in the 2-hit theory that 
defines whether an individual progresses from NAFLD to NASH. If this pathway is not 
regulated, stellate cells may remain activated causing excessive fibrosis progressing to 
cirrhosis and NKT cells to activate. Can isoprostanes therefore be used as a possible marker 
for NAFLD and NASH severity? 
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5.6. FIGURES 
 
Figure 5.1: Lipid peroxidation markers of A) liver isoprostanes and B) malondialdehyde 
Figure 5.2: Comparison of isoprostanes and MDA 
Figure 5.3: Comparison of MDA and fat pad weight 
Figure 5.4: Comparison of isoprostanes and fat pad weight 
Figure 5.5: Comparison of isoprostanes and liver protein 
Figure 5.6: Comparison of liver weight and MDA 
Figure 5.7: Comparison of body weight and isoprostanes 
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Figure 5.3 
 
Figure 5.4 
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Figure 5.5 
 
Figure 5.6 
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Figure 5.7  
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Chapter 6  
Optimised Method for Quantification of Total F2-isoprostanes Using Gas 
Chromatography-Tandem Mass Spectrometry
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F2 -isoprostanes are produced from the oxidative degradation of  arachidonic acid and are considered 
the gold standard marker of  lipid peroxidation in  biological samples. We  developed a  liquid–liquid 
extraction method for   the determination of  total  isoprostanes  using negative chemical ionization 
gas  chromatography–tandem mass spectrometry in  plasma and tissue homogenates. Incorporating 
liquid–liquid extraction allows for greater sample through-put than current approaches. Here we describe 
the protocol and include numerous trouble-shooting suggestions. The method found healthy individuals 
with 150–250 pg of isoprostanes per ml of plasma and end stage kidney disease patients to have the high- 
est measured values of up to 1100 pg/ml. This assay has an accurate working linear range of 40–1000 pg of 
isoprostanes (100–2500 pg/ml) and an average coefficient of variance of 7%. Tissue values for healthy mice 
liver were 50–70 pg/j.tg protein. This method provides increased ion selectivity and detection capabilities 
with economical sample through-put. 
© 2013 Elsevier B.V. All rights reserved. 
 
 
 
1.  Introduction 
 
Oxidative stress is involved in the development and progression 
of numerous chronic diseases including kidney disease [1], cardio- 
vascular disease, neurodegenerative conditions and malignancies 
[2].  Markers of  lipid peroxidation are  the most commonly used 
determinants of  oxidative stress and F2 -isoprostanes are  estab- 
lished as the most accurate and stable marker for measuring lipid 
peroxidation and oxidative damage in vivo  [3,4].  Regarded as the 
“gold   standard” for  assessing oxidative damage in  humans, F2 - 
isoprostanes are  generally measured in plasma and urine but have 
also  been measured in  tissue homogenate [5,6].  F2 -isoprostanes 
are  prostaglandin-like compounds formed from the free-radical 
catalyzed peroxidation of arachidonic acid.  There are  four  groups 
of F2-isoprostanes regioisomers formed from arachidonic acid  (5- 
, 8-,  12-  and 15-series isoprostanes), each containing 8  possible 
diastereomers making 32 different F2-isoprostanes possible [7,8]. 
Due  to  the complex methodologies and expensive equipment 
required to separate F2 -isoprostanes from other prostaglandins and 
their metabolites, measurement of  F2 -isoprostanes in  biological 
samples is  difficult. There are   numerous approaches for  quan- 
tifying F2 -isoprostanes including enzyme-linked immunosorbent 
 
 
∗ Corresponding author at: School of  Human Movement Studies, University of 
Queensland, St Lucia, QLD 4072, Australia. 
E-mail address: jcoombes@uq.edu.au (J.S. Coombes). 
assay (ELISA) [9,10], gas  chromatography–mass spectrometry 
(GC/MS)  [6,10,11], gas  chromatography–tandem mass spectrom- 
etry (GC/MS/MS) [12,13], liquid chromatography–mass spectrom- 
etry (LC/MS) [14,15] or  liquid chromatography–tandem mass 
spectrometry (LC/MS/MS) [16–18]. The majority of published stud- 
ies  measuring isoprostanes in  vitro use  the ELISA approach and 
while it is economical and reproducible, it provides vastly differ- 
ent and varied results compared to  a GC/MS approach [19].  The 
mean and median ELISA results were 30-fold greater than results 
from GC/MS results (range 9–138-fold). The differences were spec- 
ulated to be due to the non-specific binding properties of the ELISA 
plate compared to the specificity and separation of mass spectrom- 
eter. The comparison between ELISA kits has also been shown to be 
unreliable, with correlations between different ELISAs being very 
poor [20].  GC/MS and LC/MS are  accurate but often require elab- 
orate extraction methods leading to  low  through-put. The GC/MS 
approach also  requires additional derivatization steps and has  dif- 
ficulty separating isomers compared to  LC/MS. Advancements in 
technology have led to greater affordability and availability of tan- 
dem mass spectrometry (MS/MS). Although still expensive, MS/MS 
gives increased selectivity of compounds compared to MS, allowing 
for improved isolation and quantification of F2 -isopostanes. 
Despite the technology in  use  for  detecting isoprostanes, the 
majority of limitations for quantifying F2 -isoprostanes remain with 
the extraction from biological samples. Current methods incor- 
porate solid phase extraction (SPE)  [11,18,21–23], liquid–liquid 
extraction (LLE) [6,17], thin-layer chromatography (TLC) [24,25], 
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affinity column [14],  silica  gels  [21]  and reverse-phase cartridges 
[11]. These methods are time consuming with low sample through- 
put making them expensive. The method presented here uses LLE 
that uses inexpensive reagents overall allowing for  greater sam- 
ple through-put (50 extractions per day). The greatest limitation to 
sample through-put with this method is the GC/MS/MS run time. 
Our  laboratory spent considerable time unsuccessfully 
attempting to   develop GC/MS,  LC/MS  and LC/MS/MS  methods 
with and without SPE. This led us to GC/MS/MS and the refinement 
of previous methods from Taylor et al. [17]  and Mori  et al. [11]  and 
the use  of negative chemical ionization and LLE. We  now have a 
protocol that has  high sample through-put capacity, is economical, 
sensitive and very reliable. Here we  describe the protocol along 
with a discussion of important issues encountered during method 
development to allow for ease of replication and trouble-shooting. 
 
2.  Methods 
 
2.1.  Reagents and  standards 
 
Chemicals were sourced from Labscan (ethylacetate;  Gliwice, 
Poland), LiChrosolv (methanol, hexane, acetonitrile and hydrochlo- 
ric  acid; Merck, Darmstadt, Germany) and Chem-Supply (sodium 
hydroxide pellets; Gillman, SA, Australia). Derivatization reagents 
N,O-bis-(trimethylsilyl)trifluoroacetamide 1% trimethylchlorosi- 
lane  (BSTFA + TMCS,  99:1) were  purchased from Supelco and 
pentafluorobenzylbromide (PFBBr), N,N-diisopropylethylamine 
(DIPEA) and pyridine purchased  from Sigma–Aldrich (NSW, 
Australia). Standards used (8-iso prostaglandin F2a  and 8-iso 
prostaglandin F2a -d4 )  were  purchased  from Cayman Chemical 
(Ann  Arbor, MI, USA). Methanolic sodium hydroxide was made as 
per previously published by Taylor et al. [17].  Briefly, 12 g of NaOH 
was dissolved in  28 ml  of water and 160 ml  of methanol added. 
Hydrochloric acid  was diluted to 3 M using deionised water. 
 
2.2.  Plasma collection 
 
Samples were collected by drawing blood into a vacutainer con- 
taining ethylenediaminetetraacetic acid  (EDTA) and centrifuged 
immediately or  placed on  ice  and centrifuged within 30 min of 
collection at 2000 × g at 4 ◦C. Aliquots of samples (>850 j.tl) were 
placed into tubes containing 10 j.tl of 100 mM  butylated hydroxy- 
toluene (BHT) and stored at −80 ◦C  until required. Serum is also 
suitable for  use.  The  protocol below describes plasma extraction, 
but would be the same for serum. 
 
2.3.  Tissue collection 
 
Liver tissue was collected from mice at the time of termination, 
cut  into small pieces (∼50 mg  pieces) and snap frozen using liquid 
nitrogen. Samples were stored at −80 ◦C until required. 
 
2.4.  Extraction and  derivatization 
 
Table  1 contains the protocol for extraction and derivatization 
of plasma and tissue samples. 
 
2.5.  Gas chromatography–tandem mass  spectrometry analysis 
 
Samples were analyzed for  total isoprostanes concentration 
using a Varian 320  MS/MS,  with a Varian 450  gas  chromatograph 
equipped with a CP8400 auto sampler. Data was analyzed using 
the Varian MS Workstation-System control software version 6.9.2 
(Varian, Australia). 1 j.tl of sample was introduced in splitless mode 
using a 10 j.tl Hamilton syringe. After  1 min the injector port was 
switched to  a  1:20 split. The  injector operated at 250 ◦C  with a 
 
 
Fig.  1.  Two quality control plasma samples spiked with 0,  200, 400 or 800 pg/ml 
of  isoprostanes.  Recovery of  isoprostanes from spiked plasma sample showed a 
recovery of >90% and an accuracy of >96%. 
 
 
Varian FactorFour Capillary Column (VF5 MS 30 m × 0.25 mm ID, 
DF = 0.25) using helium as the carrier gas at a flow rate of 1.0 ml/min. 
The  column oven was started at 160 ◦C  and held for  1 min, then 
increased at 20 ◦C/min  to  300 ◦C,  and held for  10 min. The  total 
column oven run time is 18 min with the isoprostane peak eluted 
around 9–10 min (Fig. 1). 
Running in  negative chemical ionization mode (NCI) at 70 eV, 
the chemical ionization gas  was argon run at an  ion  source pres- 
sure of 4.20 Torr and the collision gas was argon run at 2.00 mTorr. 
The mass spectrometer was operating at a transfer line temperature 
of 250 ◦C, ion volume temperature of 200 ◦C and collision energy of 
17 V. The detector operated at 1700 V. Isoprostanes peak identifica- 
tion of a sample was established by comparing the retention time 
and fragmentation pattern of a standard and deuterated standard. 
The   mass size   and transition of  isoprostanes and the  respec- 
tive  deuterated standard were established at m/z 569.3/299.3 and 
573.3/303.3 respectively. 
 
 
2.6.  8-iso-PGF2˛  standard preparation 
 
Three different standard concentrations were made by adding 
80, 160  or 320 pg of isoprostanes to a silanized vial  inserts from a 
concentrated stock solution of 500 j.tg/ml of 8-iso-PGF2a (diluted 
using methanol). Standards were made in  batches, immediately 
dried under nitrogen, capped and stored at −80 ◦C  for  later use. 
Upon removal from the freezer for  use,  the vial  was allowed to 
equilibrate to room temperature before the same amount of deuter- 
ated standard as added to the samples (400 pg/ml equivalent), was 
added. These standards were derivatized along with the samples 
and gave a final concentration equivalent to 200, 400 and 800 pg/ml 
when 400 j.tl of sample was extracted. 
 
 
2.7.  Intra- and  inter-assay variability and  accuracy 
 
Intra-assay variability was determined  by  the average coef- 
ficient of variance of over 1000 different samples analyzed in 
duplicate over 12  months. Inter-assay variability was assessed by 
the inclusion of high level (pooled samples from sick  individuals) 
and low  level (pooled samples from young, healthy individuals) 
quality control (QC) samples, extracted in conjunction with study 
samples each day. 
Accuracy was assessed by  comparing plasma samples spiked 
with known amounts of isoprostanes. Known amounts of 8-iso- 
PGF2a (0, 200,  400  and 800 pg/ml) were added to  our  QC plasma 
samples and  analyzed in  duplicate on   multiple  occasions. F2 - 
isoprostane concentrations were separately quantified in  these 
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Table 1 
Summarized protocol for  extraction and derivatization of plasma or tissue samples for  F2-isoprostanes measurement using GC–MS/MS. 
 
Plasma extraction  Tissue extraction 
• In a 10 ml screw cap glass tube add 160 pg of 8-iso-PGF2a -d4 + 400 j.tl sample + 800 j.tl 
methanolic NaOH for  saponification + 800 j.tl dH2 O and vortex for  5 s 
• Place 30–100 mg of tissue in a microfuge tube containing 1 ml of methanolic NaOH 
• Incubate in a water bath at 42 ◦ C for  60 min • Incubate in water bath at 42 ◦ C for  30 min 
• Place on ice  for  10 min • Homogenize the tissue 
• Precipitate proteins out of solution by  adjusting to pH  3 using 450 j.tl of 3 M HCl – vortex for  5 s • In a 10 ml screw cap glass tube add 160 pg of 8-iso-PGF2a -d4 + 400 j.tl tissue homogenate + 400 j.tl 
methanolic NaOH for  saponification + 800 j.tl dH2 O and vortex for  5 s 
• Remove neutral lipids by  adding 3 ml hexane • Incubate in a water bath at 42 ◦ C for  45 min 
• Gently mix (end over end at 20–30 rpm) for  10 min, centrifuge for  10 min (3000 × g) at room 
temperature and remove the supernatants and discard using glass Pasteur pipette 
• Place on ice  for  10 min 
• Extract isoprostanes with 3 ml ethyl acetate and vigorously shake for  10 s • Precipitate proteins out of solution by  adjusting to pH  3 using 450 j.tl of 3 M HCl – vortex for  5 s 
• Gently mix (end over end at 20–30 rpm) for  10 min, centrifuge for  10 min (3000 × g) at room 
temperature and remove the supernatants using glass Pasteur pipette to clean glass tube 
• Remove neutral lipids by  adding 3 ml hexane 
• Dry  extracts under dry nitrogen stream at 40 ◦ C (approximately 60 min) • Gently mix (end over end at 20–30 rpm) for  10 min, centrifuge for  10 min (3000 × g) at room 
temperature and the supernatants remove and discard using glass Pasteur pipette 
• Reconstitute in 200 j.tl acetonitrile, vortex for  5 s and transfer into 400 j.tl silanized glass inserts  • Extract isoprostanes with 3 ml ethyl acetate and vigorously shake for  10 s 
• Dry  under nitrogen stream at 40 ◦ C ready for  derivatization (about 15–20 min) • Gently mix (end over end at 20–30 rpm) for  10 min, centrifuge for  10 min (3000 × g) at room 
temperature and the supernatants remove using glass Pasteur pipette to clean glass tube 
• Dry  extracts under dry nitrogen stream at 40 ◦ C (approximately 60 min) 
• Reconstitute in 200 j.tl acetonitrile, vortex for  5 s and transfer into 400 j.tl silanized glass inserts 
• Dry  under nitrogen stream at 40 ◦ C ready for  derivatization (about 15–20 min) 
Derivatization [11] 
• Add 40 j.tl of pentafluorobenzylbromide (PFBBr,  10% in acetonitrile – 4 j.tl of PFBBr and 36 j.tl of ACN) and 20 j.tl di-isopropylethylamine (DIPEA,  10% in acetonitrile – 2 j.tl DIPEA and 18 j.tl of ACN) and vortex for  5 s 
• Incubate at room temperature for  30 min 
• Dry  for  30 min under nitrogen 
• Add 10 j.tl anhydrous pyridine and 20 j.tl bis-(trimethylsilyl)trifluoroacetamide and trimethylchlorosilane (BSTFA + TMCS, 99:1), cap and vortex for  5 s 
• Incubate for  20 min at 45 ◦ C 
• Add 60 j.tl of anhydrous hexane 
• Cap  with PTFE lined cap in autosampler carrier vial 
• Place on auto sampler rack for  analysis 
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Fig.  2.  Plasma QC sample from a healthy individual. (A)  Total isoprostanes peak 
representative of 200 pg/ml of plasma and (B) internal standard peak. 
 
 
samples, unspiked samples and aqueous standards (Fig. 1a). Regres- 
sion lines were calculated using Microsoft Excel. 
 
2.8.  Calculations 
 
A standard curve was developed by  injecting known amounts 
of F2-isoprostane (200, 400 and 800 pg/ml) and F2-isoprostanes-d4 
(internal standard). By comparing the ratio of internal standard to 
isoprostanes in both the aqueous standards and biological samples 
allows for quantification of the total isoprostanes. The percentage 
recovery of the internal standard added to biological samples com- 
pared to  the aqueous standards determines the efficiency of the 
extraction process. Internal standard addition allows for the vari- 
ability in recovery of every sample to be accounted for. Our recovery 
data is based on  multiple data sets where a sample and standard 
were injected sequentially. 
 
2.9.  Protein analysis 
 
Protein concentration was analyzed using a Pierce BCA protein 
assay kit  (Thermo Scientific Australia). Briefly, 40 j.tl  of  homog- 
enized tissue (described earlier) was diluted in  1 ml  of  distilled 
water. Of this solution, 15 j.tl was added to a well of a 96 well plate 
and 200 j.tl of BCA reagent added. Protein concentration was deter- 
mined by a standard curve using the protein standard provided in 
the kit. 
 
3.  Results 
 
3.1.  Range 
 
Samples were analyzed from young (20–35 years) healthy indi- 
viduals (Fig. 2) and patients with chronic kidney disease (n = 1040), 
end stage kidney disease (n = 172) or metabolic syndrome (n = 41). 
The isoprostanes concentration ranged from levels found in healthy 
subjects of 100–250 pg/ml (typically 150–200 pg/ml) to the highest 
concentrations found in end stage renal disease patients reaching 
1100 pg/ml (typically >400 pg/ml). 
 
Pooled QC samples were collected from young, healthy indi- 
viduals (low QC) or  from surplus plasma collected from a  local 
hospital (high QC). The  QC material was a plasma mixture from 
de-identified waste samples from a pathology laboratory and from 
our  own venepuncture laboratory. As such, ethics approval was 
not necessary. The  low  QC gave a  mean of  189.7 pg/ml (95% CI 
187.1–192.0 pg/ml) and the high QC gave a mean of 567.2 pg/ml 
(95% CI 557.8–579.1 pg/ml). 
Samples collected from mice showed a healthy mouse liver to 
have a concentration of 50–70 pg/j.tg of protein. 
 
3.2.  Sample  recovery and  accuracy 
 
When the chemical ionization gas  was methane, there was 
degradation over time in the mass spectrometers signal/sensitivity. 
This  made it difficult to  be  accurate with our  recovery data. With 
argon as our  chemical ionization gas [26],  the signal remained sta- 
ble and recovery and accuracy data was able to be determined. Our 
extraction method consistently recovers >90% (typically >95%) of 
added internal standard with an accuracy of >96% (Fig. 1a). 
 
3.3.  Inter- and  intra-assay variability 
 
The inter-assay variability of the low  and high QC’s was 7.6 and 
5.9% respectively with an  intra-assay variability from more than 
1000 samples of 7.0%. 
 
4.  Discussion 
 
Following failed attempts  to   replicate previously published 
methods for  measuring isoprostanes, we  felt  the need to  develop 
and refine a reliable, sensitive and reproducible method capable 
of high sample through put. Modifying methods by  Taylor et al. 
[17]  and Mori  et al. [11],  we  developed a LLE method that gives 
consistent and reliable results. 
Previous methods rely  on a combination of TLC, SPE, HPLC prep 
columns and/or LLE. These are  time consuming with limited sam- 
ple through-put capability and expensive with low  recoveries. Our 
method only uses LLE requiring inexpensive reagents, and allowing 
for greater sample through-put (50 samples per day). The greatest 
limitation to sample through put with this method is the run time 
on the mass spectrometer. 
Previous methods have commonly measured isoprostanes using 
a single quadrupole MS [6,10,11,14,15], only capable of running in 
selective ion monitoring (SIM) mode. Our method incorporates tan- 
dem MS giving increased selectivity capable of pairing a precursor 
ion  with a product ion  through fragmentation. This  allows accu- 
rate measurement of specific compounds and may explain why our 
reported value for healthy controls (150–200 pg/ml) is often lower 
than other published values (400 pg/ml) [23]. 
 
4.1.  Purification 
 
Once    we   established  an   adequate  methodology,  we   pro- 
ceeded to  further purify the extract. One  attempt to  purify the 
chromatograms was to remove the supernatant following the pre- 
cipitation of the proteins. Once  the samples had been saponified, 
the samples were placed on  ice  and centrifuged allowing us  to 
extract the supernatant into a  clean tube leaving the proteins 
behind. However, extraction of the supernatant resulted in  very 
poor recoveries (∼10%). We  concluded that the majority of  iso- 
prostanes were still  isolated in the protein pellet leaving only the 
free  isoprostanes in the supernatant. When the proteins were left 
in the bottom of the tube, recovery returned to  >90% of total iso- 
prostanes. 
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To maximize the recovery of isoprostanes, tests were carried 
out to  check the recovery of  one, two and three ethyl acetate 
extractions. Results showed that the first ethyl acetate extraction 
recovered >90% of  the total isoprostanes, the second extraction 
recovered <5% and the third extraction recovered <1%. However, the 
second and third extractions carried over more impurities, result- 
ing  in a reduction in the signal to  noise ratio (data not shown). It 
was therefore deemed that one ethyl acetate extraction is the most 
efficient for recovering the majority of isoprostanes and giving the 
best signal to noise ratio. 
As a further means to reduce impurities and maximize sample 
volumes, 200 j.tl and 300 j.tl aliquots of sample were assayed. The 
use  of 200 j.tl and 300 j.tl of sample increased the detection limit 
from 50 pg/ml for  400 j.tl of  sample to  200 pg/ml and 100 pg/ml 
respectively due to  a reduction in  signal to  noise ratio resulting 
in poor peak resolution. Therefore, 400 j.tl of sample was deemed 
optimal. Using an  instrument with greater sensitivity may enable 
the use  of less  sample volume. 
 
4.2.  Emulsion formation 
 
During development of this method, numerous complications 
were faced. During sample extraction, when hexane was added 
to   the  acidified solution an   emulsion interphase between the 
aqueous and organic phase occurred, resulting in  the formation 
of  a  gel  like  layer that is  unable to  be  separated. A number  of 
things were attempted to  reduce the emulsion including: replac- 
ing  the methanolic NaOH  with methanolic potassium hydroxide 
(KOH), altering the amount of water added for hydrolysis, altering 
the concentration and volume of  NaOH  added, altering the vol- 
ume of  hexane added, adjusting the pH  of  the solution, adding 
surfactants and changing the  temperature  and/or duration for 
saponification and protein precipitation. Of these, the only effec- 
tive  changes that prevented emulsion formation was to  increase 
the temperature for  saponification (from 37◦  to  42◦)  and cool- 
ing  the samples prior to  protein precipitation. The  emulsion 
formation  was  even  more  pronounced  when  a   second  hex- 
ane extraction was attempted, regardless of the pre-treatment 
conditions. Due  to  this, only one hexane extraction was incorpo- 
rated. 
 
4.3.  Isoprostanes bond  to glass 
 
Early  on  we  noted a great deal of variability in our  results. The 
recovery of our  internal standard from extracted samples would at 
times exceed 100% of our  internal standard added to the standard 
vials.  Upon investigation, we  discovered the glass vial  inserts we 
used were the cause of  the problem. From different batches of 
vials,  differing amounts of both isoprostanes and internal standard 
would bond to the glass surface, causing variability in the results. 
This problem became even more pronounced when standards were 
dried in  vial  inserts and stored. This  problem was no  longer evi- 
dent once we  switched to  silanized vial  inserts. Storing standards 
in silanized inserts for 6 months at −80 ◦C has  had no effect on the 
stability of the standards to date. 
 
4.4.  Hydrolysis 
 
Of the whole extraction process, the crucial step is at derivatiza- 
tion. If adequate drying time between derivatization steps (PFBBr 
and TMCS) was not provided, moisture would remain within the 
vial  causing irreversible hydrolysis of  the sample. This  reduced 
the chromatogram quality and altered the yield of isoprostanes. 
While investigating the glass vial inserts for isoprostanes bonding, 
silanized limited volume inserts (tapered) were trialed as silanized 
narrow flat  bottom inserts, as  previously used were unavailable.  
However, due to the shape of the insert, drying the sample proved 
difficult with samples often unable to  be  dried completely, even 
after >3 h  under nitrogen. This  led   to  a  great deal of  samples 
hydrolysing and the sample unable to be analyzed. Therefore 400 j.tl 
silanized flat  bottom inserts were used with a greater volume of 
hexane added to make up volume adequate volume for an injection. 
 
 
4.5.  CI gas/NCI mode 
 
One  major downfall with GC/MS/MS  for  isoprostanes analysis 
is  the requirement to  operate in  NCI mode where it  is  common 
practice to use methane as the CI gas. We started out using methane 
as  the CI gas  and found the instrument rapidly loss  sensitivity 
requiring calibration, cleaning or  maintenance on  a  daily basis. 
The  signal degradation would often result in periods of no  signal. 
This  resulted in our  peaks of interest having part of the peak fall 
below the baseline with no  way to  confidently quantify the peak. 
Upon continued investigation, it was discovered that our  degrada- 
tion was primarily due to the ion  volume becoming contaminated 
and affecting ion  generation. After  changing to  a  clean ion  vol- 
ume and re-tuning, the sensitivity would return to 100%. However, 
within the first 5–10 injections the sensitivity would decrease by 
up to 90% and continue to gradually decline. When operating with 
methane as the CI gas, re-tuning once the ion  volume had become 
contaminated was not possible. However, based on  the publica- 
tion of Eckstein et al. [26],  we  switched to argon as the CI gas  and 
re-calibrating following numerous injections was possible. While 
calibrating returned some of the sensitivity, a complete change of 
the ion  volume was still  the only way to  fully  restore the instru- 
ments sensitivity. Currently we are capable of injecting >60 samples 
before the need to change the ion volume or re-tune. Our particular 
instrument does not require venting (no  down-time) in order for 
the ion volume to be changed. Changing to argon as the CI gas also 
provided other benefits: methane is highly flammable and there- 
fore  a safety hazard and methane is an  expensive gas  so changing 
to argon provided an economical alternative. 
 
 
 
 
Fig. 3.  A single plasma sample from an end stage renal disease patient showing the 
presence of  an unidentified interfering compound. (A)  Sample extracted with the 
addition of  400 pg/ml of  the F2-isoprostanes-d4 internal standard and (B)  sample 
extracted without the addition of any internal standard. 
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Fig.  4.  A single plasma sample from an end stage renal disease patient using m/z 
573/277 as the transition mass. (A) Sample extracted with the addition of 400 pg/ml 
of  the F2-isoprostanes-d4 internal standard and (B) sample extracted without the 
addition of any internal standard. 
 
 
4.6.  Interfering compound 
 
Mas et al. [27] has  previously shown there is a compound found 
in  urine that interferes with the isoprostane internal standard 
peak. We  have found that there is  a  compound in  the blood of 
end stage renal disease patients that also  interferes with the iso- 
prostane internal standard  peak when m/z 573.3/299.3 is  used 
(Fig. 3). To overcome this problem we  introduced a second tran- 
sition  at  m/z 573.3/277.3. The   interfering compound was not 
identified at this mass but gave a  reduced signal to  noise ratio 
(Fig. 4). The interfering compound was not identified but is poten- 
tially a uremic toxin or a drug, treatment or supplement common 
to  this population. This  observation was not seen in  any  other 
population. 
 
4.7.  Free versus total isoprostanes 
 
Total  isoprostanes, as  measured in  this paper, is the quantifi- 
cation of both free  (non-esterified) and esterified isoprostanes. By 
removing the methanolic NaOH  incubation step from the extrac- 
tion, free  isoprostanes can  also  be measured. Free isoprostanes are 
the biologically active compound, however both free  and esteri- 
fied  isoprostanes are  the result of oxidation. Therefore to quantify 
oxidation, both the free   and esterified isoprostanes need to  be 
quantified. Morrow et al. [28]  demonstrated that while esterified 
isoprostane levels are  significantly greater than free  isoprostane 
levels in plasma, both levels increased and decreased at a similar 
rate. 
5.  Summary 
 
We  have developed a  simple method for  the accurate mea- 
surement of total isoprostanes using liquid–liquid extraction. This 
method allows for  high through-put of  both plasma and tissue 
samples. Results of the new method are  generally below current 
published normative values due to the specificity gained by incor- 
porating GC/MS/MS analysis. 
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7.1 ABSTRACT  
Hfe-/- mice fed a high calorie diet develop steatohepatitis and fibrosis. Therapy with curcumin 
or vitamin E has proved beneficial in nonalcoholic steatohepatitis. I investigated the 
synergistic properties of these agents by using them in combination in an Hfe-/- high calorie 
diet model of steatohepatitis.  Wild-type C57BL/6J and Hfe-/- mice were fed either laboratory 
chow or a high calorie diet for 20 weeks. In treatment groups, mice were fed a high calorie 
diet for 10 weeks followed by 10 weeks of either of the following diets: chow; or a high 
calorie diet in combination with; 1% curcumin; 1.5% vitamin E; 1% curcumin + 1.5% 
vitamin E. Hfe-/- mice fed a high calorie diet for 20 weeks developed steatohepatitis. Minimal 
residual steatosis was observed in those mice switched to the chow diet.  Combination 
treatment resulted in a greater reduction of macro- and micro-vesicular steatosis and lobular 
inflammation than either vitamin E or curcumin therapy alone. Pericentral fibrosis was 
present in Hfe-/- mice fed a high calorie diet with upregulation of fibrosis-related genes.  
Combination therapy in this group resulted in significant reduction in monocyte 
chemoattractant protein-1 mRNA expression, and lower expression of α1(I)-procollagen and 
tissue inhibitor of metalloproteinase. Wild-type and Hfe-/- mice fed curcumin and vitamin E 
showed an upregulation in carnitine palmitoyl transferase 1A, peroxisome proliferator-
activated receptor α and adiponectin receptor 2 mRNA expression which was consistent with 
an upregulation of fatty acid oxidation pathways. Hfe-/- mice fed a high calorie diet developed 
steatohepatitis and fibrosis which was absent in mice switched back to chow from the high 
calorie diet.  Combination treatment of curcumin and vitamin E decreased liver injury 
indicating that this treatment may be of therapeutic value in nonalcoholic fatty liver disease.  
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in Western 
countries 230, 231. NAFLD encompasses a range of hepatic pathologies from simple steatosis to 
the more aggressive lesion nonalcoholic steatohepatitis (NASH).232 The HFE gene regulates 
intestinal iron absorption and systemic iron balance, and homozygosity for the C282Y 
mutation in the HFE gene is the most common cause of hereditary hemochromatosis (HH).233 
Steatosis is common in patients with HH234 and is associated with increased hepatic fibrosis, 
and conversely, heterozygosity for the C282Y mutation in HFE is common in patients with 
NAFLD.235 Even mild increases in hepatic iron concentration (HIC) may play an important 
role in the transition from simple steatosis (a benign lesion), to the pathologically more 
significant lesion, NASH. Hfe-/- mice fed a high calorie diet develop NASH, impaired anti-
oxidant activity and accelerated liver injury.236 Thus animal and human clinical studies 
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suggest a relationship between HFE, altered iron metabolism and the development of 
NAFLD, and the basis of this association probably includes increased oxidative stress. This 
relationship could be the target for therapeutic strategies that may attenuate disease 
progression in NASH. Curcumin is a widely available plant product which has antioxidant, 
anti-inflammatory and iron chelating properties.237 Curcumin has been shown to improve 
insulin sensitivity in obese mice.238 Enhancement of insulin sensitivity and inhibition of 
gluconeogenesis has been implicated in the effects observed with curcumin.239 Several 
studies have shown benefit of vitamin E administration in liver diseases associated with high 
levels of oxidative stress, and vitamin E supplementation has been associated with 
improvements in liver injury in animal models of liver disease and in humans with 
NAFLD.240, 241  
 
Both of these agents have been used individually in experimental models of NASH and 
curcumin has been shown to have some therapeutic benefit,242 however these agents have not 
been tested in combination. I hypothesised that these two agents may have synergistic activity 
in attenuating disease progression in NASH viz. the Hfe-/- - high calorie diet animal model.  
To date, these agents have mostly been used as preventative treatment which does not 
replicate the usual clinical situation of ongoing exposure to hepatic toxins in the setting of 
underlying liver injury.  In the present study, I have investigated the potential use of a 
combination of curcumin and vitamin E in the treatment of wild type and Hfe-/- mice with 
established liver injury induced by a high-fat, high-carbohydrate or high calorie diet, and with 
ongoing exposure to the diet. My results show that combination treatment of curcumin and 
vitamin E decreased liver injury suggesting that this treatment may be of therapeutic value in 
nonalcoholic fatty liver disease. 
 
7.2 Methods 
Animals. 
All animals received humane care under the guidelines and approval of the Queensland 
Institute of Medical Research and the University of Queensland Animal Ethics Committees, 
detailed in the Australian Code of Practice. Eight week old male C57BL/6J wild-type (WT) 
mice (Animal Resources Centre, Perth, WA, Australia) and Hfe-/- mice (on a C57BL/6J 
background, originally supplied by Professor William Sly, St Louis University, MO) 243, were 
fed either a standard laboratory control chow diet (n = 9) for 20 weeks or a high fat diet 
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(HFD) (SF03-020, Speciality Feeds, Glen Forrest, Australia) (n = 109) for a period of 10 
weeks.  The mice fed the HFD diet were then randomly assigned to receive either HFD alone 
(n=9), chow (n=9) or HFD plus 1% curcumin (n=9-10), HFD and 1.5% vitamin E (n=7-10) 
or HFD and a combination of 1% curcumin and 1.5% vitamin E (n=9-10) for a further 10 
weeks. All treatment diets were custom made by Specialty Feeds, Glen Forrest, Australia and 
the Curcumin C3 complex was supplied by Sabinsa Corporation, Sami Labs Ltd, India.  The 
fat-derived caloric contribution for HFD was 43%; the cholesterol content was 0.19% and 
sucrose content was 405 g/kg. The chow diet contained 6% fat and the sucrose content was 
7g/kg. Animals were allowed ad libitum access to diets and drinking water and were 
maintained on a 12hr light/dark cycle, at a temperature of 19°C to 23°C and at a humidity of 
50%.  After 20 weeks of dietary treatment, animals were sacrificed under anesthesia 
following cardiac puncture for blood collection.  The livers were removed and portions were 
snap-frozen in liquid nitrogen and stored at -80°C for determination of markers of oxidative 
stress and inflammation as listed below.  Separate portions were collected for histology or 
dried for the determination of hepatic iron concentration. Epididymal fat pads were weighed 
and stored at -80⁰C.  Proximal small intestines were harvested immediately and either snap 
frozen for RNA extractions or fixed in 10% formalin for histology or kept cold in ice for the 
extraction of duodenal and jejunal enterocytes as described previously.244 
 
Histopathological analysis.   
Liver samples were fixed in 10% neutral-buffered formalin, embedded in paraffin, sectioned 
and stained with hematoxylin-eosin (H&E). Histological parameters were staged and graded 
according to accepted criteria by a specialist liver pathologist in a blinded fashion.245-247 
Steatosis was graded according to the percentage of steatotic hepatocytes (grade 0, < 5% 
affected; grade 1, 5 - 33% affected; grade 2, 34 - 66% affected; and grade 3, > 66% affected) 
and necroinflammatory activity was graded according to severity (0, none; 1, mild; 2, 
moderate; and 3, severe) according to criteria established by Brunt et al.245  
 
Lobular inflammatory activity was scored based on the number of inflammatory foci per 
200x field (0, none; 1, < 2 seen; 2, 2 - 4 seen; and 3, > 4 seen) and ballooning was scored 
based on the degree of hepatocyte ballooning (0, none; 1, few; and 2, many) according to 
established criteria.247 Portal inflammation was also scored according to severity (0, none; 1, 
mild; 2, moderate; and 3, severe) according to established criteria.245 Activity was also scored 
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using NAFLD activity score (NAS) established by the NASH Clinical Research Network 
(CRN), which is an unweighted sum of scores for steatosis (0-3), lobular inflammation (0-3) 
and ballooning (0-2).247 
 
Fibrosis stage was assessed following Picro Sirius red staining for collagen according to the 
criteria established by Brunt et al245 (stage 1, zone 3 perisinusoidal only (1a, 1b) or 
portal/peri-portal only (1c); stage 2, zone 3 perisinusoidal and portal fibrosis; stage 3, 
bridging fibrosis; and stage 4, cirrhosis). Additionally, the centrilobular and portal 
components of fibrosis were also each independently scored according to the extent of 
fibrosis (0, none; 1, < 50% of central or portal areas; 2, > 50% of central or portal areas; 3, 
bridging fibrosis; and 4, cirrhosis).  
 
Serum biochemistry and hepatic triglyceride assay. 
Serum concentrations of alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST) were measured on a Cobas Integra 400 Chemistry Automated Analyser as per 
manufacturer’s instructions (Roche Diagnostics, Castle Hill, NSW, Australia).  
Triacylglycerol was extracted from liver homogenates as previously described248, 249 and 
assayed using a commercial kit (Wako diagnostics, Virginia, USA). Serum ferritin was 
measured using a commercial available ELISA (Kamiya Biomedical, Seattle, WA, USA).  
 
Hepatic antioxidant enzyme assay. 
Total cellular glutathione peroxidase (GPx), reduced (GSH) and oxidised glutathione (GSSG) 
and catalase and mitochondrial manganese superoxide dismutase (MnSOD) activities were 
measured on homogenised liver tissue using commercial assay kits as per manufacturer’s 
instructions (Cayman, MI, USA). 
 
RNA extraction and Quantitative Real-time Polymerase Chain Reaction. 
Total RNA was extracted using TRIzol reagent (Invitrogen, Mount Waverley, Victoria, 
Australia), subjected to deoxyribonuclease I digestion and transcribed into cDNA using 
Superscript III according to the manufacturer’s instructions (Invitrogen).  Quantitative gene 
expression was performed by real-time polymerase chain reaction (RT-PCR) (ViiATM 7, 
Applied Biosystems, Life Technologies Corporation, Carlsbad, California, USA) using 
Quantifast SYBR green as per manufacturer’s conditions (Qiagen, Chadstone Centre, 
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Victoria, Australia).  The expression of individual genes were normalised to the geometric 
mean of three house-keeper genes: basic transcription factor 3 (Btf-3), Glyceraldehyde-3-
phosphate dehydrogenase (Gapdh) and β2-microglobulin (β2-m).  Oligonucleotides were 
custom synthesised by Sigma Genosys (Castle Hill, NSW, Australia).  Mouse primer 
sequences for genes investigated are shown in Supplementary Table 1. 
Statistical analysis. 
Normally distributed data were analysed using one-way ANOVA with a Bonferroni multiple 
comparison post-test using GraphPad Prism 5 software (GraphPad Inc, San Diego, CA) and 
expressed as the mean + standard error of the mean (SEM).  All other variables were 
analysed using Kruskal-Wallis ANOVA with a Dunn’s multiple comparison post-test as 
appropriate.   
 
7.3 RESULTS 
Effects on Tissue Weight. 
Feeding a HFD caused a significant increase in total body weight in WT and Hfe-/- mice 
compared to chow-fed mice (42%, p<0.001 and 38%, p<0.001 respectively) (Figure 7.1A and 
1D).  WT and Hfe-/- mice which were switched back to chow after 10 weeks of feeding HFD 
had similar end of study weights to chow fed controls (Figure 7.1A and 7.1D). WT and Hfe-/- 
mice fed the combination of curcumin and vitamin E had lower total body weight than HFD 
fed mice.  However, there was no difference in total body weights between groups of animals 
fed either curcumin, vitamin E or the combination treatment (Figure 7.1A and 7.1D).  
Visceral adipose tissue (VAT) and liver weight were increased in WT and Hfe-/- mice fed 
HFD compared to chow (Figure 7.1B, 7.1C, 7.1E and 7.1F). VAT and liver weight were 
similar in all treatment groups for WT and Hfe-/- mice.   
 
Severe steatosis and lobular inflammation following hfd feeding is attenuated by 
curcumin and vitamin e combination therapy 
WT and Hfe-/- chow-fed mice showed no evidence of steatosis or liver injury (Table 1, 
Figures 7.2A, 7.2D, 7.3A and 7.3D). WT HFD-fed mice developed moderate to severe 
steatosis with hepatocyte ballooning and necroinflammation present in 67% of mice meeting 
criteria for steatohepatitis.  The remaining 33% were classified as simple steatosis (Table 1 
and Figure 7.2B). Hfe-/-- mice fed the HFD developed severe micro- and macro-vesicular 
steatosis with hepatocyte ballooning and inflammatory cell infiltration in all mice (Table 7.1 
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and Figure 7.3B).  WT and Hfe-/- mice switched from HFD to chow had normal liver 
pathology in almost all cases. NAS, steatosis grade and percent steatosis were all lower in the 
HFD to chow group compared to HFD-fed mice (Table 1 and Figures 7.2C and 7.3C). 
Treatment with either curcumin or vitamin E had minimal effects on hepatic histology (Table 
7.1). Combination treatment with curcumin and vitamin E reduced micro- and macro-
vesicular deposits throughout the liver, NAS and percent steatosis in WT and Hfe-/- mice 
(Table 7.1 and Figure 7.3F).  
 
HFD feeding in of WT and Hfe-/- mice led to increases in ALT (5 fold, p < 0.001; 7.5 fold, p 
< 0.001 respectively) and AST (2 fold, p < 0.01; 2.5 fold, p < 0.01 respectively) compared to 
chow-fed mice (Figure 7.4).  Transaminases were significantly decreased in the WT and Hfe-
/- HFD to chow fed mice.  Combination treatment in WT mice resulted in transaminase levels 
similar to HFD to chow fed levels. Hfe-/- mice fed combination treatment had significantly 
lower ALT (5 fold, p < 0.001) and AST (1.8 fold, p < 0.001). Curcumin treatment in WT 
mice significantly reduced ALT (2.2 fold, p < 0.01) but not AST concentration, while Hfe-/- 
mice had significantly lower ALT (3 fold, P < 0.001) and AST (1.7 fold, P < 0.01) 
concentrations. Vitamin E treatment in WT mice significantly reduced ALT (2.2 fold, P < 
0.01) but not AST levels while in Hfe-/- mice significantly reduced ALT 2 fold (P < 0.01) and 
AST 1.4 fold (P < 0.01).   
 
Centrilobular (stage 1) fibrosis (as detected by Sirius red staining) was observed in the 
majority of Hfe-/- mice fed the HFD.  The prevalence of fibrosis was reduced in all treatment 
groups (Figure 7.5). In WT mice, only minimal fibrosis was present (Supplementary Figure 
7.S1).  
 
Gene expression of monocyte chemoattractant protein-1 (Mcp-1), (a product of activated 
stellate cells),250 was elevated in WT and Hfe-/- mice fed HFD and was significantly reduced 
with combination treatment (p<0.01 respectively) (Figure 7.6A and 7.6D). Treatment with 
either agent reduced Mcp-1 expression in WT mice only (p<0.05) (Figure 7.6A).  
 
Expression of α1(I)-procollagen (Col1a1) and tissue inhibitor of metalloproteinase (Timp-1) 
(genes related to hepatic fibrogenesis) were significantly elevated in WT and Hfe-/- HFD-fed 
mice compared to chow-fed mice (5 fold, P < 0.001 and 9 fold, P < 0.001 respectively).  The 
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HFD to chow WT- and Hfe-/-  fed mice had levels similar to those seen in the chow-fed only 
groups (Kruskal-Wallis, P < 0.003 and P < 0.0001 respectively for all treatment 
comparisons) (Figure 7.6B and 7.6E). Combination therapy reduced Col1a and Timp-1 
expression in WT and Hfe-/- - fed mice however this change did not reach statistical 
significance. 
 
Dysregulated lipid signalling pathways due to curcumin and vitamin e combination 
therapy 
HFD feeding in both WT and Hfe-/- mice led to increased serum glucose and serum 
cholesterol compared to CH fed mice (1.5 fold, p<0.05; 1.3 fold, p<0.05 respectively and 2 
fold, p<0.0001 and 2.3 fold, p<0.001 respectively) and decreased serum triglyceride (2 fold, 
p<0.01; 2.7 fold, p<0.001 respectively). An increase in serum glucose implies an increase in 
hepatic lipogenesis through insulin signalling resulting in increased TG storage in the liver. 
Indeed, HFD feeding resulted in an increase in hepatic TG content in both WT and Hfe-/- 
mice (10 fold, p<0.01; 4 fold p<0.01 respectively) compared to chow fed mice. However, in 
WT and Hfe-/- mice, HFD feeding resulted in the downregulation of the expression of 
lipogenic genes such as Srebp-1c, and Fas and an increase in the phosphorylation of ACC1 
protein which are consistent with downregulation of fatty acid synthesis. It is possible this 
reflects a dysresgulation in the ability of the liver to respond effectively to insulin. Also 
contributing to increased hepatic TG levels is an increase in FA uptake as reflected by an 
increase in serum NEFA….. and an increase in CD36 mRNA expression in WT and Hfe-/- 
mice compared to CH fed mice (3 fold, p<0.01 and 2 fold, p<0.001 respectively. 
Treatment with curcumin or vitamin E did not alter serum cholesterol or triglyceride levels in 
both WT and Hfe-/- mice compared to HFD feeding and caused a slight elevation in serum 
glucose levels in Hfe-/- mice compared to HFD fed mice. In contrast to HFD mice however, 
hepatic TG levels were significantly reduced in both WT and Hfe-/- mice fed a combination of 
curcumin and vitamin E (2 fold, p<0.05; 4 fold, p<0.01 respectively). This suggests that 
pathways such as FA synthesis and FA oxidation pathways are affected by treatment with 
curcumin and vitamin E. Western blot analysis on the rate limiting enzyme ACC in FA 
synthesis indicates a suppression on FA synthesis and lipogensis in treated WT and Hfe-/- 
mice compared to HFD fed mice (Fig….) There was also a return to normal CH fed levels of 
Srebp-1c and Fas mRNA expression in all WT treatment groups (3-4 fold, Kruskal-Wallis, 
p<0.01 for all comparisons compared with HFD alone) and a return to normal CH fed levels 
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of Srebp-1c expression in Hfe-/- mice fed a combination diet (2 fold, p<0.01). Similar to HFD 
fed mice however, treatment with curcumin, vitamin E and co-treatment increased fatty acid 
uptake to the liver as evidenced by elevated CD36 mRNA expression compared to CH fed 
mice. In Hfe-/- mice this increase was significantly higher than HFD fed mice, implying there 
is additional FA uptake by the liver. Combined with a decreased TG content this suggests the 
FA are channelled into β-oxidation pathways by mitochondria and peroxisomes. 
Switching the mice back to chow after 10 weeks resulted in reducing serum cholesterol back 
to CH fed levels in both WT and Hfe-/- mice (p<0.01 for both WT and Hfe-/- comparisons) but 
no change in serum glucose. Serum triglyceride levels in these mice returned to normal CH 
fed levels in WT mice and increased compared to that in HFD fed mice (2 fold, p<0.05) 
approaching 50% of normal CH fed levels. Hepatic TG levels followed a very similar pattern 
with a 4 fold reduction seen in the WT mice switched back to chow compared to HFD fed 
mice and a return to normal CH fed levels in Hfe-/- mice. The slight reduction in FA uptake as 
seen by reduced CD36 mRNA expression shows one mechanism by which TG storage has 
been reduced in this group in contrast to treatment groups. Also in contrast to treatment 
groups, no changes were seen in the expression of FA synthesis genes, Srebp-1c, Fas or Scd1 
to account for this reduction in hepatic TG content.  
 
Enhanced gene expression of fatty acid oxidation pathways with curcumin and vitamin 
e combination therapy 
Treatment of WT mice with curcumin, vitamin E and combination therapy resulted in a 
significant increase in hepatic adiponectin receptor 2 (AdipoR2) mRNA expression compared 
to the HFD control group (Figure 7.7A). Treatment of Hfe-/- mice with vitamin E and 
combination therapy also significantly increased hepatic AdipoR2 mRNA expression (Figure 
7.7D). There was an increase in both peroxisome proliferator-activated receptor α (Pparα) 
and carnitine palmitoyl transferase 1A (Cpt1a) mRNA expression in WT mice with 
curcumin, vitamin E and combination treatment compared to HFD alone (Figure 7.7B and 
7.7C). Cpt1a expression was increased in Hfe-/- mice with vitamin E treatment and Hfe-/- mice 
with combination treatment and Pparα mRNA expression was increased in Hfe-/- mice with 
combination therapy compared to HFD alone (Figure 7.7F).  
 
Effects on hepatic antioxidant enzyme activities and mitochondrial function 
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There was no difference in GPx activity between both WT- and Hfe-/--HFD fed mice and 
chow fed mice (data not shown).  Hepatic mitochondrial manganese superoxide dismutase 
(MnSOD) activity was similar across all groups (data not shown). There was no significant 
change in GSH/GSSG ratio for WT and Hfe-/- mice and therefore no indication of oxidative 
stress (data not shown).  
 
Effects on hepatic iron    
Hfe-/- mice fed the chow diet had mild iron overload with a mean HIC of 42 µmol/g (dry 
weight) and as shown previously,236 the HFD- fed mice had a significantly lower mean HIC 
of 24 µmol/g (p< 0.01) (Supplementary Figure 7.2).  Interestingly, in the group of mice that 
were switched from HFD to chow, the mean HIC increased 3-fold to 59 µmol/g (ANOVA, 
p<0.001) when compared to HFD- fed mice.  Hepcidin anti-microbial peptide 1 (Hamp1) 
mRNA levels were similar across all groups (data not shown). All other treatments did not 
affect the amount of iron in the liver and were similar to the levels found in the HFD-fed 
mice.  
 
7.4 DISCUSSION 
In this study, it was demonstrated that the combination of curcumin and vitamin E therapy 
attenuated steatosis and steatohepatitis in wild type and Hfe-/- mice fed a HFD. WT mice fed a 
HFD for 20 weeks developed steatosis and 67% had histological features consistent with 
steatohepatitis. The histological injury was more severe in the Hfe-/- mice, with all animals 
showing features of steatohepatitis, and the majority of these showing centrilobular fibrosis. 
Monotherapy with either vitamin E or curcumin was associated with an improvement in some 
components of steatohepatitis, but combination therapy markedly reduced micro- and 
macrovescicular steatosis and percent hepatic steatosis as well as lobular inflammation, 
ballooning degeneration and fibrosis. 
 
The administration of HFD for 20 weeks caused a marked elevation of ALT and AST, and 
increased gene expression of Mcp-1, Col1a1 and Timp-1 in WT and Hfe-/- animals.  Hepatic 
collagen deposition, as assessed by Sirius red staining, was not increased in wild type 
animals, but a characteristic ‘chicken wire’ appearance seen in NASH developed in Hfe-/- 
animals fed a HFD. Previously it was demonstrated similar changes after 8 weeks of feeding 
of HFD to Hfe-/- animals.236 In the current study a group of animals fed a HFD for 10 weeks 
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were switched back to a chow diet for a further 10 weeks before sacrifice. This HFD to chow 
group provided an excellent comparator group and in these animals there was minimal to no 
hepatic fibrosis, and serum ALT and AST concentrations as well as Col1a1, Mcp-1 and 
Timp-1 gene expression all normalised.  Combination therapy with curcumin and vitamin E 
was not as effective as the HFD to chow switch, but virtually every measure of liver injury 
was improved with dual treatment and the improvement with combination treatment was 
greater than with either monotherapy. This implies that vitamin E and curcumin exert a 
synergistic effect over that provided by each individual therapy.  
 
Curcumin is the yellow pigment of the plant Curcuma longa (turmeric) and has potent 
antioxidant and chemo preventative effects. The administration of curcumin has been shown 
to produce beneficial effects in many animal models of liver diseases, including alcohol–
related injury,251, 252 carbon tetrachloride-induced injury253 and the cholestatic injury seen in 
Mdr2-/- mice.254 Curcumin ameliorates the early stages of experimental steatohepatitis and 
limits the development and progression of fibrosis in mice fed a methionine choline deficient 
diet.255 Several studies have shown benefit of vitamin E administration in liver diseases 
associated with high levels of oxidative stress,256 and vitamin E supplementation has been 
associated with improvements in liver injury in animal models of liver disease and in humans 
with NAFLD.241 The mechanism by which the combination therapy of vitamin E and 
curcumin offered therapeutic advantage was explored in this study. I did not find evidence of 
increased oxidative stress in both wild type and Hfe-/- animals fed a HFD and there was no 
effect of either monotherapy with either vitamin E or curcumin, or combination therapy on 
hepatic mitochondrial manganese superoxide dismutase (MnSOD) activity, catalase activity 
or GSH:GSSG ratio. Thus the improved histology in animals fed a combination of vitamin E 
and curcumin appears to be independent of antioxidant properties. Higher curcumin 
concentrations are achievable in vitro, where the primary effect is through its antioxidant 
action. However, recent research has suggested that the effects of curcumin at lower 
concentrations which are achieved in vivo are independent of its antioxidant properties and 
are via signal transduction and gene expression.257, 258 Indeed, treatment was associated with 
changes in the gene expression of proteins involved in fatty acid oxidation.  Of interest, the 
gene expression of AdipoR2 was attenuated in Hfe-/- mice fed a HFD consistent with previous 
observations. Combination therapy resulted in a 2.5 fold increase in AdipoR2 mRNA 
expression and this was accompanied by significant increases in Ppar-α and Cpt1a gene 
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expression consistent with increased mitochondrial uptake of free fatty acids and increased β-
oxidation in the treated animals. WT animals treated with combination therapy also 
demonstrated increased gene expression of AdipoR2, Ppar- α and Cpt1, but this was also 
seen in monotherapy treatment groups. AdipoR2 has been shown to activate Ppar-α and fatty 
acid oxidation genes, as well as inhibit lipogenesis.175 These results might imply that 
combination therapy is effective due to AdipoR2 upregulation resulting in increased gene 
expression of fatty acid oxidation pathways and therefore protection against steatohepatitis. 
However, it is worth noting that the change in AdipoR2 expression in mice treated with either 
monotherapy alone was similar to that achieved by combination therapy. This would suggest 
that additional mechanisms are involved in the combination treatment groups. 
 
Curcumin has also been reported to have iron chelating properties,237 but the HIC of the 
treated animals was not different from the animals that received HFD, thus iron chelation 
seems an unlikely explanation for the observed benefit. Regardless, the change in the hepatic 
iron concentration of the Hfe-/- animals fed a HFD was of interest. Hfe-/- fed chow for 20 
weeks had an HIC of 42 µmol/ g and the back-to-chow group had a final HIC 59 µmol/g, 
whereas Hfe-/- animals fed a HFD for 20 weeks had a significantly lower HIC. This finding 
remains difficult to explain but it confirms previous findings, and it has been suggested by 
others that a HFD alters intestinal iron absorption.259 In my animals, Hamp1 mRNA levels 
were similar across all groups suggesting that any effect on iron absorption is independent of 
hepcidin gene expression.  
 
The principal difficulty with oral administration of curcumin is low systemic bioavailability 
due to poor oral absorption; therefore alternative methods of administration may need to be 
developed before these observations can be translated into clinical treatments. The dose of 
curcumin administered in the current study was sufficiently high to ensure absorption, 
although serum concentrations of curcumin were not analyzed. 
 
The high prevalence of obesity and the metabolic syndrome means that many patients with 
liver disease of varying etiologies will have co-existent nonalcoholic fatty liver disease. 
Indeed contemporary clinical practice in hepatology is often characterised by the need to 
address multiple co-toxins in one patient. The results of the present study are an excellent 
illustration of the concept of co-toxic liver disease since slight increases in HIC as seen in the 
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Hfe-/- animals fed a HFD were associated with necroinflammation and hepatic fibrosis. 
Because of the beneficial effect of combination therapy, I believe vitamin E and curcumin 
should be investigated in other animal models of NASH, and could be moved rapidly into 
human studies if a beneficial effect is demonstrated, and if appropriate dosing strategies can 
be developed.      
 
7.5 Figures  
Figure 7.1. Body Weights. Effects of diets on (A) total body, (B) liver, and (C) visceral 
adipose tissue (VAT) weights in wild-type (WT) mice, (D) total body, (E) liver and (F) VAT 
weight in Hfe-/- mice. Values are means + SE. *P < 0.05 compared to HFD alone. #P < 0.05 
compared to Chow alone.  N = 7-10 per group. 
 
Figure 7.2. Assessment of liver injury and fibrogenesis in Wild-Type mice. Representative 
liver histology stained with hematoxylin and eosin (H&E) on paraffin-embedded sections 
(original magnification x 20).   
 
Figure 7.3. Assessment of liver injury and fibrogenesis in Hfe-/- mice. Representative liver 
histology stained with hematoxylin and eosin (H&E) on paraffin-embedded sections (original 
magnification x 20).   
 
Figure 7.4. Assessment of liver injury. Serum alanine aminotransferase (ALT) (A) and serum 
aspartate aminotransferase (AST) (B) levels in wild-type (WT) mice and ALT (C) and AST 
(D) in Hfe-/- mice. *P < 0.05 compared to HFD alone. N = 7-10 per group. 
 
Figure 7.5: Hepatic collagen deposition as assessed by Picro-Sirius red staining in Hfe-/- 
mice. (original magnification x 20). Representative liver histology stained with Picro-Sirius 
red on paraffin liver sections.   
 
Figure 7.6. Assessment of fibrogenesis. Reverse transcriptase-polymerase chain reaction 
(RT-PCR) for hepatic fibrogenic pathway gene expression of α1(I)-procollagen (Col1a1), 
monocyte chemoattractant protein-1 (Mcp-1); tissue inhibitor of metalloproteinase -1 (Timp-
1). *P < 0.05 compared to HFD alone. N = 7 - 10 per group. 
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Figure 7.7. Assessment of hepatic lipid pathways. RT-PCR for hepatic expression of fatty 
acid oxidation genes  adiponectin receptor 2 (AdipoR2), peroxisome proliferator-activated 
receptor α (Pparα), carnitine palmitoyl transferase 1A (Cpt1a). *P < 0.05 compared to HFD 
alone. N = 7-10 per group. 
 
Table 7.1. Results of H&E on liver sections for Wild-Type and Hfe-/- mice. Steatosis was 
graded (0 to 3) and lobular inflammation (0 to 3) on H&E staining. Values are expressed as 
the median (range). Nonalcoholic Steatohepatitis Activity Score (NAS) is expressed as 
median values (range). N = 7 - 10 per group. 
 
Supplementary Figure 7.S1. Hepatic collagen deposition as assessed by Picro-Sirius red 
staining in Wild-Type mice. (original magnification x 20).   Representative liver histology 
stained with Picro-Sirius red on paraffin liver sections. 
   
Supplementary Figure 7.S2. Hepatic iron concentration (HIC). Hepatic iron concentration 
(HIC) in livers from (A) wild-type (WT) mice and (B) Hfe-/- mice. *P < 0.05 compared to 
HFD alone. N = 7 - 10 per group. 
 
Supplementary Table 7.1. Mouse primer sequences for genes used in RT-PCR.
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 Figure 7.2 
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 Figure 7.3 
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 Figure 7.5 
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Figure 7.7 
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Supplementary Figure 7.S1 
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Supplementary Figure 7.S2 
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Chapter 8 
Continuing with investigations into the role of probiotics in chronic diseases, this study was 
designed to show that probiotics are capable of providing beneficial effects in disease and 
animal models that are not conventionally used. Observations made in the laboratory led us to 
investigate the influence of bacteria and probiotics on tumour development. Unfortunately 
due to unforeseen changes, this study had to be terminated and no further progression of the 
study hypothesis could be made.  
 
 
Probiotics administered to atm-/- mice 
 
The effects of probiotics on tumour development and survival times in Atm-/- mice 
 
8.1 Abstract 
Background: Ataxia telangiectasia (AT) is a rare autosomal recessive genetic disorder. 
Modification of the ataxia telangiectasia mutated (atm) gene provides a model to study AT. 
atm-\- mice spontaneously develop tumours and when housed in a non SPF facility, tumour 
development has been noted to be accelerated and life expectancy is reduced. Aim: The main 
aim of this study was to prolong the life expectancy of atm-/- mice housed in a “dirty” 
environment through supplementation with probiotics. Methods/Results: Following 6 months 
of supplementation with probiotics, neither the control nor the experimental group showed 
signs of tumour development and the study was terminated. Discussion: Recent removal of 
other animal species from the animal house and the introduction of filter top cages reduced 
the pathogens that the mice were exposed to. This is suspected to have prevented the 
previously noted acceleration in tumour development when atm-/- mice were housed in a non 
SPF facility. 
 
8.2 Introduction 
Ataxia telangiectasia (AT) is a rare autosomal recessive genetic disorder that affects many 
parts of the body causing severe disability. It is estimated that AT affects 1 in 40,000-100,000 
people worldwide260. Individuals with AT have a several hundred fold increased risk of 
developing cancers, particularly leukaemia and lymphomas.261, 262 Other disorders associated 
   
163 
 
with AT are neurodegeneration with progressive ataxia, variable immunodeficiency, 
premature ageing and recurrent infections. AT has also been referred to as an 
immunodeficiency disorder, a chromosomal instability disorder or a DNA repair disorder.  
 
Ataxia telangiectasia mutated (ATM) is a protein kinase activated by DNA double strand 
breaks, initiating the phosphorylation of several key proteins. Among the proteins 
phosphorylated, activation of the tumour suppressor protein p53 results in cell-cycle arrest 
and DNA repair restoring cellular and genetic stability. In the event of irreparable DNA 
damage, the cell undergoes apoptosis. Damage to the ATM gene product changes the cell-
cycle checkpoint control leading to accumulation of DNA damage. An accumulation of DNA 
damage can destabilise the genome and result in the formation of cancer.  
 
A large problem faced by patients with AT is recurrent autoimmune disorders. Patients with 
AT production fewer T-cells263, 264 and have an increased T-cell activation compared with the 
healthy population.265, 266 T-cells originate in the thymus as naive T-cells and migrate around 
the body. Once a T-cell comes into contact with an antigen through an antigen-presenting 
cell, the T-cell differentiates into either a TH1 or TH2 phenotype. Following differentiation, 
the T-cell produces cytokines to help facilitate an immune response. A high percentage of T-
cells activation leads to a high rate of cytokine production and subsequent immune activation. 
Continuous activation of the immune system leaves the host susceptible to new infections and 
a higher degree of inflammation. Respiratory tract infections are amongst the more prevalent 
infections that occur in patients with AT.267  
 
Currently there are no treatments specifically for AT. Rather treatments are directed at the 
specific symptoms presented. Studies have reported that increasing the dietary intake of 
various foods, such as fish oils, helps reduce the development of some cancers (colon, 
prostate and breast).264, 268 Reduced levels of antioxidant micronutrients are commonly 
reported in immunodeficiency diseases and cancer.269, 270 AT patients often present with 
elevated levels of reactive oxygen species (ROS) and low levels of reactive-scavenger 
enzymes (antioxidants).271 This imbalance leads to oxidative damage, resulting in cell 
damage. Supplementing Atm-/- mice with antioxidants retards the formation of thyoma 
tumours.272, 273 
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In an attempt to help understand and develop treatments for AT, an Atm-/- mouse model has 
been developed. Among the observations made using Atm-/- mice, is that Atm-/- mice housed 
in a ‘dirty’ environment rapidly develop tumours and typically require euthanasia around five 
months of age. In contrast, Atm-/- mice housed in a ‘clean’ environment tend to live 
significantly longer. One possibility that might explain the greater longevity of animals living 
in a ‘clean’ environment is the lack of pathogenic bacteria present. Pathogenic bacteria 
invade the gastrointestinal tract initiating an immune response that can result in dysregulated 
inflammation causing problems varying from muscular pain, fatigue and diarrhoea to tumour 
and cancer development.274 
Probiotic therapy may help to modulate the immune response of AT. Probiotics have been 
shown to have immunomodulating effects, with the capability to alter cytokine production, 
systemic antibody responses, tight junction protein distribution and dendritic cell 
distribution.6, 33, 35, 36, 61, 62 The beneficial effects of probiotics are not only limited to the 
gastrointestinal tract, however. Probiotics have also been shown to help with liver function275, 
dermatological conditions276, 277 and respiratory tract infections.278 
 
The main aim of this study was to prolong the life expectancy of Atm-/- mice by regulating 
the immune system and inflammation. A subsequent aim was to map the metabolic profile of 
Atm-/- mice to find significant changes in metabolite production. The primary hypothesis was 
that administering probiotics would significantly increase the quality of life and delay the 
time to euthanasia of Atm-/- mice by enhancing the beneficial bacteria content of the 
gastrointestinal tract, subsequently reducing inflammation and immune activation. 
 
8.3 Methods 
Probiotics 
Four strains of water soluble lyophilised probiotics (B. bifidum, B. longum, L. rhamnosus or 
S. thermophilus) were provided by BioCeuticals. These strains were administered as a        
multi-strain blend to the drinking water at a total concentration of 1 × 108-9 cfu/mL. 
Animals 
Probiotics or a placebo were administered to Atm-/- mice in drinking water for the duration of 
the study. Freely available food and water were changed at least twice a week. Mice were 
monitored daily at the start of the project for signs of distress using an animal welfare 
monitoring sheet. Animal welfare scores were assessed daily initially and reduced to weekly 
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following consistent low scores. If the welfare scores of the animals increase, the frequency 
of monitoring were adjusted accordingly. Any animal scoring high were considered under 
severe stress and were euthanized. Faecal matter and blood were collected at regular intervals 
and stored for later analysis. 
Atm-/- and wild type mice were supplied by QIMR and housed in a ‘dirty’ environment at the 
Mt. Gravatt facility. The animals were housed under conventional conditions (light cycle, 
temperature and atmospheric conditions) and have free access to food (standard chow) and 
water. The animals were split into 3 groups: 1) Atm-/- mice receiving a combination of four 
probiotic strains (n=13); 2) Atm-/- mice receiving a placebo (n=10); and 3) wild type litter 
mates with no intervention (n=6). Three animals from group 1 were euthanized when the 
majority of the animals in group 2 are considered to be under severe stress for later 
comparison. 
 
8.4 Results 
No evidence of tumour development was present after 6 months. The animals were 
terminated as per instructed by the animal ethics committee. 
 
8.5 Discussion 
In this study, I aimed to show probiotics were capable of prolonging the life expectancy of 
Atm-/- mice by regulating the immune system and inflammation. This aim was based on 
observations from previous studies that observed when atm-\- mice were housed in a “clean” 
SPF facility, tumour development was delayed and the life expectancy of the mouse was as 
long as 1-2 years. However, when the animals were housed in a “dirty” non-SPF facility, 
tumour development was accelerated and the life expectancy was reduced to as little as 3 
months.  
Following 6 months of housing atm-/- mice in a “dirty” animal house I failed to observe any 
tumour development and ethics requested I terminate the study. It was later learnt that recent 
changes to the animal house facility had made the facility as “clean” as a SPF facility. These 
changes included removing other animal species so only mice remained and introducing filter 
top cages. These changes resulted in a pathogen report comparable to a SPF facility. With the 
tighter control over pathogens, the mice were no longer exposed to pathogens that may 
aggravate the intestinal tract initiating an inflammatory response and subsequently an 
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immune response. This may therefore allow the immune system to focus on suppressing 
tumour development, allowing the mice to live longer. 
Future studies would benefit by housing atm-\- mice in an environment where they are 
exposed to a wide variety of pathogens. This would ensure the mice have the maximal 
exposure to pathogens that may initiate inflammation of the intestinal tract and accelerate 
tumour development. Unfortunately such a facility is difficult to find in today’s society that 
minimises bacteria growth and exposure. 
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Chapter 9 
Thesis summary and Conclusion 
 
The GIT and its microbiota population are commonly overlooked organs of the body. With a 
growing prevalence of food intolerances and inflammatory conditions of the GIT (IBD & 
IBS), there is an increasing emphasis on the health of the GIT. As such, new products 
(probiotics, prebiotics, synbiotics) are being introduced to the market. One area with still 
limited research is the link between the GIT/microbiota and other organs and systems of the 
body. Receiving 70% of its blood supply from the GIT, the liver is influenced by the health 
of the GIT. Increased consumption of ‘Western’ high calorie diets, particularly high in 
saturated fat, is a major contributor to obesity and its comorbidities. NAFLD is one such 
outcome. Due to the multitude of products on the market today, and the limited data in the 
area, this thesis set out to explore the link between a popular commercial probiotic blend and 
chronic diseases derived from intestinal inflammation. The primary focus of the thesis was on 
lipid metabolism associated with over nutrition and NAFLD. The initial investigation 
involved searching the literature to identify strains of probiotics that have been studied, in 
what medium were they studied in (cells, animals or human) and to summarise the research 
findings. The findings of this investigation are discussed in great length in chapter 1. 
 
Study 1 (chapter 3) 
This study examined the effects of high-fat feeding with or without probiotics on the 
development of NAFLD. It was hypothesised that probiotics supplementation is capable of 
reducing the effects of a HFD and the development of NAFLD by altering the inflammatory 
profile of the GIT and liver subsequently decreasing intestinal permeability. The reduction of 
HFD-induced steatosis by a multi–strain probiotic supplement supports the posit that multi–
strain probiotics may assist with lipid disposal from a HFD by reducing the accumulation of 
fat deposits in the liver. Following the consumption of a HFD, expression of tight junction 
proteins ZO-1 and ZO-2 was reduced. Probiotics supplementation increased the expression of 
the tight junction proteins, indicating a potential mechanism through which probiotics 
supplementation may protect against the development of NAFLD. The increased liver mass 
that occurred following probiotics supplementation warrants further studies. Theoretically, an 
enlarged liver is not a healthy response. However, some of the larger livers from the 
probiotics fed group showed little or no sign of NAFLD or fat deposits. Therefore, the larger 
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liver mass may be a healing response to the initial HFD injury. Once the body mass of mice 
reached approximately 45g, the mice seemed to store most of their additional mass in the 
liver. This response may be related to HSC activation altering the lipid metabolism within the 
liver. The cellular mechanisms responsible for the observed lipid clearance from the liver 
when probiotics were administered are uncertain. Nevertheless, responses that may help to 
identify cellular mechanisms were found. The findings from this study indicated that in chow 
fed mice, as the liver triglyceride content increased, so too did the serum triglyceride 
concentration. By contrast, in the HFD fed mice, as the liver triglyceride content increased, 
the serum triglycerides decreased. Following the signalling pathway back to find mechanisms 
responsible for the removal of lipids from the liver, and the subsequent appearance of 
triglycerides in the serum, may allow us to identify mechanisms that reduce NAFLD. By 
targeting these compounds/signalling molecules, it may be possible to increase lipid 
clearance from the liver, and restore a balanced lipid profile within the liver. 
 
Study 2 (Chapter 4) 
High extracellular iron and/or mutation in the HFE gene are common in patients with 
NAFLD.136, 137 Mutation to the HFE gene dysregulates iron absorption, resulting in increased 
extracellular iron.138, 139 Increased extracellular iron alters the microbiome within the GIT. 
Probiotics have been proposed as a potential therapeutic option that may rescue a dysbiotic 
GIT by readjusting the local commensal bacterial cohort and its environment. This study 
investigated the effects on the GIT and liver of a multi-strain probiotic blend combining 
strains of Bifidobacteria, Lactobacilli and a Streptococcus in hfe-/- mice fed a HFD so as to 
induce NAFLD. The findings from this study showed that compared to the HFD group, a 
multi–strain probiotic blend increased the expression of genes involved in lipid metabolism 
(PPAR-α, Cpt1A and AdipoR2), increased liver function (ALT and AST), and partially 
attenuated portal inflammation and Mallory’s hyaline. Probiotics also increased the gene 
expression of iron transporters (TFR-1 and TFR-2) removing additional iron from the GIT 
and allowing the natural microbiota to be restored. The results of this study show that 
probiotics have potential for increasing lipid metabolism and iron uptake and reducing fat 
deposits within the liver. The findings of this study have implications for both clinical and 
non-clinical populations. Individuals who suffer from NAFLD, iron overload, GIT symptoms 
or lipid metabolism dysregulation may all benefit from probiotics supplementation. This 
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study not only offers evidence of the beneficial effects probiotics, but also provides novel 
insights into how iron levels influence the GIT and the metabolism of lipids. 
 
Study 3 (Chapter 5) 
Quantification of lipid peroxidation has been a long–standing measure of cellular oxidative 
damage. Isoprostanes are formed by the oxidative degradation of arachidonic acid and is the 
“gold standard unit” marker of oxidative damage. The production of ROS is not spontaneous 
as is widely published,183 but rather part of a regulated process.  Recently it has been 
proposed, and scientifically supported, that intracellular generation of ROS are important 
signalling molecules essential for the normal functioning of the human metabolome.183, 185, 186 
The aim of this study was to investigate the effects of lipid peroxidation in response to a high 
fat diet with a secondary aim to examine whether probiotics altered this response. It was 
hypothesised that a diet high in fat would cause increased lipid peroxidation, and that 
probiotics could rescue the altered lipid peroxidation by modifying the gut microbiota and re-
regulating the gut-liver-axis. Mice fed a high fat diet for 20 weeks had significantly lower 
liver isoprostanes and malondialdehyde content compared to chow fed mice. Probiotics 
supplementation did not significantly either of these markers of lipid peroxidation. Reduced 
lipid peroxidation in HFD fed mice may be a response to prevent cirrhosis of the liver 
through deactivation of stellate cells. Stellate cell activation, rather than lipid peroxidation, 
may be the second hit in the ‘2-hit theory’ that defines whether an individual progresses from 
NAFLD to NASH. If this pathway is dysregulated, stellate cells may remain activated, 
causing excessive fibrosis progressing to cirrhosis and NKT cells to activate. 
 
Study 4 (Chapter 7) 
Single therapy with either curcumin or vitamin E, agents which have antioxidant, iron 
chelation and anti-inflammatory properties has proven beneficial in liver disease.279, 280 This 
study investigated the synergistic properties of these agents by using them in combination in 
the Hfe-/- model of NAFLD. The findings from this study demonstrated that the combination 
of curcumin and vitamin E therapy attenuated steatosis and steatohepatitis in wild type and 
Hfe-/- mice when concomitantly fed a HFD. Histological injury was more severe in the Hfe-/- 
mice compared to wild type mice, with all animals showing features of steatohepatitis, and 
most animals showing evidence of centrilobular fibrosis. Monotherapy with either vitamin E 
or curcumin was associated with an improvement in some components of steatohepatitis, but 
combination therapy markedly reduced micro- and macrovescicular steatosis and percent 
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hepatic steatosis as well as lobular inflammation, ballooning degeneration and fibrosis. The 
results of the present study lend support to the use of a combination therapy, because slight 
increases in HIC as seen in the Hfe-/- animals fed a HFD were associated with 
necroinflammation and hepatic fibrosis. Combination therapy of vitamin E and curcumin 
should be investigated in varying combinations and doses in further animal models of 
NAFLD. This would allow rapid progression into human studies if a beneficial effect is 
demonstrated. 
 
Study 5 (Chapter 8) 
This study investigated the potential importance of the microbiota in reducing or preventing 
tumour growth. Specifically, this study examined whether probiotics supplementation 
prolonged the life expectancy of atm-/- mice when housed in a non SPF ‘dirty’ facility by 
regulating their immune system and inflammation. This aim was based on observations from 
previous studies that noted when atm-\- mice were housed in a ‘clean’ SPF facility, tumour 
development was delayed compared to mice housed in a non SPF facility prolonging life 
expectancy of the mouse. However due to unannounced changes in the non SPF animal 
housing conditions the mice were no longer exposed to the level of pathogens as when 
previous observations were made. These changes resulted in a lack of tumour development 
even after 6 months of housing. Despite the lack of tumour development, the fact the mice 
lived for 6 months in a facility where prior to the environmental changes tumours developed 
resulting in euthanasia by 3 month indicates the relationship between bacteria and tumour 
development warrants further investigation. 
 
General Limitations 
All of the studies herein are limited by the relatively small sample size, due to the availability 
of animal housing space, time constraints to use additional experimental animals at the same 
time, and the expense of conducting animal studies. The use of mice rather than humans is 
also not ideal, because this approach assumes that the microbiota is comparable in mice 
versus humans, and that humans will react to probiotics interventions the same as mice. 
Sample analysis was restricted due to the amount of tissue that could be obtained from the 
mice. The environment in which the animals were housed in is also a limitation, because a 
SPF facility limits the exposure of mice to bacteria. This may alter the microbiota 
composition of each mouse, and affect the effectiveness of each strain of probiotic. In 
addition, the pathogens may differ between animals house facilities, making it difficult to 
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compare the results of experiments performed in different animal houses. 
 
Further Research Recommendations 
Further directions for the future would be to investigate the prophylactic versus the 
therapeutic effects of these therapies on NAFLD. The majority of individuals consume 
products as part of a therapeutic treatment. However for those at risk of NAFLD or 
haemochromatosis, a prophylactic therapy may be ideal. Further investigation into the role 
that lipid peroxidation compounds play in lipid signalling/metabolism would also be 
warranted. The relationship between isoprostanes and HSC in lipid metabolism and cirrhosis 
would be of interest also. If lipid peroxidation can be maintain at suitable levels while 
reducing HSC activation it may allow for increased lipid metabolism/clearance while 
preventing cirrhosis from developing. The relationship between serum triglycerides and 
hepatic triglycerides concentrations also warrants further investigations. If these questions 
can be successfully answered in an animal model, transition into human trials and dosing 
trials will follow. 
 
Thesis Summary 
Probiotics were effective at maintaining tight junction proteins and subsequently maintaining 
the epithelial barrier integrity. This prevents pathogens from crossing from the intestinal tract 
in to the circulatory system where they can induce inflammation in the liver. Probiotics were 
also shown to prevent the development of steatosis and hepatic triglyceride accumulation by 
rescuing lipid peroxidation and serum triglyceride concentrations. A relationship between the 
concentration of hepatic triglycerides and serum triglycerides was noted which requires 
further investigation. In the presence of high iron probiotics were also proven to have a 
beneficial effect. Probiotics increased the expression of genes involved in lipid metabolism 
(PPAR-α, Cpt1A and AdipoR2), increased liver function (ALT and AST), and partially 
attenuated portal inflammation and Mallory’s hyaline. A combination therapy of Vitamin E 
and curcumin demonstrated beneficial properties when given in conjunction with a HFD. The 
combination therapy markedly reduced micro- and macrovescicular steatosis and percent 
hepatic steatosis as well as lobular inflammation, ballooning degeneration and fibrosis above 
either individual therapy. In conclusion, this thesis shows neutraceutical compounds are 
capable of reducing the severity of a HFD and the resulting NAFLD. Overall I can conclude 
that while further investigation is required, probiotics and a combination therapy of Vitamin 
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E and curcumin is capable of at least in part attenuating the effects of a HFD and reducing the 
rate of development/progression of NAFLD. These results have implications for millions of 
individuals worldwide who suffer from NAFLD, are at risk of NAFLD, have lipid 
metabolism imbalances or elevated iron concentrations due to genetic or dietary reasons.  
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